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Biologisten lääkkeiden hintakilpailu on ollut vaatimatonta ennen biosimilaarien tuloa markkinoille. 
Ensimmäinen biosimilaari, somatropin, sai EU:ssa myyntilupansa 2006 ja vuonna 2013 sai myyn-
tiluvan ensimmäinen biosimilaari monoklonaalinen vasta-aine, infliximab. Suomi oli yksi ensimmäi-
sistä maista, johon tuote Euroopassa 2013 lanseerattiin. Esimerkiksi, Pohjoismaista Ruotsi ja 
Tanska lanseerasivat myöhemmin, 2015 helmikuussa. Infliximabin alkuperäisvalmiste, Remicade, 
oli Suomessa tukkuohjehinnoin vuoden 2014 ja 2015 tilastoissa suomen viiden myydyimmän lää-
kevalmisteen joukossa. 
 
Infliximab on sairaalavalmiste ja biosimilaarin infliximabin tultua markkinoille, oletettiin sen aiheut-
tavan hintakilpailua ja tuovan sairaaloille säästöjä. Opinnäytetyön tarkoituksena oli selvittää biosi-
milaarien käyttöönottoa Suomen sairaaloissa, selvittää toteutuiko hintakilpailu, saavutettiinko sääs-
töjä ottamalla biosimilaari käyttöön, sekä mihin säästetyt rahat käytettiin. Tutkimus toteutettiin 
Word-pohjaisella kyselyllä, ja lähetettiin sähköpostitse ryhmille, joilla on käyttökokemusta biosimi-
laarista infliximabista, tai jotka ovat vastuussa lääkehankinnoista tai budjeteista. Teoriaosuudessa 
on selvitetty mitä biologisilla ja biosimilaareilla lääkkeillä tarkoitetaan, kartoitettiin biosimilaarien 
asemaa muissa Euroopan maissa sekä selvitettiin biologisten lääkkeiden käyttöä ja kustannuksia 
Suomessa. Tiedon lähteinä käytettiin mm. IMS-tilastoja, Fimean ja EMA:n julkaisuja, sekä alan 
lehtiä. Tietoja etsittiin myös PubMedin kautta. Mielenkiinto tehdä opinnäytetyö aiheesta lähti kirjoit-
tajasta itsestään.  
 
Tutkimuksista saatujen tulosten mukaan, infliximab oli vuonna 2015 sairaaloiden kolmanneksi kal-
leimpien biologisten lääkkeiden joukossa (ostohinnoin laskettuna) ja biosimilaarin infliximabin ai-
heuttaman hintakilpailun avulla sairaaloissa saavutettiin lääkekustannussäästöjä, jotka useimmiten 
käytettiin lääkekustannusten hallintaa. Toisaalta biosimilaarin infliximabin käyttöönotto mahdollisti 
myös uusien lääkkeiden käyttöönoton sairaalan valikoimassa sekä useamman potilaan hoidon in-
fliximab-valmisteella. Myös yritys, joka markkinoi infliximabin alkuperäisvalmistetta, Remicadea, 
lähti hintakilpailuun mukaan laskemalla hintaansa ainakin osissa sairaaloissa jo ennen kuin biosi-
milaari infliximabi osallistui ensimmäisen kerran tarjouskilpailuun. Apteekkareilta saatujen arvioiden 
mukaan markkinoille tulevien uusien biosimilaarien odotetaan mahdollistavan kustannussäästöjä 
seuraavan viiden vuoden aikana yksittäiselle sairaalalle enimmillään jopa 5 miljoonaa euroa. 
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Uusia biosimilaareja on tulossa markkinoille lähitulevaisuudessa ja olisikin mielenkiintoista selvittää 
myös näiden valmisteiden osalta millaiseksi hintakilpailu sairaaloissa muodostuu. Lähtevätkö käy-
tettävät alkuperäisvalmisteet hintakilpailuun mukaan ja millainen hintaero on biosimilaariin. Toi-
saalta markkinatilanne on myös muuttumassa biosimilaarien osalta, kun biosimilaareja, jolla on 
sama vaikuttava aine, tulee markkinoille ja tuotteet alkavat kilpailla keskenään. Olisi mielenkiin-
toista tietää, miten tämä tulee vaikuttamaan lääkkeiden hinnoitteluun.  
 
Asiasanat: Biosimilaari, biologinen lääke, kustannussäästöt, kustannuspaineet, lääkekustannukset  
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Price competition for biological medicines has been modest before the arrival of biosimilars on the 
market. In Europe, the first biosimilar, somatropin, was approved in 2006 and the first biosimilar 
monoclonal antibody, infliximab, more complex biological medicinal product, was approved in 2013. 
Finland was one of the first European countries to able to launch the biosimilar infliximab in the 
autumn of 2013. Several other countries, such as Denmark and Sweden, launched the product in 
February 2015. The originator infliximab, Remicade, was one of the ten best-selling pharmaceuti-
cals in wholesale prices in Finland in 2014 and 2015. 
 
Infliximab is a hospital product and after biosimilar infliximab entered the markets, it was assumed 
to cause price competition and to generate savings for hospitals. The purpose of the thesis was to 
find out about the introduction of biosimilars in Finnish hospitals, to determine whether price com-
petition was achieved, whether savings were achieved by using the biosimilar and how the savings 
were used. The study was carried out using a Word-based questionnaire which was emailed to 
groups with clinical experience of biosimilar infliximab or who are responsible for budgets or drug 
purchasing. In the theoretical part, what is meant by biological and biosimilar medicines,  
the situation of biosimilars in other European countries, and the use and cost of biological medi-
cines in Finland were investigated. The sources of information were, IMS statistics, Fimea and EMA 
publications, and professional magazines. Information was also searched through PubMed. The 
author's own interest in and familiarity with the topic were the reasons for the choice of subject. 
 
 
According to the results of the studies, in 2015, infliximab was among the third most expensive 
biological medicines in the hospitals (at purchasing prices). Hospitals were able to achieve cost 
savings by using biosimilar infliximab and in most cases savings were used to manage medication 
costs. In addition, the cost savings did enable commissioning of new medicinal products to the 
pharmaceutical formulary and made also possible to treat more patients with the infliximab. Also, 
a company that markets the infliximab originator product, Remicade, participate in the price com-
petition by lowering its price (at least in some hospitals) already before the biosimilar infliximab took 
part in the tendering for the first time. According to estimates from pharmacists, new biosimilars 
entering the market are expected to provide cost savings of up to EUR 3 - 5 million for a single 
hospital over the next five years. 
 
More biosimilars are coming into the market in the near future, and it would be interesting to follow, 
how biological medicines price competition in hospitals evolves. Will the originator products partic-
ipate in the price competition and what will be the price difference between the biosimilar and orig-
inator? On the other hand, the market situation is also changing with regards to biosimilars because 
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more biosimilars with the same active substance enter the market and the biosimilars start to com-
pete against each other. It would be interesting to know how this will affect the pricing of biological 
medicines. 
 
Keywords: Biosimilar, biological medicines, cost savings, cost pressure, cost of medicines 
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1 INTRODUCTION 
Pharmaceuticals have a vital role in the healthcare system. The affordability and financing of new 
medicines challenges governments worldwide and policy makers are balancing the access of pa-
tients to new effective pharmaceuticals with limited healthcare budgets. 
 
Biological medicines are often remarkably expensive due to the highly demanding manufacturing 
processes, high drug development costs and significant therapeutic values. However, one of the 
main reasons for the high price tag has been the lack of competition in prices. Most biological 
medicines have been under patent protection, and have not therefore been under price competition 
which would have lowered their prices. In recent years, first patents of biological products have 
expired and biosimilars have become to the market.  
 
Biosimilar medicines are an important subclass of biopharmaceuticals, versions of existing biophar-
maceuticals, for which marketing exclusivity rights have expired. The active substance of the bio-
similar is, from a scientific and regulatory point of view, just another version of the active substance 
of the originator product. In Europe, first biosimilar was approved in 2006 (somatropin/Omnitrope) 
and first biosimilar monoclonal antibody (infliximab/Remsima and Inflectra), more complex biologi-
cal medicinal product, was approved in 2013. Biosimilar infliximab challenged hospital decision-
makers and clinicians to think about the status of a biological originator product in a new competitive 
environment. 
 
Biosimilar products are increasingly entering the market, not only from the so-called generic phar-
maceutical companies but also from companies traditionally known as innovative pharmaceutical 
companies. Biosimilars are expected to increase price competition and reduce prices of biological 
medicines. Competition in the market resulting from the introduction of cost-effective biosimilars 
will save the EU several billion euros annually and when biosimilar monoclonal antibodies are in-
cluded, will potential savings be much greater.  
 
Finland was one of the first European countries to be able to launch the biosimilar infliximab in the 
autumn of 2013. Several other countries, such as Denmark and Sweden, launched the product in 
February 2015. Biosimilar infliximab challenged hospital decision-makers and clinicians to think 
about the status of a biological originator product in a new competitive environment. 
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2 RESEARCH PROBLEM AND THE OBJECTIVES OF THE STUDY 
The author had worked with biosimilar products for several years in pharmaceutical industry and 
the author's own interest in and familiarity with the topic were the reason for the choice of subject. 
 
The main purpose of this research is to understand the introduction of the biosimilar infliximab in 
Finnish hospitals, the impact of biosimilar on the pricing of the originator products and to find out 
how savings, achieved by biosimilar competition, were used and what is expected of future biosim-
ilars. The objective is to reinforce awareness of the potential of biosimilars to promote price com-
petition of biological medicines and to show that biosimilars are seen in the hospitals as a cost-
effective alternative to the high-priced branded biologics, offering cost advantages to both payers 
and patients. 
 
To achieve these objectives, as well as to fill gaps discussed in the previous chapter, the main 
research questions and sub-questions are described as follows: 
1) How biosimilar product is positioned at the present time in hospital pharmaceutical 
formulary. 
2) Are the studies conducted for biosimilars extensive enough, from where the respond-
ents have received information about biosimilars and is there need for more infor-
mation. 
3) What preparations were made before switching patients from originator product to bi-
osimilar product, did switching affect the efficacy and safety and was some follow-up 
done. 
4) What do the respondents think about switching between biosimilars (same active sub-
stance) and what should be taken into account in this kind of a switch. 
5) What are the main barriers to wider uptake of biosimilars. 
6) What did the respondent expect the price difference to be between the originator and 
the biosimilar product when it was first time selected to the pharmaceutical formulary, 
what was the real price difference and did the originator product’s price change when 
compared to the previous purchasing period.  
7) Were medicinal cost savings realized and how the saved money was used. 
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8) What is expected from the future biosimilars in hospital use, are they going to affect 
the price of the originator product, what might be the price difference between the 
originator and the biosimilar product and are medicinal cost savings expected to occur. 
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3 STUDY DESIGN 
The research method of this thesis was a qualitative study. Microsoft Word spreadsheet question-
naires were designed to gather information and opinions about biosimilar experiences and the es-
timates of cost savings achieved. On top of that, medicinal cost saving in the future were questioned 
about. Questionnaire gathered data from specified target groups, which included chief physicians 
from rheumatology and gastroenterology and also hospital chief pharmacists. Chief Assessment 
Physicians, Medical Directors and Heads of Departments were also targeted, but the number of 
responses received from them was very modest. These target groups were chosen, because they 
have experience of biosimilar infliximab. When designing the questionnaire, additional expertise 
was provided by Professor, Department Head Tuulikki Sokka-Isler, Docent, Ph.D. Pekka Kurki and 
Hospital Chief Pharmacist. Oncologists were also a target group in the beginning, but the re-
sponses were not analyzed, due the lack of replies. Only one Specialist Oncology, two Heads of 
Pharmacy and two Heads of Departments returned the questionnaire.  
 
The survey was conducted by sending a questionnaire to the target group via e-mail. There were 
two types of questionnaires, which were slightly different from one another. The pharmacists re-
ceived a different form than the other target groups. The first questionnaire was sent on October 1, 
2016 and the reminder was sent from 21 to 25 October 2016. 
 
The biosimilar products chosen for questionnaire were infliximab and filgrastim. Only infliximab 
responses are analyzed in this thesis. Analysis concerning filgrastim were left out, because of lack 
the of responses from oncology. 
 
The theoretical part aimed to identify the challenges of the high costs of biological medicines and 
to explain the reasoning behind of welcoming of biosimilars to the market. In the literature review, 
the patent system, the exclusive marketing rights of biological medicines and the cost pressures 
created by biological drugs were investigated. Also as part of the  study was the introduction of 
biosimilars in the Nordic countries, and how the attitudes in different countries to biosimilars have 
changed in recent years and what is being done to reduce the pressure of increasing costs of 
medicines in Finland. Information has been searched for an example from PubMed, Fimea and 
Emea pages, and medical publications.   
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4 STUDY METHOD 
In the fourth chapter, the theory of qualitative research method is briefly presented. 
4.1 Research method 
The main focus is directed to explorative qualitative research in this study. The basic idea of qual-
itative research is to reflect the real life. As a research method, it aims for comprehensive infor-
mation acquisition, in which the research material is compiled in natural or real situations. Qualita-
tive study author often uses people as tools for data collection and trusts both conversations that 
have taken place and own observations. (Hirsijärvi, Remes & Sajavaara 2007, 157, 160.) 
 
Understanding the perspective of the participants is goal of qualitative research. The author of a 
qualitative research has an active role and the goal is to find out what the phenomenon to be studied 
is from the point of view of the people involved in the study, that is, what is reality from their point 
of view. Through this study, this reality is structured and the theory of reality is formed. (Kylmä & 
Juvakka 2007, 28-29.) 
 
Qualitative research is guided by questions such as what, why and how. In addition, qualitative 
research is characterized by the fact that only a small amount of research data is available on the 
research topic. (Kylmä & Juvakka 2007, 31.) The purpose of qualitative research is to raise unex-
pected issues and to find or reveal facts, rather than finding arguments for claims already made. 
Informants are selected appropriately, and therefore, the cases being investigated are treated as 
unique. Uniqueness is also taken into account when interpreting the collected material. Flexibility 
and modification of plans when circumstances so require fall into the features of qualitative re-
search. (Hirsijärvi, Remes & Sajavaara 2007, 157, 160.)  
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4.2 Informers 
For qualitative research, it is important that the people from whom the information is to be collected 
have as much information as possible about the matter being investigated or have personal expe-
rience with it. On the basis of this idea, reporting informants are chosen with discretion. (Tuomi & 
Sarajärvi 2003, 87-89.) 
4.3 Collection of material 
Generally, a qualitative study is a discretionary sampling. The units, that are being investigated, 
are not selected a very large amount, are thoroughly explored, and the quality of the material is 
important. The size of the material is also important and the material should be comprehensive in 
relation to what kind of analysis and interpretation it is intended to make. The aim is to select the 
material appropriately and explain it theoretically. (Eskola & Suoranta 2014, 18, 60-61.) 
4.4 Handling and analysis of material 
When processing the data, the responses were compiled into tables by target group and were 
summarized. The compilation revealed the dispersion of the closed questions, and all the options 
for open issues. 
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5 REVIEW OF LITERATURE 
The literature review deals the theory of biological and biosimilar drugs and surveys how biosimilars 
have affected the market and cost of biological medicinal products. 
5.1 What is biological medicinal product? 
A biological medicinal product contains one or more active substances made by or derived from a 
biological source. Some of the active substances of biological medicines may already be present 
in the human body, like insulin, growth hormone and erythropoietin. The active substances of bio-
logical medicines are larger and more complex than those of non-biological medicines and such 
complexity can be reproduced only by living organisms. Biological medicines complexity and the 
complex process of the production may result in a degree of variability in molecules of the same 
active substance, particularly in different batches of the medicine. Because of live cells and com-
plex manufacturing and purification processes, the active substances of the biological medicinal 
products are often heterogeneous mixtures. (Europeans Medicines Agency (h) 2012, 1; Fimea (a), 
accessed 6 October 2016, 1.) 
 
Previously biological medicinal products were developed mainly for rare diseases. Nowadays bio-
technology has enabled the development of treatments for a variety of serious, common diseases 
including cancers, heart attacks, stroke, multiple sclerosis, diabetes, rheumatoid arthritis and auto-
immune diseases. (European Commission 2015, 2; Fimea (a) 2016, accessed 6 October 2016, 1.) 
 
There is over 30 years of experience with biological medicines in Europe. Biosynthetic "human" 
insulin was the first approved substance for therapeutic use, first marketed in 1982.  Worldwide, 
many million patients have already benefited from approved biological medicines which are show-
ing to have better long term outcomes with fewer costly side effects. Studies have also shown that 
biological medicines treatment leads to quicker recovery time and less additional treatments. One 
of the most important advantages for the patient of being treated with biologic medicines is the 
improvement in quality of life over the long term. (European Commission 2015, 2 – 4.) 
 
  
24 
Recent analyses suggest that over 1500 medicines are currently in development, targeting dis-
eases across a wide range of therapeutic areas from cancer to diabetes and infectious diseases 
(figure 1). Biologics represent 42% of the total number of medicines in the pipeline while accounting 
just 8% of currently marketed products (figure 2). Biological medicals are typically priced at €10 
000–100 000 per patient per year or more. According the analysis from the Tufts Center for the 
Study of Drug Development, published 2013 November, the pharmaceutical industry has shifted 
its R&D focus from small molecule drugs to a biotechnology products. For example, only 13 bio-
technology products were commercially available in 1989 compared to 2012 when the number of 
marketed biotechnology products had grown to 210. Between 2001 and 2012 global biotechnology 
product sales increased from US$36 billion to US$163 billion.  Over 245 biologic medicines repre-
senting 166 different active substances were authorized in the EU and US by 2014. (WHO 2015, 
30; EvaluatePharma 2012, 8-9; Tufts Center for the Study of Drug Development. 2013; Mitragotri 
et al. .2014, 1; Medicines for Europe (a), accessed 9 November 2017.) 
 
  
FIGURE 1. New medicines in development/pipeline among the NASDAQ group of companies, by 
therapeutic area, May 2012 (EvaluatePharma 2012, 9) 
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FIGURE 2. Percentage of small molecules and biologics in the pipeline and on the market/approved 
(EvaluatePharma 2012, 8) 
“Biological medicinal products are believed to hold significant position in the future of medication, 
as already half of the products under development are biological medicinal products” (Fimea (a), 
accessed 6 October 2016, 1). 
5.1.1 Definition of European Medicines Agency 
EMA’S (European Medicines Agency) definition of biological medicinal products according Part I of 
Appendix I of Directive 2001/83/EC is that a biological medicinal product is a product that contains 
a biological substance. A biological substance is produced by or extracted from a biological source 
and needs for its characterization and the determination of its quality a combination of physico-
chemical-biological testing together with the production process and its control. (European Medi-
cines Agency (g) 2015, 6.) 
 
As biological medicinal products are considered for example, recombinant proteins, monoclonal 
antibodies, medicinal products derived from human blood and human plasma, immunological me-
dicinal products and advanced therapy medicinal products (gene- and cell therapy medicinal prod-
ucts and tissue engineered products). (European Medicines Agency (g) 2015 ,6; Fimea (a), ac-
cessed 6 October 2016.) 
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It should be noted that all substances which are extracted from a biological source are not biological 
medicinal products. These products are classified as chemical medicinal products, for example 
antibiotics which are produced in yeast/mold or polysaccharides, which can be accurately analyzed 
and for which there is no viral risk. (Fimea (a), accessed 6 October 2016.) 
5.1.2 How are biological medicinal products produced? 
Biotechnology uses modern technologies and living organisms, such as plant or animal cells, bac-
teria, viruses and yeast, to produce biological medicines. Many biological medicines are made by 
using genetically modified cells. Each manufacturer develops their own proprietary manufacturing 
processes and has their own unique cell lines. A complex process of the manufacturing of biological 
medicines involves several very sensitive processes (figure 3). It is vital to control those processes 
to obtain consistent results and to be able to guarantee the safety and the efficacy of the final 
product. (European Commission (b) 2013, 7-8.)  
 
In the European Union, approved medicine manufacturers and importers, are legally obliged to hold 
a valid Manufacturer’s and Importer’s Authorization (MIA)/Good Manufacturing Practice (GMP) cer-
tificate issued by an EU national competent authority. An MIA/GMP certificate is granted if the 
manufacturing or importing site complies with the EU Guidelines on Good Manufacturing Practice, 
including specific provisions for biological medicinal products. (European Commission (b) 2013, 8; 
Medicines for Europe (b) 2016, 18.) 
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FIGURE 3. Standard production sequence in the manufacture of biopharmaceutical product 
(adopted from Medicines for Europe (b) 2016, 18) 
5.1.2.1 Manufacturing changes of biological medicinal products 
Any biological medicine is likely to be modified several times, because the manufacturers of bio-
logical medicines frequently make changes to manufacturing processes. These changes can occur 
during development and after approval of the product and are often seen as improvements. Rea-
sons for the manufacturing changes may for example include improvement of the manufacturing 
process, increase scale, improve product stability and comply the with changes in regulatory re-
quirements.  Changes in manufacturing can be small, like change in the supplier of cell culture 
media, and range to major ones, like introducing new puriﬁcation steps or implementing new man-
ufacturing sites. For example, the infliximab biosimilar reference medicine Remicade has had about 
40 changes in the manufacturing process for the active substance or the final product since its 
initial authorization approval (figure 4). It can be argued that the medicine administered to a patient 
today is not ‘identical’, but is comparable to the medicine authorized years ago. (Schneider 2013, 
315 – 316; European Medicines Agency (a) 2005, 3 – 5; National Institute for Health and Care 
Excellence 2015, 3; Weise et al. 2014, 3191.) 
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Any changes in the manufacturing process is to be substantiated with appropriate data and ap-
proved by the EMA. When changes are made to the manufacturing process, the manufacturer 
needs to demonstrate the changes do not adversely impact the safety and efficacy of the drug 
product. So-called “comparability exercise” is required by the regulatory authorities to evaluate the 
pre- and post-change product. This evaluation focuses on the relevant quality attributes and de-
pending on the magnitude of the change and the understanding of the existing product, sometimes 
also comparative data on the non-clinical and clinical level are required. The principles of the com-
parability exercise are regulated in guidelines such as ICH Q5E, which is issued by International 
Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for 
Human Use. ICH Q5E is an internationally agreed standard which is intended to assist in the col-
lection of relevant technical information and it provides principles of the comparability of biotechno-
logical and biological products before and after changes are made in the manufacturing process 
for the drug substance or medicinal product. In the ICH Q5E is stated that “The demonstration of 
comparability does not necessarily mean that the quality attributes of the pre-change and post-
change product are identical, but that they are highly similar and that the existing knowledge is 
sufﬁciently predictive to ensure that any differences in quality attributes have no adverse impact 
upon safety or efﬁcacy of the drug product”. The manufacturers and regulators have managed 
these quality changes for years and have more than 20 years’ experience in assessing the com-
parability of different versions of a given biological medicinal product. After approval, the products 
new version is expected to have, in all therapeutic indications, same efficacy and safety. (Fimea 
(k) 2015, 1; European Medicines Agency (a) 2005, 3 – 5; Schiestl et al. 2011, 310; Schneider 2013, 
315 – 316; Weise at al 2014, 3191.) 
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FIGURE 4. Number of manufacturing process changes after regulatory approval (Schneider 2013, 
316) 
5.2 Biological medicines versus small molecules 
Biological medicines differ many ways from small molecule medicines, as shown in table 1. Small 
molecule medicines are manufactured typically by chemical synthesis whereas biological medi-
cines are generally made in genetically engineered cells. Biologic medicines are significantly more 
complex structurally than small molecule pharmaceutical medicines and are often 200 to 1 000 
times larger. The manufacturing process of biological medicines is more complex than for traditional 
small molecule medicines and minor changes in manufacturing process can have an impact on 
medicines efficacy or immunogenicity. Biological medicines are defined as mixtures of many differ-
ent form of the same protein whereas small molecule medicines have well-defined chemical struc-
ture. All the various components of the small molecule medicines can usually be determined while 
biological medicines are more difficult to characterize due to inherent variability in the molecule. 
Majority of small molecule compounds are taken orally but administration of most biological medi-
cines must be by injection or infusion because the digestive system affects proteins. (GaBi Online 
29 June 2012; European Commission (b) 2013, 8-9; Ganellin et al. 2013, 98; Ezell S 2015, 2.) 
Biological medicines contain much larger molecules than conventional pharmaceuticals (figure 5). 
As an example, a small molecule medicine aspirin measures just 180 Daltons, has 21 atoms and 
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remains relatively stable over time with little ability to initiate an immune response. Instead a typical 
monoclonal antibody biological medicine measures 150,000 Daltons and contains 20,000 atoms, 
degrades over time, and have the inherent potential to induce unwanted immune response. (GaBi 
Online 29 June 2012; European Commission (b) 2013, 9.) 
 
 
FIGURE 5. Comparison of molecular mass of small molecule medicines versus large biological 
medicines. Da: Dalton, GCSF: Granylocyte Colony-Stimulating Factor, HGH: Human Growth Hor-
mone, EPO: Erythropoiesis-Stimulating agent, mAbs: Monoclonal Antibodies (Adopted from 
Amgen (a), accessed 9 October 2016) 
TABLE 1. Characteristics of small molecule medications compared to biological medications (GaBi 
Online 29 June 2012; European Commission (b) 2013, 7-8; Mócsai et al. 2014, 2 - 3, 6; Bechtel 
2016, 37) 
  Small molecule drugs Biological drugs  
Size 
Small (single molecule). 
Large (mixture of related  
molecules). 
 
Generally low molecular weight  Generally high molecular weight   
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(< 700 Da). (> 1 kDa). 
Structure 
Homogenous drug substance,  
well defined, independent of  
manufacturing process. 
Heterogeneous mixtures, defined by 
the exact manufacturing  
process. 
 
Modification Well defined Many options  
Manufacturing 
Usually produced by organic  
or chemical synthesis. 
Produced with/from live  
cells/organisms. 
 
Predictable chemical process. 
Difficult to control from starting  
material to final API. 
 
Fewer critical process steps  Many critical process steps.  
Identical copy can be made  
Fewer critical process steps.  
Impossible to ensure identical copy. 
. 
Characterisation Well characterised. 
Cannot be characterised completely 
the molecular composition and  
heterogenicity. 
 
Stability Stable. 
Unstable, sensitive to external  
conditions. 
 
Immunogenicity Usually non-immunogenic. Often immunogenic.  
Administration Oral. Mostly by injection or infusion.  
Manufacturing 
cost 
High. Low/variable. 
 
5.3 Legal instruments for intellectual property rights protection 
In the pharmaceutical sector in the European Union, the industry has different legal instruments at 
its disposal for intellectual property rights protection. These instruments are patents, supplementary 
protection certificates, regulatory data protection and a 10-year market exclusivity for orphan drugs 
(drugs used for the treatment of rare conditions). Patent law grants patent holder a time-limited 
monopoly for an active pharmaceutical substance in which time originator companies should be 
able to recoup their R&D investments. Pharmaceutical products can be covered by several patents, 
sometimes by as many as 30 to 40 patents or more. (Tuominen 2011, 8-9, 24; Roox 2008, 5, 7; 
GaBi Online 1 July 2011.) 
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“The large number of patent litigations surrounding launch of generics and biosimilars is a conse-
quence of the difficulty to appreciate the actual date of the loss of Intellectual Property (IP), and the 
value of some additional patents that research based companies use to reinforce their IP protec-
tion” (Creativ-Ceutical 2012, 36). Obstacles with biosimilar entry timing are caused by the facts that 
there is no centralized listing of biological patents, expiration dates are proprietary information to 
the companies and each biological medicinal product has formulation patents which are difficult to 
assess. (Creativ-Ceutical 2012, 36; GaBi Online 30 September 2011.) 
5.3.1 Patent system of the EU Pharmaceutical medicinal products 
The special characteristics of the patent system influence the pharmaceutical market. The patent 
system enables pharmaceutical companies, which have research activities, to cope with the com-
petitive pressures of early patent application and the delays in drug approval. (Tuominen 2011, 2.) 
 
Patent system is not completely harmonized within the EU, but it is assumed that the patent sys-
tems of the Member States are roughly similar, at least at the level of general principles. This is 
due to TRIPS Agreement, Member States are parties to the European Patent Convention 2000 and 
have also adopted some key provisions of the Community Patent Convention. (Tuominen 2011, 9; 
European commission (d) 2009, 99 – 100.) 
 
Patents in the EU can be obtained either by filing a national application at the national patent offices 
or by filing application at the European Patent Office (EPO). Most pharmaceutical companies prefer 
to use the European Patent Office (EPO) which handles centralized patent applications. Most pa-
tent filling by European pharmaceutical companies are made in accordance with the Patent Coop-
eration Treaty (PCT), which gives the possibility of designating almost 140 countries. (Tuominen 
2011, 9-10; European commission (d) 2009, 100, 103, 114.) 
 
According Art. 28 of the TRIPs Agreement, third parties are forbidden to manufacture, market or 
import the product for such purposes. Also, if the patent concerns a process, third parties are pre-
cluded from using or marketing that process. (Tuominen 2011, 9 – 10.) 
 
The period of protection is 20 years from the date of the filling from which medicines enjoy roughly 
8 to 10 year’s effective protection, see figure 6. Usually patent applications are filled early in the 
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research phase. A branded pharmaceutical derives most profits during the first five- to eight-years 
of market exclusivity. (Tuominen 2011, 6 – 7.) 
5.3.2 Supplementary Protection Certificate (SPC) 
For new products, EU has introduced a Supplementary Protection Certificate (SPC), which ensures 
a maximum of 15 year’s market exclusivities, figure 6. Supplementary Protection Certificate ex-
tends the initial patent protection by up to 5 years, figure 6. Overall purpose of the Supplementary 
Protection Certificate regulation is to compensate the patent holder and the holder of the marketing 
authorization for the time lost while gaining approval for the medicinal product to be placed on the 
market for human use. (Tuominen 2011, 7, 10 – 11; Intellectual Property Office 2013, 16.) 
 
Regulation EC 1901/2006 grants additional intellectual property protection for exclusive rights 
against imitation. This regulation aims to facilitate the development and accessibility of medicinal 
products for use in the pediatric population. As compensation for conducting the pediatric research, 
the patent holder is entitled to a six-month extension of the protection period.  (Tuominen 2011, 11; 
Official Journal of the European Union 2006, 1.) 
5.3.3 Regulatory Data Protection (RDP) 
“Regulatory data protection (RDP) is a form of exclusive right enforced through the marketing au-
thorization procedure”. When an originator company releases a new medicine on the market it must 
provide vast amount of information on its product order to obtain the necessary market authoriza-
tion.  When generic manufacturer brings the same product on the market it must either generate 
its own data or wait a certain period until it would be permitted to rely on the data provided by the 
innovator.  (Tuominen 2011, 11 – 12.) 
 
In practice the exclusivity rendered by the regulatory data protection is weak for several reasons 
and data protection period would only be relevant if there was no other intellectual property protec-
tion. (Tuominen 2011, 12.) 
 
The generic manufacturer’s application for authorization can be used after defined periods of time. 
Application using the abridged procedure cannot be made in the first 8 years from the date of first 
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authorization in the Community. After this, requests for generic authorization can be made, but 
actual marketing cannot take place before 10 years from the first Community authorization have 
elapsed (figure 6). (Tuominen 2011, 12.) 
 
 
FIGURE 6. Data exclusivity and market protection of the originator product. The 8+2(+1) exclusivity 
period came into effect in the EU in late 2005 and it does not affect exclusivity periods for products 
for which applications were submitted before the effective date. SPC = Supplementary Protection 
Certificate, MA = Marketing Authorization, MRP = Mutual Recognition Procedure (Kurki et al. 2016; 
Europeans Medicines Agency (e) 2013, 3-5, 31; European Commission (a) 2013, 39 – 40; GaBi 
Online 1 July 2011) 
5.3.4 Examples of market exclusivity of medicines 
In EU in some countries, medicines have experienced as long as 21 years, such as Genotropin in 
Slovenia, and as low as six years, like Neupogen in Romania, exclusivity times. Genotropin was 
the first biological medicine facing biosimilar competition in the EU and experienced the largest 
exclusivity times of the three biological medicines, Genotropin, Eprex/Erypo and Neupogen. When 
comparing the market exclusivity period of three biological medicines, the median was 17 years 
and did not differ much among the three products, corresponding medians ranging from 16 to 18 
year (table 2). (Labry et al. 2013.) 
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TABLE 2. Market exclusivity time of biological product (Labry et al. 2013) 
Name of biological product Median time 
Genotropin 18 
Eprex/Erypo 18 
Neupogen 16 
 
All three biological products mentioned have been exposed to biosimilar competition in EU. Geno-
tropin’s biosimilar did receive its marketing authorization 2006, Eprex/Erypo’s biosimilar 2007 and 
Neupogen’s biosimilar 2008 (table 3). 
5.4 What Is biosimilar medicine? 
Biosimilar medicines are an important subclass of biopharmaceuticals, versions of existing biophar-
maceuticals, for which marketing exclusivity rights have expired (figure 7). The active substance of 
the biosimilar is, from a scientific and regulatory point of view, just another version of the active 
substance of the originator product. Weather a biologic medicinal product is classified as a biosim-
ilar medicine or as an original biological medicinal product is related to the degree of innovation of 
the product and/or its therapeutic application. In other words, original product may be either a new 
molecular entity, or a slightly modified existing molecule (typically called biobetters, figure 10) and 
biosimilar is aimed at replicating a well know reference original medicinal product. Biosimilar is 
intended to contain essentially the same active substance as to original product, to come in the 
same pharmaceutical form and to be administered via the same route at the same dose for the 
same, or fewer, indications. (Fimea (i), accessed 27 January 2017; Medicines for Europe (b) 2016, 
8; Mora 2015, 952 – 953; Weise et al. 2014, 3191.) 
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FIGURE 7. Biosimilar medicines are a subclass of biological medicinal products (adopted from 
Medicines for Europe 2016 (b), 9) 
The expiration of data protection or patents for the first-generation original biotherapeutics, followed 
by patent expiration on the first approved monoclonal antibodies, has led to the development and 
authorization of copy versions, termed “similar biological medicinal products” (biosimilars) by the 
European Medicines Agency in the European Union (EU). European Union was first to establish 
an approval pathway for biosimilars with the publication of the Guideline on Similar Biological Me-
dicinal Products (CHMP/473/04) in October 2005. In Europe, first biosimilar was approved in 2006 
(somatropin/Omnitrope) and first biosimilar monoclonal antibody (infliximab/Remsima and Inflec-
tra), more complex biological medicinal product, was approved in 2013 (table 3). (Creativ-Ceutical 
2012, 53; European commission 2015, 4; European Medicines Agency (f) 2013; Olech 2016, S1 -
S 2, S6). 
TABLE 3. List of EU approved medicines (January 2017). In red written products are marketed in 
Finland (21 December 2016) (Fimea (j), accessed 27 January 2017; VFA 2016; European Medi-
cines Agency (b), accessed 27 January 2017; European Medicines Agency (c), accessed 31 Jan-
uary 2017; European Medicines Agency (d), accessed 31 January 2017, European Medicines 
Agency (l), accessed 27.1.2017) 
Name of  
biosimilar  
product 
Active  
substance 
Therapeutic area Date of  
authorization 
Marketing  
authoriza-
tion holder 
(biosimilar) 
Reference 
product 
Marketing  
authorization 
holder 
(reference) 
Omnitrope® somatropin 
- Pituitary dwarfism                   
- Prader-Willi  
  syndrome            
- Turner syndrome 
12 April 2006 Sandoz Genotropin® Pfizer 
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Abseamed® 
epoetin  
alfa 
- Anemia                                 
- Autologous blood  
  transfusion                          
- Cancer                                   
- Chronic kidney  
  failure                      
28 August 2007 Medice 
Erypo® 
/Eprex® 
Janssen- 
Cilag 
Binocrit® 28 August 2007 Sandoz 
Epoetin Alfa 
Hexal® 
28 August 2007 Hexal 
Retacrit® 
epoetin 
zeta 
18 December 
2007 
Hospira 
Silapo® 
18 December 
2007 
Stada 
Ratiograstim® 
filgrastim 
- Cancer                                                              
- Hematopoietic  
  stem cell trans- 
  plantation                         
- Neutropenia   
15 September 
2008 
Ratiopharm 
Neupogen® Amgen 
Tevagrastim® 
15 September 
2008 
Teva 
Filgrastim 
Hexal® 
06 February 
2009 
Hexal 
Zarzio® 
06 February 
2009 
Sandoz 
Nivestim® 08 June 2010 Hospira 
Grastofil® 
18 October 
2013 
Apotex 
Accofil® 
18 September 
2014 
Accord 
Healthcare  
Inflectra® 
infliximab 
- Ankylosing  
  spondylitis             
- Crohn's disease                     
- Psoriasis                                
- Psoriatic arthritis                      
- Rheumatoid  
  arthritis                  
- Ulcerative colitis                                                 
10 September 
2013 
Hospira 
Remicade® 
Janssen 
Biologics 
Remsima® 
10 September 
2013 
Celltrion 
Flixabi® 26 May 2016 
Samsung 
Bioepis 
Ovaleap® 
follitropin 
alfa 
- Anovulation 
27 September 
2013 
Teva 
Gonal-f® 
Merc  
Serono 
Bemfola® 27 March 2014 
Finox  
Biotech 
Abasaglar® 
insulin  
glargine 
- Diabetes mellitus 
09 September 
2014 
Eli Lilly 
Lantus® 
Sanofi- 
Aventis 
Lusduna® 
04 January 
2017 
Merck 
Sharp & 
Dohme 
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Benepali® etanercept 
- Ankylosing  
  spondylitis           
 - Psoriasis                                
- Psoriatic arthritis                     
- Rheumatoid  
  arthritis                              
14 January 
2016 
Samsung 
Bioepis 
Enbrel® Pfizer 
Inhixa® 
enoxaparin 
sodium 
- Venous  
  Thromboembo- 
  lism 
05 September 
2016 
Techdow 
Europe AB 
Clexane 
Sanofi- 
Aventis 
Thorinane® 
05 September 
2016 
Phar-
mathen 
S.A. 
Truxima® rituximab 
- Chronic lympho- 
  cytic  leukaemia                               
- Granulomatosis  
  with polyangiitis  
  and microscopic  
  polyangiitis                              
- Non-Hodgkin’s  
  lymphoma                         
- Rheumatoid  
  arthritis             
Initial  
authorization  
15 December 
2016 
Celltrion MabThera® Roche 
Amgevita® / 
Solymbic® 
ada-
limumab 
- Rheumatoid  
  arthritis  
- Juvenile idio- 
  pathic arthritis  
- Axial spondyloar- 
  thritis  
- Psoriatic arthritis 
- Psoriasis  
- Pediatric plaque  
  psoriasis  
- Hidradenitis  
  suppurativa 
- Crohn's disease  
- Ulcerative colitis 
- Uveitis  
Initial  
authorization 
26 January 
2017 
Amgen Humira® AbbVie 
 
October 2014, the European Medicines Agency (EMA) defined biosimilar medicinal products as 
follows (CHMP/437/04 Rev 1): “A biosimilar is a biological medicinal product that contains a version 
of the active substance of an already authorized original biological medicinal product (reference 
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medicinal product) in European Economic Area (EEA). Similarity to the reference medicinal product 
in terms of quality characteristics, biological activity, safety and efficacy based on a comprehensive 
comparability exercise needs to be established.” (European Medicines Agency (i) 2014, 4.) 
The European Commission has noted that biosimilars have observed enhanced price competition 
from the original biologics, leading to cost savings for patients, healthcare systems and payers, 
potentially improving patient access to these treatments. Many governments have, or are in pro-
cess, enacting legislation to allow for the regulation and licensing of biosimilars with intend to re-
duce healthcare expenditures while preserving the quality of patient care. Competition in the market 
resulting from the introduction of cost-effective biosimilars will save the EU several billion euros 
annually and when biosimilar monoclonal antibodies are included, potential savings are even 
greater. (Kurki 2015; Olech 2016, S2; Medicines for Europe (b) 2016, 9; Research Advocacy Net-
work, 47, accessed 25 January 2017.) 
At the moment, uptake of biosimilars in the EU varies widely between countries and therapeutic 
areas. Of global spending on biosimilars, Europe accounts for 80 percent. (Ekman et al. 2016.) 
5.4.1 Biosimilar is not a generic 
Biosimilars cannot be considered generics. The active substance of biosimilar is demonstrated to 
be similar to its originator, but due to complex nature and production in living systems, it is not 
feasible to exactly duplicate the approved originator biologicals. Generics, on the other hand, are 
chemically synthesized small-molecules and are considered to be chemically identical to their ref-
erence product. (Heinemann et al. 201, 510; Olech 2016, S3, S4.) 
The regulatory pathway pursued to demonstrate equivalence is longer and more complex for bio-
similar than for generics. The requirements for marketing authorization of a generic (identical chem-
ical structure, dosage formulation, route of administration and bioequivalence) is not generally suf-
ficient for biosimilars.  Instead biosimilars must undergo head-to-head comparison with the origina-
tor at every step during development to ensure high similarity in physicochemical and functional 
characteristics, as well as safety and efficacy (figure 10). (Heinemann et al. 2015, 511; Olech 2016, 
S3, S5.) 
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5.4.2 Regulatory pathways of biosimilars 
Biosimilar regulatory pathways have been established around the world to provide an abbreviated 
route for biosimilars. The European Medicines agency (EMA) pioneered the development of regu-
latory framework for the development and approval of biosimilars in 2005. In 2009, the World Health 
Organization (WHO) issued global guidelines, “Guideline on evaluating of similar biotherapeutic 
products”, generally following similar principles and requirements to those of the EMA, in attempt 
to harmonize regulations worldwide. For example, Japan, Korea, Canada, Australia and New Zea-
land have issued guidance documents and regulations that are generally in line with either WHO 
or EMA regulations (figure 8). At the moment, regulations vary substantially across countries, but 
many countries are striving towards harmonization of accepted criteria, such as those set forth by 
the EMA, FDA and WHO. It should also be noted that in some countries, synthetic copies of brand 
compounds have been approved without comparative clinical studies with the originator.  Develop-
ing countries have long-treated copies of biologics primarily as generic equivalents and in many of 
these market, these underregulated copies of some biologics have been manufactured and even 
marketed as biosimilars. (Heinemann et al. 2015, 510 – 511, 523; Olech 2016, S7 - S8.) 
 
 
FIGURE 8. Global overview of availability of biosimilar regulatory pathways (adopted from Olech 
2016, S8) 
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5.4.3 Development of a biosimilar medicine 
Pharmaceutical company, which plans to develop a biosimilar, has several advantages. Primacy 
structure, i.e. the amino acid sequence, and expected biological activity of the originator are known. 
Company can acquire the reference product to analyze its composition and assess it in detail struc-
turally and functionally and is able to analyze batch-to-batch variation (figure 9). It has also access 
to a wide range of real world clinical data of the original biologic product, licensed and marketed for 
many years, and has therefore a large body of knowledge of safety and efficacy available. The 
historical data available helps to determine what evidence and which studies are required for the 
biosimilar candidate. Also, regulators, responsible for deciding whether a biosimilar candidate is 
comparable, have extensive knowledge of the original reference product and have often access to 
information which is not publicly available. Biosimilar manufacturer has no access to the complex 
production and purification techniques used for the reference product and thus must develop its 
own manufacturing processes (figure 9). (Heinemann et al. 2015, 510; Mora 2015, 952; Olech 
2016, S5.) 
Biological medicinal products manufacturing processes are likely to be modified several times 
throughout their life cycle and thus, originator biological products are not anymore identical to the 
original version at the time of marketing authorization. Therefore, pre- and post-change version of 
the biological product needs to be demonstrated to be comparable through a comparability exercise 
to ensure that quality, efficacy, and safety are not adversely affected. Over the past decades of 
biotechnology developments, regulators and manufacturers have accumulated extensive experi-
ence in assessing the impact of such changes. When a new version of the biological product is 
approved, it is expected to have the same efficacy and safety in all therapeutic indications. ICH 
Q5E is an internationally agreed standard intended to assist in the collection of relevant technical 
information and provide principles of the comparability of biotechnological and biological products 
before and after changes are made in the manufacturing process for the medicinal substance or 
medicinal product. The scientific principles of a biosimilar comparability exercise are based on 
same standard, ICH Q5E, except that the testing is much more extensive (figure 9). (Ekman et al. 
2016; European Medicines Agency (i) 2014, 4; European Medicines Agency (a) 2005, 3 – 5; Fimea 
(k) 2015, 1; Kurki et al. 2013, 208; Weise et al. 2014, 3191.) 
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FIGURE 9. Biosimilar development stages (Medicines for Europe (b) 2016: 23; T3DB, accessed 
24 January 2017; mAbxience, accessed 24 January 2017; GE Healtcare Life Sciences, accessed 
24 January 2017) 
All existing EMA quality guidelines for biologicals are also applicable to biosimilars and thus the 
same quality requirements apply for biosimilars as for any biological medicinal products. The bio-
similar specific EU guidance is quite extensive. There is a guideline which gives the general prin-
ciple relevant to all biosimilars, below that, two general guidelines dealing with biosimilar biotech-
nology-derived proteins (one for quality, other for non-clinical and clinical issues) and below those 
are product-class-specific guidelines for the non-clinical and clinical requirements. (Table 4) 
 
TABLE 4. EMA guidelines for biosimilars (Kurki et al. 2015, 650, 652). 
Guideline Main topics Cover 
Overarching guideline - Definition of a biosimilar Biosimilars in any biological product class 
CHMP/437/04 Rev 1 - Reference medicinal product 
  - General requirements for demonstration  
  of biosimilarity 
General guidelines - Biosimilar physicochemical and structural  
  comparability exercise 
Quality, non-clinical and clinical aspects of 
biosimilars for biotechnology-derived pro-
teins - Stepwise development of the non-clinical 
  program 
- Comparability of human  
  pharmacokinetics 
- Pharmacodynamic studies 
- Clinical efficacy and safety studies 
- Post-marketing risk management 
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Product-class-specific 
guidelines 
- Non-clinical comparability Made for product-classes: somatropins,  
filgrastims, epoetins, insulins, follitropins, 
alfa-interferons, beta-interferons,  
monoclonal antibodies,  
low-molecular-weight heparins 
- Comparable pharmacokinetics 
- Pharmacodynamic markers and  
  surrogates 
- Recommended study designs and clinical  
  endpoints 
- Special safety issues, including  
  immunogenicity 
5.4.3.1 Reference product (original biologic medicinal product) 
Originally the EMA stated that the biosimilarity exercise must be conducted with a reference product 
authorized in the EEA. The updated guideline on similar biological medicinal products 
(CHMP/437/04 Rev 1) has made also possible to use non-EEA-authorized reference products 
when the aim is to promote global development of biosimilars and avoid unnecessary clinical trials. 
In this case, certain clinical and in vivo non-clinical studies may be alternatively conducted with 
non-EEA-authorized reference products if both scientific justification is provided and bridging stud-
ies are performed. The Non-EEA-authorized reference product will need to be authorized by a 
regulatory authority with similar scientific and regulatory standards as EMA (e.g. ICH countries). 
Bringing data between the proposed biosimilar, the EEA-, and the non-EEA-authorized products 
should always include a 3-way analytical comparison (structural and functional data) and may also 
include a 3-way pharmacokinetic (PK) and/or pharmacodynamic (PD) comparison. (European Med-
icines Agency (i) 2014, 5 – 6; GaBi Online 20 January 2017 (a); Olech 2016, S6.) 
5.4.3.2 Comparability to establish biosimilarity 
Development process for both originator biological products and biosimilars involve analytical, non-
clinical and clinical testing (figure 10). Originators must establish patient de novo and require ex-
tensive clinical trials to demonstrate efficacy and safety. The goal of biosimilar is not to re-establish 
patient benefit per se, but to prove that its safety and efficacy are comparable with the originator 
biologic’s (reference biological medicinal product) and therefore, clinical trials efficacy endpoints 
differ from those requested for an innovative product. (Mora 2015, 953; Olech 2016, S4 – S5.) 
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FIGURE 10. Comparative EMA requirements for biosimilar studies vs. studies defined for generics, 
original biological medicinal product and biologics after manufacturing changes (post-production 
change), API* = Active Pharmaceutical Ingredient (adopted from Mora 2015, 951) 
For a new innovative biological product with new active substance, the applicant should demon-
strate acceptable quality, non-clinical pharmacology and toxicology (figure 10). Also, human phar-
macokinetics and pharmacodynamics, safety and efficacy need to be studied in all indications (fig-
ure 10). To establish that a biosimilar meets the requirements for biosimilarity, EMA require a rig-
orous, stepwise biosimilarity assessment, with each step building on previous step (figure 11). A 
biosimilar has to demonstrate similarity to the reference biological product in terms of quality char-
acteristics, biological activity, pharmacokinetic profile, safety and efficacy based on comprehensive 
comparability exercise (figure 10, figure 11). The goal of comprehensive comparability exercise is 
to exclude any relevant differences between the biosimilar and the reference medicinal product. 
After the comparability has been demonstrated, the holder of the marketing authorization of the 
biosimilar can refer to the documentation of the reference product. EMA speciﬁes that intended 
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changes to improve efﬁcacy (biobetters) are not compatible with the biosimilarity approach, and 
“differences that could have an advantage as regards safety (for instance lower levels of impurities 
or lower immunogenicity) should be addressed, but may not preclude biosimilarity’”. (Ekman et al 
2016; European Medicines Agency (i) 2014, 5 - 6; Kurki et al. 2015, 651; Olech 2016, S5.) 
 
FIGURE 11. The EMA development and approval pathway for biosimilars. A stepwise approach to 
demonstrate comparability between a biosimilar and the originator reference product (Kurki 2014, 
103; Kurki et al. 2013, 209 - 211; Kurki et al. 2015, 653 -656; Ekman et al. 2016) 
According to EMA guidelines, a confirmatory clinical trial may not be necessary if similar efficacy 
and safety can be clearly deduced from the similarity of physicochemical characteristics, biological 
activity/potency, and PK and/or PD profiles of the biosimilar and reference product and the impurity 
profile and the nature of excipients of biosimilar have not risen a concern. Also, EMA guidance 
states that if relevant differences are observed between a biosimilar and a reference product, it is 
unlikely that biosimilarity will be established and instead, a stand-alone development to support a 
full marketing authorization should be considered. (European Medicines Agency (i) 2014, 6 – 7.) 
5.4.3.3 Extrapolation of data 
Extrapolation of data has been an established scientific and regulatory principle that has been used 
for many years. For example, in the major changes in the manufacturing process of originator bio-
logical products, clinical data is typically generated in one indication and is extrapolated to the other 
indications, after the overall information gained from the comparability exercise has been taken in 
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to account. So far, the authors are not aware of any case where additional clinical studies with the 
changed product in other or even all approved indications have been provided by the marketing 
authorization holders, or have been considered by regulators. (Weise et al. 2014, 3192.) 
 
For biosimilars, clinical comparability is usually confirmed in randomized, preferably double-blind 
clinical trial(s). The selected therapeutic approach should correspond to one of the approved refer-
ence product’s therapeutic indications, suitable to detect potentially clinically relevant differences 
(figure 11). However, the originator biological products are often used in more than one indication. 
According to EMA’s guideline on similar biological medicinal products (CHMP/437/04 Rev 1), when 
biosimilar comparability has been demonstrated in one indication, extrapolation of clinical data to 
other indications of the reference product could be acceptable with adequate scientific justification. 
It should be kept in mind that biosimilars cannot automatically claim all indications of the reference 
product. Extrapolation is the foundation of the biosimilar regulatory framework and this tailored 
regulatory package allows biosimilars to be marketed at competitive prices. (European Medicines 
Agency (i) 2014, 5; Ebbers et al. 2016, 1; Kurki et al. 2015, 655; Weise et al. 2014, 3192.) 
 
The extrapolation is usually not problematic, if the relevant mechanism of action of the active sub-
stance and the target receptors involved in the tested and in the extrapolated indications are same 
and the selected therapeutic indication is representative of other therapeutic indications. Instead, 
when the mode of action is complex and involves multiple receptors or binding sites, the contribu-
tion of which may differ between indications or may not be well known, additional data need to be 
delivered. Also, extrapolation of immunogenicity data is not self-evident and always requires con-
vincing justiﬁcation. (Weise et al. 2014, 3192.) 
 
Several learned societies have taken the position that extrapolation of indications should not be 
allowed and clinical data should be required for all indications, despite the fact that no problems 
have been encountered with the extrapolated therapeutic indications of the current biosimilars in 
the EU.  (Ebbers et al. 2016, 2; Kurki 2015.) 
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5.4.4 Interchangeability and substitution of biosimilars 
Recommendations on interchangeability and substitution of biosimilars and originator biologicals 
are not included on EMA regulatory guidelines, but are regulated at the national level. Many coun-
tries in the EU have avert automatic substitution of innovator biologics with biosimilars, and for 
example Italy, Spain and the UK have enacted laws or introduced rules to prohibit the practice 
(figure 12). However, the Italian Medicines agency (AIFA) has stated that physicians should con-
sider prescribing biosimilars to treat naïve patients, if considerable healthcare savings are 
achieved. Dutch Medicines Evaluation Board (MEB) accepts interchangeability and switching be-
tween biologics (whether originators or biosimilars) is permitted when adequate clinical monitoring 
is performed and the patient is properly informed. MEB also recommends that detailed product and 
batch information should be recorded in the patient file so that the traceability of the product is 
guaranteed. France has been the pioneer in allowing to substitute a biosimilar for the prescribed 
(reference) biologic, under certain conditions. Substitution is allowed when initiating a course of 
treatment, if the biosimilar belongs to the same group as the prescribed product and the prescriber 
has not explicitly prohibited substitution. France was the first European country to explicitly permit 
a restricted form of biosimilar substitution. (GaBi Online 19 April 2013; GaBi Online 21 February 
2014; GaBi Online 1 June 2015; Olech 2016, S6) 
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FIGURE 12. Regulators approach towards automatic substitution issues (adopted from GaBi 
Online 1 June 2015) 
The US Food and Drug Administration (FDA) published in the Federal Register on 18 January 2017 
draft guidance on biosimilar interchangeability. In order to claim interchangeability, firstly biomilar 
has to be proven to be biosimilar to the reference biological product and secondly additional infor-
mation must be submitted. The additional information should show that the biological product can 
be expected to produce the same clinical result as the reference product in any given patient and 
also for a biological product administered more than once to an individual, the risk in terms of safety 
or diminished efficacy of alternating or switching between use of the biological product and the 
reference product is not greater than the risk of using the reference product without such alternation 
or switch. (GaBi Online 20 January 2017 (b)) 
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5.4.5 Position of FIMEA – interchangeability of biosimilars 
The current position of FIMEA is that EU biosimilars are interchangeable with their reference bio-
logicals under the supervision of a health care person. The patient should be informed of the 
change of medication and switch should be documented, including brand name and batch number. 
The announcement was made in May 2015. Automatic substitution at the pharmacy level is not 
included in Finnish Medicines Agency recommendation. (Ekman et al 2016; Fimea (k) 2015, 1, 3 – 
4.) 
 
The FIMEA position paper concludes that switches between biological products, for example in 
context of hospital tendering processes, are common and usually not problematic. In paper is men-
tioned that the switches between reference products and biosimilars have been commonly associ-
ated with hospital tendering in some EU Member States and no safety signals are associated with 
the switches in the European EudraVigilance data base for serious adverse effects. Also, the con-
ducted clinical crossover studies have not given evidence of adverse effects due to a switch from 
a reference product to a biosimilar (somatotropin, epoetin alpha, filgrastim, insulin glargine, inflixi-
mab). The risk of adverse effects is expected to be similar to the risk associated with changes in 
the manufacturing process of any biological products. (Ekman et al 2016; Fimea (k) 2015,3 – 4.) 
 
In Fimea position paper interchangeability is defined as follows: “the medical practice of changing 
one medicine for another that is expected to achieve the same clinical effect in a given clinical 
setting and in any patient on the initiative, or with the agreement of the prescriber.” (Fimea (k) 2015, 
1.) 
5.5 Pharma Industry Finland statement about biological medicines 
Lääketeollisuus ry (Pharma Industry Finland) comments that biological medicines have opened 
new possibilities for the treatment of many serious and chronic diseases and novel medicines also 
mean revised treatment practices. Lääketeollisuus ry has listed diseases in which most important 
biological medicines are used to treat. List includes diabetes by substituting for the body’s own 
insulin production, various cancers, difficult skin and joint diseases, asthma and inflammatory bowel 
diseases (IBD). (Lääketeollisuus ry (c), accessed 2 October 2016) 
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Biological medicines are normally administered as infusions or injections to remain their effective 
and efficient, but the administration of biomedicines is undergoing development to simplify the 
methods. Lääketeollisuus ry states, that pharmaceutical industry’s major aim is to be able to crys-
tallize the large-molecule biological pharmaceutical substances and turn the injectable solutions 
into orally administered tablets and this way help to transfer the treatments from hospitals to homes. 
Pharmaceutical development has been possible to lighten the healthcare structures, when wards, 
and even entire hospitals, have been replaced by treatments given in outpatient care. 
(Lääketeollisuus ry (c), accessed 2 October 2016.) 
 
Lääketeollisuus ry sees that biological medicines might seem expensive if only price is considered. 
They argue that the medicine is inexpensive and efficient if all the societal impacts are taken into 
the calculations. Through biological pharmacotherapies the patients gain additional working years, 
costs of the invalidity pension and sick leave are reduced and also because therapies work faster, 
less hospital beds are needed. Lääketeollisuus ry states the cost-effectiveness perspective should 
be taken, when using biological medicines. (Lääketeollisuus ry (c), accessed 2 October 2016.) 
5.6 Biosimilar pricing 
Biosimilars can lead to significant savings, but because biosimilar medicines have a more sophis-
ticated and costly development program, those cannot offer the same price reductions as generic 
medicines. While generic medicines are estimated to cost 2 - 5 million dollars to develop and take 
2 – 3 years to produce, are biosimilars development costs much higher, 100 - 200 million dollars, 
and take longer to produce, 8-10 years (figure 13). Despite of this, the absolute price difference for 
expensive originator biopharmaceuticals can be substantial between biosimilar and originator prod-
ucts. For example, it’s been estimated that a 20 percent price reduction of 5 off-patent biopharma-
ceuticals would save the EU 1.6 billion euros annually and the US federal government 9 - 12 billion 
dollars over the next 10 years. (European Commission (c) 2015, 4; Weise et al 2012, 5115.) 
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FIGURE 13. Development time and cost of biologics, biobetters, biosimilars and generics (OP-
TUM 2016; Pharmaceutical Research and Manufacturers of America: Key Facts) 
The hospital markets, through tenders, have received dramatic price discounts, but at the same 
time the discounts through the retail distributions have remained fixed and limited. For example, for 
erythropoietin and filgrastim, which price discounts at hospital level were an 85 percent on brand 
price, retail market discount was only an average of a 30 percent. In EU, some countries have set 
biosimilar prices at a fixed percentage below the price of the reference biological. In Spain, the 
mandatory discount is 30%, in Italy at least 20%, in Austria 40–70% and in France 15%. (Creativ-
Ceutical 2012, 73; Fuhr et al 2015.) 
Biosimilar infliximab (Remsima/Inflectra) was launched in March 2015 in the UK. There, a 100 mg 
vial of Remicade costs 419,62 British pounds and the list price of a 100 mg vial of Remsima and 
Inflectra is only 377,66 British pounds. The NHS (National Health System) has further negotiated 
lower prices for the biosimilars and discount has approached 50 percent of the cost of the originator 
medicine, Remicade, price. (GaBi Online 7 October 2016; GaBi Online 5 February 2016.) 
 
In France, the price of medicines is negotiable in the hospital setting and for example for filgrastim, 
the discount is currently more than 90%. In French hospitals, this has led to the widespread and 
almost exclusive use of biosimilars. By contrast in the outpatient setting (community pharmacies), 
the price of reimbursed medicines is fixed and concerning biosimilar filgrastim and epoetin alfa, the 
discount is far less than that obtained in hospitals, being only 10–15% of the reference product’s 
price. (GaBi Online 2 September 2016.) 
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National tendering has decreased infliximab prices in Norway. In 2014, the Norwegian Medical 
Agency published the hospital tender prices for the biosimilar infliximab’s, Inflectra being offered at 
a 33% discount and Remisima offered a 39% discount over the Remicade tender price (45 % dis-
count compared with the Remicade list price). Remsima was chosen because it provided the gov-
ernment the lowest priced product. In 2015, prices were further reduced, being 69 percent lower 
than the reference product tender price (72 % compared with the Remicade list price). This made 
biosimilar infliximab the preferred bDMARD for all six indications when initiating a bDMARD or 
switching to a TNF-infliximab in naive patients. In the Norwegian tender for 2016, biosimilar inflixi-
mab was still the cheapest alternative, price difference being about 60 percent lower than Remi-
cade. Also, biosimilar version of etanercept (Benepali) was offered with 47 percent lower price 
compared to regular price of reference etanercept (Enbrel) and as of May 2016, etanercept biosim-
ilar has garnered 40 percent of overall market share. (Collins 2016; Dörner et al. 2016, 2, 5; Fuhr 
et al. 2015; GaBi Online 13 March 2015; Mack 2015; Welch 2016.) 
 
In Norway, biosimilar epoetin and filgrastim have high discounts in hospital tender prices, up to 89 
%. The discounts for use outside of hospitals are lower than tender discounts, around 50 % for 
filgrastim and even lower for epoetin, around 25 %.  Somatropin is not included in any tenders in 
Norway. The prices for biosimilar somatropin has varied 18-29 % below the average for the origi-
nator’s somatropin. (Mack 2015.) 
 
Biosimilar version of Lantus (insulin glargine), Abasaglar, entered to Finnish markets in November 
2015. The price of Abasaglar was set 22 percent lower than the reference product. Infliximab bio-
similar has had similar discounts in Finland than introduced in Norway. In May 2016, Council for 
Choices in Health Care in Finland (COHERE Finland) gave its recommendation of biosimilars. It 
recommends that biosimilars are included in the publicly funded healthcare services, according to 
the principles of the overall economy. Also, on the basis of government proposal HE 184/2016, a 
set of amendments, intended to create savings to public medical costs in Finland, have been intro-
duced in the Finnish Health Insurance Act (1224/2004). The amendments entered into force on 1 
January 2017. The New Health Insurance Act involves price regulation concerning biosimilars. In 
order to increase the use of and price competition between biological medicines and biosimilars, 
the suggested reimbursable price for the first biosimilar entering the reimbursement system cannot 
exceed 70 percent of the list price of the original biologic. Also, the list price of the reference med-
icine will be re-examined, after the biosimilar is launched (Choices in Health Care 2016; Fimea (g); 
Finlex 2016; GaBi Online 13 March 2015; Kela (b) 2016, 3.) 
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5.6.1 Price differences between biosimilar and originator medicines in Finland 
In Finland, first recorded biosimilar sales are from year 2008, when biosimilar versions of somatro-
pin and erythropoietin got sales (IMS Health June 2016, 9,13). In beginning of 2017, the price 
differences between biosimilar and reference product (biosimilar less expensive) vary between 
therapeutic areas quite hugely, 4% - 43% (table 5). Omnitrope, the oldest biosimilar had lowest 
difference in price when compared to its reference product Genotropin and highest difference was 
seen between Remsima and Remicade. Of the EEA countries, Finland, along with Norway, was 
one of the few countries able to launch biosimilar infliximab in Q4 2013, and managed to have sales 
at same year (IMS Health November 2015, 9; IMS Health June 2016, 16). Loss of exclusivity in 
most countries in the EEA occurred as late as February 2015 (IMS Health November 2015, 9). It 
should be noted that Infliximabs (Remicade, Remsima, Inflectra) are sold only to hospitals in Fin-
land, and hospital discounts are not included here.  
 
Biosimilar filgrastim’s (Ratiograstim, Zarzio, Nivestim, Accofil) reference product Neupogen (for 
dosages 30MU, 48MU) has no price available, but as seen in table 5, prices of biosimilars vary 
also. For example, 30MU Ratiograstim price is 299,96€ and Accofil 222,87€. First recorded biosim-
ilar filgrastim sales are from year 2009 (IMS Health June 2016, 11). 
 
Eprex has lost its reimbursement, but both biosimilar versions of erythropoietin’s (Binocrit, Retacrit) 
are reimbursed. Slight price difference can be seen between biosimilars, and price difference grows 
when dosage increases. (Table 5) 
 
Abasaglar’s price is 16 percent lower than its reference product (Lantus) price (table 5). It has been 
reimbursed since February 2016 (Vuorisalo 2015).  In Finland, first recorded Abasaglar sales are 
from year 2015 (IMS Health June 2016, 21). 
  
TABLE 5. Biosimilar products marketed in Finland (January 2017). Originator biological medicine 
price is price of the company which is the holder of the marketing authorization (table 3). The prices 
shown are based on price notifications submitted by pharmaceutical companies. The Price column 
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shows the retail price including value-added tax (VAT). If a product is not reimbursable, the phar-
maceutical company can price it freely (Kela (a), accessed 31 January 2017) 
Name of  
biosimilar  
product 
Price of biosimilar, 
€ 
Reim-
bursabil-
ity 
Reference 
product 
Price of  
reference product, 
€ 
Reim-
bursabil-
ity 
Price difference, 
% 
(biosimilar less 
expensive) 
Omnitrope® 
635,18/5x5mg 
(Cartridge) 
Special Genotropin® 
663,93/5x5mg 
(powder for  
concentrate) 
Special 4 
Binocrit® 
113,99/6x2000IU 
(syringe) 
Special 
Eprex® 
173,12/6x2000IU 
(syringe) 
No 
34 
Retacrit® 
113,99/6x2000IU 
(syringe) 
Special 34 
Binocrit® 
211,51/6x4000IU 
(syringe) 
Special 
309,72/6x4000IU 
(syringe) 
No 
32 
Retacrit® 
215,73/6x4000IU 
(syringe) 
Special 30 
Binocrit® 
307,05/6x6000IU 
(syringe) 
Special 
449,08/6x6000IU 
(syringe) 
No 
32 
Retacrit® 
315,03/6x6000IU 
(syringe) 
Special 30 
Binocrit® 
403,68/6x8000IU 
(syringe) 
Special 
582,27/6x8000IU 
(syringe) 
No 
31 
Retacrit® 
414,51/6x8000IU 
(syringe) 
Special 29 
Binocrit® 
483,60/6x10 000IU 
(syringe) 
Special 
669,79/6x10 000IU 
(syringe) 
No 
28 
Retacrit® 
513,57/6x10 000IU 
(syringe) 
Special 23 
Ratiograstim® 
299,96/5x30mu 
(syringe) 
Special 
Neupogen® Not available 
Not avail-
able 
Not available 
Zarzio® 
296,51/5x30mu 
(syringe) 
Special Not available 
Nivestim® 
268,00/5x30mu 
(syringe) 
Special Not available 
Accofil® 
222,87/5x30mu 
(syringe) 
Special Not available 
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Ratiograstim® 
469,62/5x48mu 
(syringe) 
Special Not available 
Zarzio® 
466,10/5x48mu 
(syringe) 
Special Not available 
Nivestim® 
436,00/5x48mu 
(syringe) 
Special Not available 
Accofil® 
349,99/5x48mu 
(syringe) 
Special Not available 
Inflectra® 
567,31/100mg 
(powder for  
 concentrate) 
No 
Remicade® 
793,18/100mg 
(powder for  
concentrate) 
No 
28 
Remsima® 
457,41/100mg 
(powder for  
 concentrate) 
Special 42 
1303,56/3x100mg  
(powder for  
concentrate) 
No 
2298,90/3x100mg 
(powder for  
concentrate) 
No 43 
Bemfola® 
103,64/300iu  
(prefilled pen) 
Basic 
Gonal-f® 
145,39/300iu  
(prefilled pen) 
Special 29 
151,80/450iu  
(prefilled pen) 
Basic 
209,48/450iu  
(prefilled pen) 
Special 28 
Abasaglar® 
55,95/5x100u  
(prefilled pen) 
Special Lantus® 
66,51/5x100u  
(prefilled pen) 
Special 16 
 
Table 5 does not include all dosages available in Finnish market, just the ones which biosimilar and 
reference product have common. 
5.6.2 Price reductions following the launch of biosimilar 
Price reductions (for originators as well as biosimilars, i.e. accessible market) have varied consid-
erably between EU5 countries and therapeutic areas. In Italy and Germany, the observed price 
reduction for EPOs, following the introduction of biosimilar competition varied hugely, being lowest 
in Italy, 10 % and highest in Germany, 56 %. For G-CSFs, price reduction has been highest in 
Spain, 41 % and lowest in UK, 5 %. For Anti-TNF, the price reduction was really mild in 2015, 
varying between 0 % to only 10 % and also the uptake of biosimilar infliximab’s has been low in 
EU5 countries. (Figure 14.) It should be noted, that highest price reduction may not be same as the 
lowest price (IMS Health June 2016, 4). 
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Same trend which is seen in EU5 countries can also be seen in Nordic countries (Finland, Sweden, 
Norway and Denmark). Price reduction for EPOs ranged from 12 % in Denmark to as high as 41 
% in Norway, being in Finland 34 %. The price reduction of filgrastim medicines, was in 2015 lowest 
in Finland 31 % and highest in Norway 56 %.  Infliximab price reduction was mild in Finland and 
Sweden, only 10 %, and differentiates from Norway, where reduction was much higher, 48 %. 
(Figure 14.) As will be mentioned later, the hospital tender discounts for infliximab have been much 
higher in Finland than discounts seen in list prices (infliximab is hospital-only product in Finland) 
and hospital discounts are not included here. 
One exception in price reduction can also be seen in figure 14. In Germany, the rise can be seen 
in somatropin average price, 3%, since launch of biosimilar version. 
 
FIGURE 14. Price changes per treatment days (%) across the medicine class (biosimilar accessible 
market) for HGH, EPO, G-CSF and anti-TNF in Nordic and EU5 countries in 2015, following the 
launch of the biosimilar versions. Price development is calculated as price per TD 2015 compared 
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with price in the year before the first biosimilar medicinal product was launched. Prices are a volume 
weighted ex-manufacturing price averages, without taking into account rebates or discounts (IMS 
Health June 2016, 8 - 14,16, 24; Appendix 13) 
Biosimilars are expected to increase price competition and reduce prices of biological medicines. 
Biosimilar competition in therapeutic areas of EPOs, G-CSFs, HGHs and Anti-TNF show a con-
sistent reduction in average prices in European Economic Area countries (figure 15). The increased 
competition has affected, not only the price of reference products, but also price of the whole prod-
uct class. Price competition might also have similar impact on the total therapy area price as it has 
on the biosimilar/reference products price (IMS Health June 2016, 4). 
 
 
FIGURE 15. Price changes per treatment days in 2015 (%) in European Economic Area (EEA) 
countries. Price development is calculated as price per TD 2015 compared with price in the year 
before the first biosimilar medicinal product was launched (IMS Health June 2106, 3 - 4, 8- 14, 
16, 24; Appendix 13) 
In Finland, a consistent reduction in prices can also be seen in different therapeutic areas. Reduc-
tion in prices in Finland has been comparable or even slightly higher than average price reduction 
in EEA countries. (Figure 16.) 
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FIGURE 16. Price reductions (%) in Nordic and EEA countries (HGH, EPO, G-CSF and Anti-TNF 
products). Price development is calculated as price per treatment days (TD) 2015 compared with 
price in the year before the first biosimilar medicinal product was launched (IMS Health June 
2016, 4, 9, 11, 13, 16; Appendix 13) 
5.6.3 Lower prices increase patient access? 
In Finland, Norway and Sweden Biosimilar and the Reference product volume of EPO, G-CSF and 
Anti-TNF products have increased compared the year before their first biosimilar medicinal prod-
ucts were launched (figure 17). The Biosimilar and Reference product volume increase of EPOs 
has been highest in Finland,1033%, same time the full accessible market volume has decreased 
48 % (only shorter acting EPOs) and total market volume has increased 2 % (shorter and longer 
acting EPOs). For example, in renal anemia in 2011, the share of patients with longer acting eryth-
ropoiesis-stimulating agents was 72 %, while shorter acting EPOs accounted only 28 % of the 
patients (Kastarinen et al 2013, 2768). Same trend can be seen with cancer patients, of which 66 
% of all patients use longer acting EPO and only 34 % are using shorter acting agents (Kiviniemi 
et al 2013, 10). 2012, biosimilar EPOs accounted little under 30 % of total short acting epoetin 
consumption (DDD) and little over 5 % of total erythropoiesis-stimulating agent’s consumption 
(Kastarinen et al 2013, 2769). Even though biosimilar EPOs are not used much and total consump-
tion on erythropoiesis-stimulating agents is shifted to longer acting EPOs, still the price reduction 
in total market of EPO analogs has been 21 % and in biosimilar accessible market 34 % in 2015 
compared to year before the first biosimilar version of Eprex (shorter acting EPO) was launched 
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(figure 16, Kela (b) 2016, 3). The same pattern can also be seen in Sweden and Norway, both in 
volume and price (figure 16; figure 17). 
 
FIGURE 17. Volume development of EPO, G-CSF and Anti-TNF products in treatment days com-
paring 2015 versus the year before the first biosimilar product was launched in Nordic and EEA 
countries (IMS Health June 2016, 8 - 11, 13, 14 – 16, 24; Appendix 13) 
With G-CSF medicinal products, Biosimilar and Reference product volume has increased in Finland 
61 %, which is less than average increase, 99%, in EEA countries. Sweden has highest increase 
216%. In Biosimilar accessible market (only shorter acting G-CSF agents) Finland differentiates 
from Norway and Sweden where consumptions have increased 36 % and 187 % and in Finland it 
has instead decreased 58 %. Of the total market volume (shorter and longer acting G-CSF agents), 
highest increase has been in Norway 115 % while the increase in Finland was lower, 41 %. (Figure 
17.) In Finland, longer acting G-CSF agent pegfilgrastim has clearly the highest consumption of G-
CSF medicinal products in 2015. Its hospital consumption has decreased from 16 % in 2012, to 7 
% in 2015 (Fimea (d), 33). Shorter acting filgrastim consumption has done vice versa, hospital 
consumption has increased to 97 % compared to 2012 when it was just 33 %. (Fimea (d), 33). 
Same pattern can be seen with G-CSF agents than with EPOs. Short acting G-CSF agents (includ-
ing biosimilars) are not used much compared to longer acting agents and total consumption on G-
CSF agents is shifted to longer acting agents (Kela (b) 2016, 3). Still the price reduction in total 
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market of G-CSF analogs has been 12 % and in biosimilar accessible market 31 % in 2015 com-
pared to year before the first biosimilar version of Neupogen (shorter acting G-CSF) was launched 
(figure 16). 
 
In all Nordic countries, Anti-TNF agent’s Biosimilar and the Reference product consumption, Bio-
similar accessible market consumption and total market consumption have increased compared 
the year before the first biosimilar medicinal products was launched (figure 17).  Same time price 
reduction has occurred in all Nordic countries, in biosimilar accessible market as well as total Anti-
TNF market (figure 16). In Finland consumption of infliximab has increased 2013 – 2015 from 0,60 
DDD/1000 inhabitants/day to 0,89 DDD/1000 inhabitants/day (Fimea (d), 34). Biosimilar version of 
infliximab was launched 2013. 
 
Even if biosimilar product does not end to be the product sold, it may generate a more competitive 
environment, which leads to lower prices. Reduced prices may increase patient access to the same 
molecule and/or expand access to other medicines. Also, lower prices make possible in hospitals 
to treat more patients with in the existing budget of the respective medicine program. 
5.7 Penetration of biosimilars in Nordic and EU5 countries 
In the EU, uptake of biosimilars varies widely between therapeutic areas and countries mainly be-
cause of differences in the healthcare systems between different countries. Eastern Europe is lead-
ing the way in biosimilars penetration, maybe driven by economic factors. Acceptance of biosimilars 
has been dependent on the attitude of physicians, patients, pharmacists, third-party payers and 
policymakers. (Ekman et al. June 2016; GaBi Online 17 August 2012.) 
 
In Nordic countries biosimilars have higher penetration of G-CSFs and EPOs than for human 
growth hormones. In 2015, biosimilar EPOs accounted for 90 - 100 % of market (biosimilar + ref-
erence product) in treatment days, while somatropin biosimilar accounted only 25 – 33 % in Nor-
way, Sweden and Finland, Denmark being exceptional with 96 % market share. (Figure 18.) 
 
Filgrastim market is also dominated by biosimilars in Nordics. Biosimilar market share was highest 
in Finland, 97 % and lowest in Norway, 84 % (figure 18). In Finland originator, reference product 
Neupogen, lost its reimbursement in March 2013 (Apteekkari 2012), which explains the high market 
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share of biosimilar filgrastims in Finnish market. Beginning of 2017, there is only one Neupogen 
dosage in market, 0,3mg/ml solution for injection (Kela (a), accessed 31 January 2017). 
 
In United Kingdom (UK), first biosimilar version of the Neupogen was launched in November 2008. 
After the launch, a number of Strategic Health Authorities opted to reassess their existing guidance 
of the use of G-CSF-medicines. The updated guidelines reflected the improved cost-effectiveness 
of biosimilar filgrastim versus alternative treatments. As a result of this, G-CSF was moved to first-
line cancer treatment. The impact was that the overall uptake of filgrastim (originator and biosimilar) 
increased markedly, which was seen in the period between January 2009 and January 2014, when 
overall consumption of filgrastim short-acting increased by 104%. The launch of biosimilar filgrastim 
enabled a greater number of patients to be treated with filgrastim therapy in a more cost effective 
manner than before. Also, biosimilar filgrastim enabled greater number of patients to access these 
treatments at an earlier stage of the therapy cycle. In 2015 biosimilar filgrastim markets share was 
in UK, 98 %.  (Figure 18; IMS Institute for Healthcare Informatics March 2016, 9.) 
 
In Sweden’s Southern Healthcare Region, regional authorities eased restrictions on prescribing 
filgrastim due to the launch of biosimilar filgrastim and the associated reduction in treatment costs 
for patients receiving G-CSF therapy for febrile neutropenia. Before introduction of biosimilar fil-
grastim, the agreement of three physicians was required to commence treatment with the originator 
product. After the launch of biosimilar filgrastim, individual physicians were permitted to prescribe 
the biosimilar version without the assent of other medical professionals. Because of this, uptake of 
G-CSF increased five-fold in the Southern Healthcare Region, driven by usage of biosimilar fil-
grastim. In Sweden, market share of biosimilar filgrastim was, in 2015, 93 % (figure 18). (IMS Insti-
tute for Healthcare Informatics March 2016,14.) 
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FIGURE 18. Biosimilar market share %, in Nordic and EU5 countries in 2015. Market share is 
number of biosimilar treatment days (TD) as a share of reference + biosimilar product volume. EPO 
(epoetin alfa, epoetin zeta), G-CSF (filgrastim), HGH (Genotropin, Humatrope and Omnitrope) and 
anti-TNF (infliximab). Market share TD (treatment days) is calculated in treatment days/DDDs (IMS 
Institute for Healthcare Informatics March 2016, 3, 9, 11, 13, 16, 23) 
In the beginning of 2015, the market share of infliximab biosimilar versus reference biological med-
icine (Remicade) was low in Finland, but in 2016 situation in Denmark, Norway and Finland has 
changed dramatically (market share over 90 %), after originator medicine (Remicade) treatments 
were nearly totally switched to biosimilars (Inflectra/Remsima) (figure 18, figure 19, Welch 2016). 
Denmark launched biosimilar version of Remicade over one years later (February 2015) than Fin-
land and Norway (September and December 2013) (Danish Medicines Agency February 2016, 6; 
Fimea (j); Mack 2015). Because infliximab is only in-hospital treatment in Finland, the purchasing 
periods of hospital districts have partly affected the uptake of biosimilar infliximab. Purchasing pe-
riods vary from two years to four years depending of the district (table 6). There are tough excep-
tions mentioned in invitations for tender which may allow hospital pharmacies to terminate the ex-
isting contract, when biosimilar enters to Finnish market and if market situation is expected to 
change essentially (HUS apteekki 2015, 8). These exceptions may help biosimilars enter hospital 
markets quicker, if the discount of the biosimilar is low enough to cause high enough reduction in 
price level of the medicine. This might accelerate biosimilar medicine’s access to hospital markets 
in future. 
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FIGURE 19. Biosimilar infliximab (Remsima/Inflectra) uptake in Nordic countries and United King-
dom (UK) (adopted from Troein 28 April 2016, 8; Troein 17 May 2016) 
Compared to Denmark, penetration of biosimilar infliximab has been low in EU5 countries, being 
lowest in France, 4 % and highest in Spain, 13 % (figure 18). This is even though EU5 countries 
launched biosimilar infliximab at same time with Denmark, February 2015 and first recorded sales 
are also in all countries from 2015 (IMS Health June 2016, 16; GaBi Online 20 March 2015). For 
example, in UK, market share was 2015 only 9 % of reference product, and February 2016 it has 
increased only up to 30 % despite the fact that UK has one of the highest market shares of generics 
in Europe (figure 18, figure 19, GaBi Online 29 April 2016). The British Society of Gastroenterology 
(BSG) did not recommend switching in their 2014 guideline, which was stating that “for patients 
already on therapy, avoidance of switching from parent drug to biosimilar, or vice versa, at least 
until we have safety data” (BSG 2014). BSG updated their guideline in February 2016, year after 
launch of biosimilar infliximab, and is now recommending that “patients who are in a stable clinical 
response or remission on Remicade therapy can be switched to Remsima or Inflectra at the same 
dose and dose interval. This should be done after discussion with individual patients, with expla-
nation of the reason for switching” (BSG 2016). NHS England (National Health Service), has made 
efforts to improve the uptake of biosimilars in the UK. In September 2015, the NHS launched a 
‘What is a biosimilar’ briefing, in collaboration with industry and regulatory partners (GaBi Online 
29 April 2016). This document provided an update for key clinical and non-clinical stakeholders 
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about the developing role of biosimilar medicines in the NHS in England and support the safe, 
effective and consistent use of all biological medicines, including biosimilar medicines, to the benefit 
of patients (GaBi Online 29 April 2016; NHS 2015, 5). Also, NICE (National Institute for Health and 
Care Excellence) has published guideline on January 2016, covering seven biologicals, abatacept, 
adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and tocilizumab (GaBi Online 
5 February 2016). The NICE recommendation will lead to increased use of biosimilar infliximabs, 
Inflectra and Remsima, due to their lower price compared to the originator infliximab, Remicade 
(GaBi Online 5 February 2016). 
5.7.1 Uptake of biosimilar infliximab and etanercept in Denmark 
In Norway and Denmark, physicians have been at the heart of the decision-making process in 
relation to biosimilar medicines. In these countries, the uptake of biosimilar infliximab has been 
rapid and sustained and demonstrates that a key component of ensuring the longer-term sustain-
ability of the market is the trusting and empowering physicians to make the right decisions. (IMS 
Institute for Healthcare Informatics March 2016,18.) 
For example, in Denmark biosimilar infliximab Remsima covered about 98 percent of infliximab 
consumption in the third quarter of 2016. The biosimilar infliximabs received their marketing date 
of authorization in Denmark in the beginning of 2015 (Inflectra February and Remsima March 
2015).  It seems that Danish regions have followed the Council for Use of Expensive Hospital Med-
icines (RADS) recommendations to switch Remicade treatments to Remsima. It is noteworthy that 
total consumption of infliximab has increased 2015 and did continue to do so also in 2016 (figure 
20). Total consumption increase is caused by RADS’ guidelines for biological treatment in the field 
of rheumatology and gastroenterology, in which infliximab (Remsima) appears as first-line product. 
In Denmark infliximab medicines are used only in hospitals. Also, Ministry of Health in Denmark did 
set up an action plan in partnership with the Danish Medicines Agency (DKMA) on “Biological Med-
icines, Biosimilars and Vaccines for 2015 – 2016”, after patients’ organizations had approached 
the Ministry of Health with their concerns regarding of biosimilar information available. The aim of 
the action plan was to ensure targeted and product-specific monitoring of biologicals. One purpose 
was also to raise patients and patient organizations awareness on biosimilarity through targeted 
information and have physician targeted communication activities. (Danish Medicines Agency Feb-
ruary 2016, 6; Danish Medicines Agency November 2016, 5, 6; Lunddahl 2016.) 
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FIGURE 20. DDD consumption of infliximab medicines in Denmark, broken down by Remicade 
and Remsima between Q1 to Q4 2015 and Q1 to Q3 2016 (adopted from Danish Medicines 
Agency November 2016, 5) 
Another example from Denmark is etanercept-biosimilar uptake. Benepali came to Danish market 
February 2016 and already in Q3 2016, Benepali accounted 77 percent share of etanercept con-
sumption (figure 21). In the RADS’ guideline for patients treated with etanercept, new patients and 
patients whose other biological treatment has failed, should be treated with the cheapest version 
of medicine (Benepali), excluding children, because there is no low-dose formulation available. 
Also, patients who are stable on etanercept treatment should be switched to the cheapest version 
of the medicine, if there are no exceptional individual concerns. Consumption data shows that re-
gions have switched originator Enbrel to biosimilar Benepali in line with the RADS’ guidelines. 
Etanercept medicines can be used in hospitals and in specialist practices in Denmark. (Danish 
Medicines Agency November 2016, 6.) 
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FIGURE 21. DDD consumption of etanercept medicines in Denmark, broken down by Enbrel (orig-
inator product) and Benepali (biosimilar product) between Q1 to Q3 2016 (adopted from Danish 
Medicines Agency November 2016, 6) 
5.7.2 What slows down uptake of biosimilars 
Several factors have influenced to the penetration of biosimilars. Different stakeholder groups, such 
as physicians, patients, and payers, have all increasingly important role to play as the biosimilars 
market develops (figure 22). 
 
 
FIGURE 22. Factors influencing the uptake of biosimilars 
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Biggest problem, which has slowed down uptake of biosimilars, has most likely been lack of 
knowledge of biological medicines and biosimilars. Without understanding the life cycle/history of 
biological medicines, the understanding what biosimilars are and why study requirements differ 
from originators is challenging. Also, the biosimilar information given for payers, physicians, pa-
tients, patient organizations, and key decision makers has not been consistent due to fact that 
originator and biosimilar companies have approached the subject from the perspective which 
serves their purpose. Biosimilar companies might have, in the beginning, concentrated too much 
to price difference, and did not educate properly what biosimilarity is. Health authorities should 
have had more recourses in the beginning with their educations for patient organizations, physi-
cians and payers and this way all stakeholders would have received more objective information 
about biosimilars. Health authorities should be responsible for providing unbiased, continuously 
updated information on the use of biosimilars. 
 
Merikoski and Enlund have studied the introduction and use of biological medicinal products in 
Finland. During the study, Oncologists were already using biosimilar product and Rheumatologists 
were in the position where first biosimilar monoclonal antibody was entering market. Physicians 
were willing to use biosimilars, especially if cost savings could be achieved and efficacy, safety and 
quality of the product can be guaranteed. Some did think biosimilars were different medicines and 
other considered those to be equivalent to originator medicines. Also, others considered biosimilars 
as interchangeable and same time some doubted their efficacy and safety. Many of the comments 
were cautious and physicians wanted to have more information and practical experience. Uncer-
tainties of biosimilar products were related to research processes and manufacturing processes, 
the country of manufacture and quality of the product. The physicians yearned more objective in-
formation relating to basics of biosimilars and their studies. (Merikoski et al. 2016, 66 – 69.) 
 
Even though physicians have expressed their need for real-world-data, their willingness to partici-
pate biosimilar studies and their success in recruiting patients to those, has not been high. The 
reasons might be the lack of innovation for biosimilar medicines, and the limited opportunities to 
publish on innovative research. Those reasons may remove an invaluable center of influence for 
the transition from branded biologic to a biosimilar medicine during the commercialization period. 
This is especially relevant within academic research centers in Western Europe and in the United 
States, where the need for professional and institutional recognition is marked (Rompas et al 
2015,134). 
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Extrapolation of indications has been one issue with biosimilars. For example, biosimilar infliximab 
has studies for rheumatoid arthritis (phase III) and ankylosing spondylitis (phase 1) patients and 
did not have clinical studies for IBD-patients in time of approval of marketing authorization. Still 
biosimilar version of infliximab received all the same indications than originator product. This made 
gastroenterologists cautions with IBD-patients and many wanted to wait until more data and expe-
rience of the biosimilar version is available. Norway did fund clinical studies in which patients’ treat-
ments were switched from originator biological medicines to biosimilars. However, there was some 
speculation that the NOR-SWITCH study did actually slow the adoption of biosimilar infliximab in 
Norway (Mack 2015). 
Switching originator biological medicine to biosimilar has been big issue. Data on reverse, multiple 
and cross-switching among biosimilars were lacking as well as switching originator to biosimilar 
and reverse and many physicians were reluctant to start switching without evidence. EMA has not 
issued guidance on biosimilar interchangeability or substitution. Many countries in the EU have 
avert automatic substitution of innovator biologics with biosimilars and some countries have en-
acted laws or introduced rules to prohibit the practice. Also, several learned societies have pub-
lished recommendations and position papers advising prescribers to refrain from using biosimilars 
in therapeutic indications that have not been studied in clinical trials. One concern, for example, 
with biosimilar infliximab was that tender period changes may cause reverse switching or switching 
to another biosimilar and that raised for example concerns of immunogenicity. However, published 
switching data of Lantus to Abasaglar (biosimilar Lantus) did not convince physicians of switching 
either and uptake of Abasaglar has been slow in Finland. One issue of switching Lantus to its 
biosimilar has been different prefilled pen. Abasaglar has prefilled KwikPen-pen and Lantus has 
SoloStar-pen (SPC (a, c), accessed 27 February 2017). Though it would be interesting to know 
than how many Lantus users are also using rapid-acting Humalog, which has same KwikPen-pen 
as Abasaglar (SPC(b), accessed 27 February 2017).). 
 
In the beginning, the biosimilar companies have not been necessarily perceived as pharmaceutical 
companies (for example Samsung Bioepis). Biosimilar companies might have had smaller organi-
zations and less money to spend to marketing compared to bigger and well-established originator 
companies with much bigger organizations and much more money to spend to protect their origi-
nator product. This has led to situations of which originator companies have been able to “domi-
nate” the market with their information while biosimilar companies have not had same potential to 
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use. Situation is thought now changing, after global big companies have also entered to the bio-
similar market. For example, Pfizer completed its acquisition of Hospira on September 2015. Hos-
pira was the world’s leading provider of injectable drugs and infusion technologies and a global 
leader in biosimilars (Hospira 2015). Also, Amgen has large biosimilar pipeline, including for exam-
ple adalimumab, trastuzumab, rituximab and infliximab (Amgen (b), accessed 21 February 2017). 
It is very exciting to see, how companies which are competing with biosimilars and originators in 
same therapy area, will position their educational information about biosimilars. 
 
In addition to the development of new products, manufacturers of originators and biosimilar medi-
cines may differentiate their products by offering value-added services, like patient support or make 
device enhancements. Also, originator companies are developing second-generation biologics that 
offer improvements over their older products (for example new formulations and different dosing 
regiments). These products do compete with biosimilars for market share and payer’s, patient’s, 
and prescriber’s willingness to switch to these next generation biologics rather than to biosimilars 
depends of the biosimilar’s safety, efficacy, convenience, and cost and not just relative to originator 
products, but also to the next-generation biologics. Also, how payers structure the relative reim-
bursement incentives of new generation products will affect the competition. In Finland for example, 
Toujeo (next generation product of Lantus) reimbursement was limited 1.1.2017, so that a limited 
basic or special reimbursement is available for the product and will be granted if patient has had 
repeated or severe hypoglycemia during glargine insulin treatment (Lantus/ biosimilar Abasaglar) 
(Kela (c) 2016). Thought patients’ whose Toujeo-treatment was started end of 2016 with special 
refund category 103, could continue with special rate of reimbursement without having to make 
new application for reimbursement (Kela (c) 2016). 
 
Price difference between biosimilar and originator product should be high enough to awake interest 
of different stakeholders. The estimated price reduction of biosimilar has not been as low than with 
generics, because of their higher manufacturing and development costs. Price reduction varies in 
different product classes and across countries and in the EU, biosimilars have been typically 15-
30% cheaper. Though, much higher price reductions have been seen in hospital tenders and this 
has possibly affected the biosimilar penetration rates, which have been much higher in hospitals 
than in retail sector in different therapy areas. If the price reduction is not substantial, price compe-
tition will not occur and either payers, physicians or patients will not see the benefit of biosimilar. 
The question is, what is substantial price difference and does it vary between hospital-only and 
reimbursed medicines or between therapeutic areas (number of patients treated with originator 
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product, original price of reference product, total cost of treatment etc.). Also, it might be, that the 
total cost of biological originator medicine is not seen substantial, especially in smaller hospitals 
and hospital districts where number of patients may be small, and because of that possible cost 
savings are also not seen substantial. 
 
The biosimilar medicine might have entered to market after the standard of care has evolved. Man-
ufacturers of second-generation products might have had the ability to shift the standard of care 
paradigm and convert patients to an improved molecule, for example towards the use of longer 
acting products, which have limited the need for biosimilar medicines. 
 
When physicians are at the heart of decision-making the uptake of biosimilars has been much 
higher and faster. In Norway for example, the role of the Norwegian Drug Procurement Co-opera-
tion (Legemiddelinnkjøpssamarbeidet, LIS) is critical and physicians are afforded a central role in 
the decision-making process. LIS is responsible for organizing tenders for the procurement of med-
icines for state hospitals and LIS’ evaluation panels are comprised of physician experts and repre-
sentatives from all four of the country’s healthcare regions. In the LIS model, physicians take into 
account a range of clinical- and cost-related factors, when deciding to award a tender to a particular 
product. In addition, as state hospitals are funded via a DRG-system (Diagnosis-Related Group), 
which includes the cost of the medicines, hospital physicians are able to observe the benefits of 
the reduced costs associated with biosimilar medicines. This incentive and the trust of hospital 
physicians to the LIS evaluation system, helps further drive biosimilar uptake. In Denmark, the 
Council for the Use of High-Cost Hospital Medicines (RADS) has a similar role than LIS in Norway. 
(IMS Institute for Healthcare Informatics March 2016, 20.) 
 
The problem might have been, that physicians have not necessarily been shared what has been 
done with the money saved with biosimilars or what will happen the money if they start to use 
biosimilars. If physicians are able to take part of decision making, and information of the decision 
and its influence would be shared widely, the idea what society and/or hospital district, hospital, 
physician and in the end patient will benefit from using biosimilar (more treated patients, new inno-
vative medicine to use etc.), would possibly motivate the individual physician to initiate biosimilar 
treatments or even to switch stable patients (at least to some extent) to biosimilars. 
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5.8 Outcomes from the use of biosimilar medicines 
The introduction of biosimilar medicines has already had a significant impact on health care costs 
and patient care. Biosimilars present opportunities to payers, physicians and patients, including 
cost containment and increased availability of therapeutic options (figure 23). 
 
 
FIGURE 23. The outcomes from the use of biosimilar medicines 
Biosimilar competition in different therapeutic areas have showed a consistent reduction in average 
prices in European Economic Area countries. The increased competition has affected the price of 
reference products and as well as price of the whole product class.  
 
Biosimilars have the potential to lower costs and for example, in Nordic countries infliximab biosim-
ilar price has been up to 69 % lower than the reference product tender price. From the beginning 
of 2016, HUS, which is the largest district providing specialized medical care in Finland (table 6), 
estimated to achieve significant savings (several millions of euros) by switching the use of infliximab 
treatment mostly to Remsima (biosimilar infliximab), instead of originator product Remicade (HUS 
2015, 10). 2009 in Germany, approximately one third of prescriptions for the granulocyte colony-
stimulating factor (G-CSF) were for its biosimilar and using the biosimilar over the reference biologic 
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medicine resulted significant savings (Henry et al. 2014, S14). Also, in the United States, savings 
from biosimilars are estimated to range from 3,0 to 4,5 billion dollars annually (Henry et al. 2014, 
S14).  
 
Physicians, payers and patients are more aware what biological medicinal products are and objec-
tive biosimilar information provided by health authorities is more available and better targeted to 
different stakeholders compared to time, when first biosimilar were launched. For example, Fimea 
(Finnish Medicines Agency) has several publications explaining biosimilars and biological medi-
cines, including a plain language summary of biological medicines and biosimilars. 
 
Earlier and broader use of biologic medicines are seen in markets where biosimilar competition has 
occurred. As a consequence, biosimilar medicines support improved patient access to certain ther-
apeutic areas compared to the originator. Cost-related restrictions on prescribing of biologics might 
have been in place for the biologics and after biosimilars have accessed to market and their price 
has been lower the situation has changed. It can be argued that the launch of biosimilar G-CSF 
has led to improved patient outcomes, by enabling greater numbers of patients to access these 
treatments at an earlier stage of the therapy cycle. For example, in the United Kingdom, Germany, 
and the Netherlands, the availability of a lower cost biosimilar to G-CSF correlated with 10% to 
20% increased use of a G-CSF agent and G-CSF was used earlier in the course of therapy, result-
ing in a shift of its use as a secondary to primary prophylactic agent against febrile neutropenia 
(Henry et al. 2014, S14).  
 
Lower treatment costs of biosimilar vs. originator medicines has led to loosened usage/prescription 
controls in hospitals, leading to higher freedom of prescribing for physicians. For example, Southern 
healthcare region in Sweden relaxed restrictions on prescribing G-CSF for patients receiving G-
CSF therapy for febrile neutropenia after biosimilar launch and the associated reduction in treat-
ment costs. As a result, uptake of G-CSF increased five-fold in this region. Also, in 2008 NICE 
guidance did not recommend use of infliximab for the treatment of ankylosing spondylitis, but fol-
lowing launch of biosimilar infliximab, in new 2016 guidance NICE recommends infliximab in this 
indication in case the treatment is started with the least expensive infliximab product (NICE 2008; 
NICE 2016, 4).  
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As more biosimilar medicines become available, there may be opportunities for manufacturers to 
improve packaging and administration methods for these medicines. For example, Zarzio (biosim-
ilar version of Neupogen) was the first G-CSF with an innovative automatic needle guard specifi-
cally designed for prefilled glass syringes (GaBi Online 2 August 2013). Sandoz was also the only 
company that provided ‘Patient Support Kit’ which allowed patients to administer the medicine at 
home instead of having to go to a clinic or hospital (GaBi Online 2 August 2013). 
 
Several learned societies have updated their recommendations and position papers lately. The 
European Crohn’s and Colitis Organization (ECCO) has published results of a consensus meeting, 
held October 2016. This statement marks a significant shift in attitude from the previous ECCO 
position statement, which advised switching from an originator biological medicine to a biosimilar 
to be inappropriate and emphasized lack of data and benefit of biosimilars in general. The updated 
ECCO statement is, by contrast, supporting switching from the reference infliximab to a biosimilar 
infliximab and recommending that switching from originator to a biosimilar should be performed 
following appropriate discussion between physicians, nurses, pharmacists and patients, and ac-
cording to national recommendation. (GaBi Online 27 January 2017.) The European Society for 
Medical Oncology (ESMO) published on January 2017 a position paper on biosimilars, saying that 
“biosimilars create opportunities for sustainable cancer care”. The paper covers several aspects, 
including switching and interchangeability, which should be permitted if the physician is well-in-
formed about the products, the patient is fully briefed by the physician and a nurse is closely mon-
itoring the changes and tracking any adverse events. The first biosimilar cancer medicines are 
expected to reach the European market during 2017. (GaBi Online 20 January 2017 (c).) In June 
2015, the Finnish Society for Rheumatology published a statement of the use of biosimilars in 
rheumatological therapeutical indications. It is stating that substitution at pharmacy level is not ac-
ceptable and the switch of an original medicinal product to a biosimilar should be based on a deci-
sion of the treating specialist and after patient is fully briefed. Also, “for patients who are treat-
ment naive regarding biologicals, either an original or a biosimilar can be initiated on the same ra-
tionale”. (The Finnish Society for Rheumatology 2015, 1.) 
 
Several countries have updated national and regional guidelines to recommend to start treatment 
with a more cost-effective option (biosimilar or originator product). Also, increasing number of coun-
tries have developed guidelines that specify standards for conducting economic evaluations to be 
included in reimbursement applications (Henry et al. 2014, S15). 
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5.9 Biosimilar medicine pipeline for four key original biological medicines 
A number of biosimilar players have emerged in the last few years, including innovative companies 
(Pfizer, Novartis, Boehringer Ingelheim), generics companies (Teva) and some companies with no 
prior pharmaceutical expertise who are moving into the biosimilar business (Samsung Bioepis, LG 
Life Sciences). The innovator companies like Pfizer and Amgen have one of the biggest biosimilar 
portfolios, but also, several Korean companies have entered to biosimilar market, like Samsung 
Bioepis and Celltrion. (figure 24.) 
 
 
FIGURE 24. Number of biosimilar products in registration, pre-registration and phase III (adopted 
from Troein 17 May 2016, 8) 
There were 41 biosimilar medicines in the pipeline for four key original biological medicines at the 
end of 2015 from multiple different pharmaceutical companies (figure 25). Of those Samsung Bio-
epis has received approval in the EU for its biosimilar etanercept, SB4 (refence product Enbrel) 
January 2016 and biosimilar infliximab, SB2 (reference product Remicade) May 2016.  
 
In December 2016, Celltrion received initial authorization for its biosimilar rituximab, CT-P10 (ref-
erence product MabThera) and Amgen received initial authorization for its biosimilar adalimumab, 
ABP501 (reference product Humira), in January 2017. Amgen applied for marketing authorization 
for its biosimilar adalimumab under two names, Amgevita and Solymbic. Humira has been block-
buster since 2005 and AbbVie announced 2016 sales to be 16 billion dollars worldwide and sales 
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increase 16,1 percent on an operational basis with last year (AbbVie 2017; Brennan (a) 2017). 
More than a dozen other companies are also developing biosimilar adalimumab’s, including 
Boehringer Ingelheim, Momenta Pharmaceuticals, Sandoz and a joint venture between Samsung 
Biologics and Biogen (Brennan (a) 2017, figure 25). 
 
Additional biosimilar products are also in development for other biologics like tocilizumab (reference 
product, RoActemra), golimumab (reference product Simponi), and abatacept (reference product 
Orencia). (IMS Institute for Healthcare Informatics March 2016, 10.) 
 
 
FIGURE 25. Biosimilar pipeline at the end of 2015 (adopted from IMS Institute for Healthcare In-
formatics March 2016, 11) 
The global biologic medicines market is projected to exceed 390 billion US dollars by 2020 and 
account for 28% by value of the total global pharmaceutical market. Therefore, biosimilars have an 
increasingly important role to play.  By 2020, biosimilars have the potential to enter markets for a 
number of key biological medicines, whose current sales account more than 40 billion euros. As a 
result of biosimilars, the cumulative potential savings for healthcare systems in the five major Eu-
ropean Union (EU) markets (i.e. EU5) and the U.S., could exceed 50 billion euros in aggregate 
over the next five years and reach as much as 100 billion euros. IMS study estimates that almost 
50 distinct biosimilars are currently in development and will likely result in a highly competitive 
marketplace over the next five years. (IMS Institute for Healthcare Informatics March 2016, 1.) 
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5.10 Challenge of high costs of medicines 
Pharmaceuticals have a vital role in the health system. The affordability and financing of new med-
icines challenges governments worldwide and policy makers are balancing the access of patients 
to new effective pharmaceuticals with limited health care budgets. At the same time policy makers 
should provide the right incentives to manufacturers to develop new generations of pharmaceuti-
cals.  (OECD 2015, 178; WHO 2015, 17.) 
 
In European countries policy makers consider the high prices of medicines be the main challenge 
of access to new medicines given the budgetary restraints they have. A special concern is, in the 
context or pursuing equitable and comprehensive health care and against the backdrop of the 
global economic crisis, ageing populations and the continuing increase in non-communicable dis-
eases, the continual introduction of new high-price medicines. Some health authorities are already 
struggling to fund new high-price pharmaceuticals and this has already led to situations where 
some pharmaceuticals, including pharmaceuticals providing important benefits, may not be availa-
ble at all, or not accessible to all patients who need them. The IMS Institute of Healthcare infor-
mation has predicted that worldwide pharmaceutical sales are 30% higher in 2018 than in 2013. 
The major contributor to pharmaceutical spending growth will continue to be specialty medicines. 
The reason to this is that there will be more specialty medicines which prices will be in very high 
levels and more patients need them. Specialty pharmaceuticals are novel drugs and biologic agents 
that require special handling and ongoing monitoring, are administered by injection or infusion and 
sold in the marketplace by a small number of distributors and are often considered part of the 
“personalized medicine” paradigm (right medicine to the right patient at right time).  (Hirsch et al. 
2014, 1714; OECD 2015, 40-41; WHO 2015, 17, 109, 112.)  
 
Consumption of medicines has increased and pushed pharmaceutical medicine spending up. Ris-
ing prevalence of chronic diseases, population ageing, changes in clinical practices (guidelines), 
coverage extension and new treatment opportunities have increased demand for pharmaceuticals. 
Recent years cost-containment policies and patent expiries of a many top-selling products have 
put pressure on pharmaceutical prices. Price pressure has resulted a slower pace of growth over 
the past decade.  Coming years’ proliferation of high-cost specialty medicines will be the driver of 
health care spending growth, expected to account for 50 percent or more of pharmaceutical spend-
ing growth in near future. Some of these medicines will bring benefits to patients and others will 
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have only marginal improvements of patient’s outcomes. According to standard thresholds, many 
of these medicines are not cost-effective.  (OECD 2015, 29-30, 34, 41.) 
 
Of the therapeutic areas, cancer has the highest expected spending growth due to the increasing 
incidence of cancer worldwide and new medicine approvals. Also, many orphan medicines approv-
als are expected in near future. (OECD 2015, 41.) 
5.10.1 Challenge of costs of biological medicines 
Increase in the cost of biological medicinal products continues to be strong compared to the cost 
of traditional medicines. Most biological medicines have been under patent protection, and have 
not therefore been under price competition which would have lowered their prices. In recent years, 
first patents of biological products have expired and biosimilars have become to the market. (HE 
2016, 10.)  
 
The increase in the number of clinical trials in the past five years is one indicator of the strong 
growth of biological medicines. The number of blockbusters, i.e. products with sales of more than 
US$1 billion per year, is another indicator. 2012 there were 33 blockbusters compared to 2006, 
when there were 20 blockbuster biologicals. (GaBi Online 31 January 2014.)  
 
The global biologic medicines market is estimated to exceed 390 billion US$ by 2020 and going to 
account up to 28 percent of the total market for pharmaceuticals, while 2002 sales were only 46 
billion US$ and share was 11 percent (figure 26). Biological medicines represent 27 percent of 
pharmaceutical sales in Europe and between 2012 – 2013 market has grown 5.5 percent in value 
sales compared to 1.9 percent of total market grew. Biologicals growth is driven by monoclonal 
antibodies (mAbs) and human insulin, with four out of the top five biologicals in 2012 being mAbs. 
(European Commission (c) 2015, 2; Baelen 2015; GaBi Online 31 January 2014; IMS Institute for 
Healthcare Informatics November 2013, 9.) 
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FIGURE 26. The biologics market. (Baelen 2015; IMS Health November 2013, 9; IMS Institute for 
Healthcare Informatics March 2016, 1) 
Biological medicines are often remarkably expensive due to the highly demanding manufacturing 
process, high drug development costs and significant therapeutic value. One of the main reasons 
for the high price however is the lack of price competition. (Fimea (l) 2014.) 
 
The high cost of biological medicines and reduced pharmaceutical budgets due to austerity 
measures mean that biological medicines are not accessible for all patients and they create finan-
cial challenges for healthcare systems. On the other hand, the entry of biosimilar medicines into 
markets, after biological originators’ patent expiries, continues to pave the way in providing a sus-
tainable supply of biological medicines across Europe. (European Commission (c) 2015, 2.) 
The importance of biological medicines is constantly growing and same time the relatively higher 
pharmaceutical expenses associated with biological medicines limit their use in hospitals, also im-
pacting their reimbursement status.  Lääketeollisuus ry sees that the biosimilars introduced to the 
market will launch a price competition that brings therapy costs down and this way may increase 
the opportunities to introduce novel medicines in hospitals, thereby contributing to their entry into 
the reimbursement system. (Lääketeollisuus ry (c), accessed 2 October 2016.) 
For example, biological medicines usage in Rheumatology has increased strongly in the 2010s. 
End of August 2009 Finnish national register for biologic treatment in rheumatic diseases (ROB-
FIN) had 3145 patients who had received biological medicine compared to end of year 2012 when 
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number was 5511. (Reumaliitto 2013.) National register for biologic treatment in rheumatic dis-
eases in Finland (ROB-FIN) is a nation-wide prospective cohort study aiming to provide observa-
tional data on safety, effectiveness and costs of biologic treatments in routine healthcare. (Dia-
GraphITAS, accessed 2 October 2016.) 
 
In Potilaan lääkärilehti (2014) is commented that biological medicine products are not new inven-
tions, because those have been on the market over thirty years. The use of the biological medicines 
is limited by high price, which is due the challenging production methods and lack of price compe-
tition. This is going to change with help of biosimilar products. (Nykopp J 2014.) 
 
The ten best-selling medicines in wholesale prices in Finland 2014 and 2015 are listed in figure 27. 
There were eight biological medicines in the list both 2014 and 2015. The first, second and fifth 
places in 2015 were claimed by the TNF-alfa inhibitors Humira (adalimumab), Enbrel (etanercept) 
and Remicade (infliximab), which are used for the treatment of rheumatoid arthritis, psoriasis and 
inflammatory bowel diseases. The best-selling antineoplastic agents in the list were Mabthera 
(rituximab), which is used for example, to treat lymphomas, Herceptin (trastuzumab), for example 
for breast cancer and Avastin (bevacizumab) for example for metastatic carcinoma of the colon or 
rectum with other antineoplastic agents. The best-selling antidiabetic medicines in the list were 
insulin Lantus (glargine) and Levemir (detemir). 2015 Cervarix (vaccine against certain types of 
cancer-causing human papillomavirus (HPV)) has drop out and Avastin (recombinant humanized 
monoclonal antibody) has taken its place in top ten. Total sales in wholesale prices of the top 10 
products were about 276 million euros and eight biological medicines sales were 233 million euros 
(figure 27). Total medicine sales in Finland 2015 was 2 958 million euros, of which hospital medi-
cines share was 19 %, 561 million euros (figure 35, figure 49). 2013 total sales of six of essential 
biological medicines was about 170 million euros, which was 8 % of whole year’s medical sales. 
(Fimea (b) 2016; Ministry of social affairs and health (g) 2016, 3 - 4; Lääketeollisuus ry (a), ac-
cessed 13 July 2016; Lääketeollisuus ry (b), accessed 13 July 2016; Talouselämä 2016.) 
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FIGURE 27. Top ten medicinal products in Finland in 2014 and 2015. Wholesale prices in million 
euros (Lääketeollisuus ry (a), accessed 13 July 2017; Lääketeollisuus ry (b), accessed 13 July 
2017) 
The link between gross domestic value, health expenditure and global medicine prices leads to 
large dissimilarities in affordability between countries and in the end, influence patients’ access to 
biologicals. In Central European countries, affordability was a relevant factor that impacted on bio-
logics access. (Laires et al. 2013, 883.) 
5.10.2 Examples of costs of new medicines 
Specialty pharmaceuticals have already transformed the pharmaceutical industry and the develop-
ment of pharmaceuticals has shifted towards those. Many of the latest breakthrough treatments, 
including treatments for cancer, rheumatoid arthritis, HIV and multiple sclerosis have been special 
pharmaceuticals. (Hirsch et al 2014, 1714.) 
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New medicines to treat cancer patients cost between 6 000 to 10 000 US$ per month. The cost of 
new cancer medicines has doubled over the past ten years without necessarily having a concomi-
tant improvement in survival. Requested prices for most new medicines launched are likely to con-
tinue to rise due to fact that new cancer medicines are launched for targeted indications, manufac-
turers seek orphan status and associated high prices. Trastuzumab emtansine costs 90 000£ - 
185 600£ per course at an estimated cost per QALY (Qualite Adjusted life year). In Finland 
trastuzumab emtansine estimated total medicine cost is about 67 700 euros per patient. In the 
Hospital District of Helsinki and Uusimaa (HUS) the most expensive medications cost more than 
200 000 euros per year per patient. They have also estimated the cost of new medicines and for 
example medicine for chronic lymphocytic leukemia (obinutuzumab) could cost for five patients per 
year about 140 000 euros and a second-line treatment for lymphoblastic leukemia patients with 
poor prognosis (blinatumomab) could cost about 150 000 euros per patient. (Helsingin ja Uuden-
maan sairaanhoitopiiri 2016, 1; HUS 2015, 9; Härkönen et al. 2015 (a), 18; WHO 2015,14, 104.) 
 
There is about 170 million Hepatitis C patients in the world and in 2013 Finland registered to THL's 
Register of Infectious Diseases a total of 1 174 new hepatitis C cases.  One of the new medicines 
for hepatitis C, 12-week course of sofosbuvir, costs in the United Kingdom from 35 908£ to 71 816£ 
depending on genotype. Same treatment costs in Finland 50 940 €. In the United States sofosbuvir 
costs about 1 000 US$ per tablet equating to 84 000 US$ for a standard course. (WHO 2015, 112; 
Färkkilä 2014, 1813, 1816.) 
 
New orphan medicinal products are challenging health authorities. Typically, annual acquisition 
costs for these medicines are 200 000 – 500 000 US$ per patient per year. In the Netherlands, 
orphan medicine Myozyme, which is used to treat Pompe’s disease, the costs ranges between 
400 000€ to 700 000€ a year. There is also case of ultra-rare disease treatment which cost about 
one million $. The medicine was Glybera, heralded as the first gene therapy in the Western world, 
for lipoprotein lipase deficiency. Only one patient has received this treatment so far. (Kalliokoski et 
al. 2016, 2042; Regalado 2016; WHO 2015,15.) 
5.10.3 Patients access to biological medicines for Rheumatoid Arthritis 
Biological medicines have proved effective for the treatment of immune-mediated inflammatory 
diseases like rheumatoid arthritis (RA). These medicines are used rarely in first-line, because the 
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European League Against Rheumatism and many national guidelines recommend biological med-
icines for RA patients who fail to respond adequately to sDMARD (synthetic disease modifying anti-
rheumatism drug) treatment alone and partly due to high costs. Even as second-line therapy, all 
clinically eligible patients do not have access to biological medicines. (Gulácsi el al. 2015; Putrik el 
al. 2014, 199.)  
 
The access and use of biological medicines varies strongly between countries across World Health 
Organization European Region and seems to be associated with socio-economic development of 
the countries (figure 28). Administrative and financial restrictions have been identified as the most 
important barriers to a treatment with bDMARDs (biologic disease modifying anti-rheumatism 
drugs). Countries in Eastern and Central Europe have particularly poor access to bDMARDs. Also, 
limited access to bDMARDs in patients with RA might be associated with poorer health. A study 
from Putrik et al showed that the cost of annual treatment with sDMARDs never exceeded GDP in 
WHO European Region (included 46 countries), but cost for 1 year of bDMARD treatment ex-
ceeded GDP in 26 countries. (Gulácsi el al. 2015; Putrik el al. 2014, 198, 203.) 
 
 
FIGURE 28. Access to treatment with biologic disease modifying antirheumatic drugs and gross 
domestic product per capita in the European Region. Size of the bubbles is proportional to the 
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population size of the country. AL, Albania; AM, Armenia; AT, Austria; BA, Bosnia and Herze-
govina; BE, Belgium; BG, Bulgaria; BY, Belarus; CH, Switzerland; CY, Cyprus; CZ, Czech Re-
public, DE, Germany; DK, Denmark; EE, Estonia; ES, Spain; FI, Finland; FR, France; GB, the 
UK; GE, Georgia; GR, Greece; HR, Croatia; HU, Hungary; IE, Ireland; IS, Iceland; IT, Italy; KZ, 
Kazakhstan; LT, Lithuania; LU, Luxemburg; LV, Latvia; MD, Moldova; ME, Montenegro; MK, Mac-
edonia; MT, Malta; NL, Netherlands; NO, Norway; PL, Poland; PT, Portugal; RO, Romania; RS, 
Serbia; RU, Russia; SE, Sweden; SK, Slovakia; SL, Slovenia; TR, Turkey; UA, Ukraine; UK, 
United Kingdom (adopted from Putrik et al. 2014, 204) 
The cost-effectiveness and budget impact of expensive and innovative medications is a major topic 
of discussion in Western countries, but same time the implications of the unaffordability for low 
income countries has received limited attention. About 320 million people in the European Region 
(almost 40 % of the population) have severely restricted access to bDMARDs for the treatment of 
RA (figure 29). (Putrik el al. 2014, 203 – 204.) 
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FIGURE 29. Access to treatment with biologic disease modifying antirheumatic drugs in the Euro-
pean Region (adopted from Putrik et al. 2014, 205.) 
There is an analyze made of the role of biosimilars in reducing costs and increasing patient access 
to bDMARDs in rheumatology. The budget impact of switching patients to biosimilar infliximab for 
RA in the UK, Italy, France and Germany is estimated over 5 years to offer savings of €233 million 
for 20 percent discount and €433.5 million for 30 percent discount. An additional 7561 patients 
could be treated across these four countries and the Netherlands with a 30% discount, using med-
icine cost savings after 1 year of biosimilar infliximab. In Europe, 30 percent price discount for 
biosimilar infliximab, would represent cost savings of more than 530 million euros every year. With 
the 50 percent price reduction seen in Nordics could be achieved across the EU, the potential 
savings to reinvest could exceed 880 million euros annually. (Dörner et al. 2016, 5 – 6.) 
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European League Against Rheumatism had an update 2013 to its recommendations for use of 
DMARDs and bDMARDs, highlighting in their overarching principles that when prescribing these 
therapies, medicinal costs should be considered. Also, American College of Rheumatology 2015 
guidelines raised cost as an important issue. Rheumatologists will be at the forefront of the use of 
biosimilar monoclonal antibodies, in terms of recommendations for use, design and analyses of 
randomized controlled trials. (Dörner et al. 2016, 6.) 
5.11 Finnish hospital districts and University hospital catchment areas 
In Finland, health services are divided into primary health care and specialized medical care. Pri-
mary health care refers to the municipally arranged monitoring of the health of the population and 
are provided by some 160 local health centers. Municipalities may organize primary health service 
alone or form joint municipal authorities or they may also procure services from private service 
providers. Specialized medical care is performed in hospitals and refers to examinations and treat-
ments provided by medical specialist. (Ministry of social affairs and health (a), (b), (c), accessed 9 
January 2017.) 
For the organization of specialized medical care, Finland (mainland) is divided into twenty hospital 
districts (health care services on the autonomous Åland Islands are provided based on the Act on 
the Autonomy of Åland) and every municipality must belong to one of them. The Hospital District 
of Helsinki and Uusimaa (HUS) is the largest of the districts, providing specialized medical care for 
1,6 million residents and smallest is at Itä-Savo 43 thousand residents. Hospital districts plan and 
develop the provision of specialized medical care so that primary health care and specialized med-
ical care form an effective entirety. They coordinate and control quality of the municipal laboratory 
and imaging services, medical rehabilitation and other specialized services, research, develop-
ment, education and training as well as the harmonization of municipal health care information 
systems. In the hospital districts, university and central hospitals are responsible for the most de-
manding medical operations. The five university hospitals locate in Helsinki, Turku, Tampere, Kuo-
pio and Oulu. Some specialized medical care services are centralized on the national level to the 
university hospitals. For example, Helsinki University Hospital is responsible for organ transplants 
and children open heart surgeries. (Figure 30; Table 6; Ministry of social affairs and health (h) 2013, 
12; Ministry of social affairs and health (c), accessed 9 January 2017.) 
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All the hospital districts belong to one of the five university hospital catchment areas, HUCH, TUCH, 
TAUH, KUH or OUH (table 6). Catchment areas coordinate the provision of specialized medical 
care, information systems, medical rehabilitation and procurement (Ministry of social affairs and 
health (h) 2013, 12). 
 
TABLE 6. Number of Residents and member municipalities in Finnish Hospital districts and expert 
responsibility areas (ERA) (Kunnat.net (a), (c), accessed 10 August 2016; Havo 2013, 50) 
Abbreviation Hospital district  Member  
municipalities 
Residents  
(31.12.2015) 
Purchasing  
period/years 
HUS Helsinki and Uusimaa 
(Helsinki ja Uusimaa) 
24 1 616 321 2 
EK South Karelia 
(Etelä-Karjala) 
9 131 155 4 
KYM Kymenlaakso 
(Kymenlaakso) 
6 171 778 2 
 
HUCH catchment area, total 39 1 919 254 (No common  
purchasing period) 
 
       
P Pirkanmaa 
(Pirkanmaa) 
23 526 941  
EP South Ostrobothnia  
(Etelä-Pohjanmaa) 
 
18 197 371  
KH Kanta-Häme 
(Kanta-Häme) 
11 174 710  
PH Päijät-Häme 
(Päijät-Häme) 
12 212 465  
 
TAUH catchment area, total 64 1 111 487 2 
    
 
VS Varsinais-Suomi 
(Varsinais-Suomi) 
28 477 372  
S Satakunta 
(Satakunta) 
18 222 957  
V Vaasa 
(Vaasa) 
13 170 212  
 
TUCH catchment area, total 59 870 541 2 
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PS Pohjois-Savo 
(Pohjois-Savo) 
19 248 129  
ES Etelä-Savo 
(Etelä-Savo)  
9 103 278  
IS Itä-Savo 
(Itä-Savo) 
4 43 453  
KS Central Finland 
(Keski-Suomi) 
 
21 251 904  
PK North Karelia 
(Pohjois-Karjala) 
 
14 168 329  
 
KUH catchment area, total 67 815 093 2 
 
       
PP North Ostrobothnia 
(Pohjois-Pohjanmaa) 
 
29 407 160  
KAI Kainuu 
(Kainuu) 
8 75 324  
KP Central Ostrobothnia  
(Keski-Pohjanmaa) 
 
10 78 608  
L Lappi 
(Lappi) 
15 117 789  
LP Länsi-Pohja 
(Länsi-Pohja) 
6 63 069  
 
OUH catchment area, total 68 741 950 3 
     
 
Mainland Finland 297 5 458 325  
 Ahvenanmaa 
(Åland) 
16 28 983  
  Total 313 5 487 308  
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FIGURE 30. Hospital districts and university hospital catchment areas. University hospital locations 
are written in red, central hospital locations in black, hospital districts are abbreviated (table 6) and 
university hospital catchment areas are in colors (Finnish Medicines Medicines Agency Fimea and 
Social Insurance Institution 2016, 40; Kunnat.net (b), (d), accessed 10 August 2016) 
5.11.1 Health and social service reform 
In the next few years’ entire system of health and social services will be reformed in Finland. The 
need for this reform emerged from problems in ensuring equal and adequate social welfare and 
health care services to citizens in all parts of the county. Currently the organisation of health and 
social services is entrusted to hundreds of municipalities and joint municipal authorities and small 
and financially weak municipalities have encountered difficulties in organising and producing ser-
vices. In the reform, responsibility for providing social welfare and health care services is being 
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transferred to larger and hence stronger administrative entities and this way, even in remote areas, 
where a small municipality’s own resources would be inadequate, provision of service could be 
ensured. The Government has decided that in future health and social services will be organised 
by 18 autonomous counties and these services will be state funded. (Ministry of social affairs and 
health (h) 2013, 38, 39; National institute for health and welfare 2016.)  
 
Aim of the ongoing reform is to safeguard access to services, ensure regional and social equality 
across the country, integrate health and social services, and restrain the growth of health and social 
expenditure.  (National institute for health and welfare 2016.) 
5.12 Medicines Policy 2020 
The main objective of pharmaceutical service is to enable efficient, safe, rational and cost-effective 
pharmacotherapy for all those in need of it. The core values of medicines policy are responsibility, 
effectiveness, quality, equality, justice and economy defined as cost-effectiveness. (Ministry of So-
cial Affairs and Health (f) 2011, 5, 10.) 
 
Five main pharmaceutical policy objectives are presented in Medicines Policy 2020 document for 
coming decade: (Ministry of Social Affairs and Health (f) 2011, 9.) 
1. The pharmaceutical service constitutes a part of the social welfare and healthcare service sys-
tem. 
2. The pharmaceutical service is of high quality, efficient and cost-effective. 
3. Rational pharmacotherapies and good medication safety promote people’s wellbeing and public 
health, decreasing the healthcare expenditure. 
4. Pharmaceutical research has a positive impact on health, wellbeing and employment. 
5. Veterinary pharmaceutical services safeguard public health and promote the wellbeing of hu-
mans and animals. 
 
These five objectives are joint objectives for the social welfare and healthcare authorities and stake-
holders in the field of pharmaceuticals. (Ministry of Social Affairs and Health 2011, 9.) 
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5.12.1 Rational Pharmacotherapy Action Plan 
According to World Health Organization (WHO), medicine use is rational (appropriate, proper, cor-
rect) when patients receive the appropriate medicines, in doses that meet their own individual re-
quirements, for an adequate period of time, and at the lowest cost both to them and the community 
(Holloway et al. 2011, 2).  
 
In Finland, The Rational Pharmacotherapy Action Plan is listed into the Government Programme 
of Prime Minister Juha Sipilä. The objective is to improve the overall treatment and functional ca-
pacity of patients, and to create a framework for using pharmacotherapies that are cost-effective 
from the perspective of both the patient and society. An interim report will be published at the be-
ginning of 2017. (Ministry of Social Affairs and Health 2016 (d), (e).) 
 
The assessment includes medical treatment processes like, evaluation of the need of medical ther-
apy, the decision of the initiation of medical therapy, the choice of the medicine, delivery of the 
medicine from pharmacy or implementation of treatment in health care unit, the reimbursement 
costs of the medicines, patient education and informing, the use of the medicine and monitoring of 
medicinal treatment, treatment changes and stoppings. Also, structures of pharmaceutical supply 
in the new social and health system is one of the themes. Rational pharmacotherapy Programme 
also surveys a range of actions that could lead to medicine cost savings. (Ministry of Social Affairs 
and Health 2016 (e); Ruskoaho 2016, 20-21.) 
 
One of the subjects in the Governments Rational Pharmacotherapy Action Plan is to promote the 
adoption of biosimilars in Finland. The purpose is, without compromising the effectiveness of phar-
macotherapy for patients, to reduce the costs arising from biological medicinal products. The plan 
supports the implementation of planned legislative reforms in order to promote the adoption of 
biosimilars. The implementation of the plan is coordinated by Finnish Medicines Agency Fimea. 
(Fimea (c) 2016; Ministry of Social Affairs and Health 2016 (d).) 
 
It is possible that the introduction of biosimilars do not lead to the objective decline in the total cost. 
In this case, money saved could be used to other medicines, including new innovative medicines. 
If the prescribing of medicine is rational, patients will eventually receive the greatest benefit. (Fimea 
(g) 2016.) 
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5.12.2 Rapid Assessment of hospital-only medicinal products 
In Finland, a new medicinal product can only be sold after marketing authorisation is granted by 
the Finnish Medicines Agency Fimea or the European Commission. The efficacy, safety and ade-
quate quality of the medicine must be demonstrated in order to obtain a marketing authorisation. 
Demonstration of a medicines therapeutic and economic value is not a prerequisite. (Fimea (e), 
accessed 8 December 2016.) 
 
For adoption of new hospital medicines, Finland has not had so far uniform assessment and deci-
sion-making process. Between hospitals, there are considerable differences how the assessments 
are being carried out. Lack of national coordination has caused regional variation in use of medi-
cines and the adoption speed. Fimea is developing a rapid assessment of hospital medicines in 
cooperation with stakeholders. The aim is to standardize procedures related to adoption of hospital 
medicine and to promote the introduction of a regionally equal access to care. Fimea coordinates 
assessment activities, produces and publishes the assessment reports. The aim is to make out-
comes available as soon as the marketing authorization has been granted or receives a new indi-
cation. (Härkönen et al. 2015 (b), 46, 47; Fimea (e), accessed 8 December 2016.) 
 
For the pharmacotherapies under evaluation, assessments of the therapeutic and economic value 
focus on relative effectiveness, safety and economic aspects and when applicable social and ethi-
cal aspects are also accounted. With the help of the assessment process, health care total costs 
can be managed, and resources for new medicines can be targeted appropriately. The assessment 
takes into account costs related to medicinal products both on hospital's point of view as well as 
from the perspective of the society. (Fimea (e), accessed 8 December 2016; Härkönen et al. 2015 
(b), 47.) 
 
The aim is to consolidate the assessment activities in 2016 - 2017. At that time, as a rule, all new 
hospital-only medicines are to be evaluated with rapid assessment. That would allow to harmonize 
guidelines for adopting of a new medicine. 2015 -2016 Fimea has made eleven assessment reports 
focused on new hospital-only medicines. (Fimea (h), accessed 12 January 2016; Härkönen et al. 
2015 (b), 47.) 
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5.13 Health care expenditures in Finland compared to Nordic and EU countries 
Year 2014 total Finland’s health care expenditures were about 19,5 billion euros (figure 31). Com-
pared to 2013, health care expenditures increased real 0,6 percent. Pharmaceutical and other 
medical non-durables expenditures decreased real 0,1 percent compared to previous year. It 
should be noted that, the relationship between pharmaceutical spending and total health spending 
can be complex, because increased expenditure on pharmaceuticals to tackle diseases may re-
duce the need for costly hospitalizations and interventions now or in the future. (OECD 2011, 154; 
Matveinen et al. 2016, 1.) 
  
In 2014, specialized medical care (6,8 billion euros), primary care (3,8 billion euros), long-term care 
for the elderly and persons with disabilities (2,8 billion euros), as well as outpatient drugs and other 
medical consumer goods (2,4 billion euros) accounted for approximately three quarters of health 
care spending. (Matveinen et al. 2016, 1, 3-4.) 
 
Since 1.1.2016 statistics have been made according System of Health Accounts (SHA) 2011. 
Health spending measures the final consumption of health care goods and services, including per-
sonal health care and collective services, but excludes spending on investments. (OECD (b) 2016.) 
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FIGURE 31. Health care expenditures 2000 – 2014, at 2014 prices, million euros (Matveinen et al 
2016) 
Per capita, health care expenditures in Finland 2015 was 3 984 US$ (figure 32) and health care 
expenditures share of GDP (Gross Domestic Product) was 9,6 percent (figure 33).  Years 2013 
and 2014 health care expenditures share of GDP was 9,5 percent (figure 34). In 2015, per capita 
number was lowest in the Nordic countries but when comparing share of GDP in European union, 
Finland share was higher (9,6) than average in European Union (8,8 percent). At same year Nor-
way’s per capita expenditure was highest in the Nordics, 6 567 US$ (figure 32). 2015 in Nordic’s, 
health care expenditure percent of GDP was lowest in Iceland 8,8 percent and Sweden had highest 
in whole European Union 11,1 percent (figure 34). 
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FIGURE 32. Health care expenditures, US dollars/capita 2011 – 2015 (OECD (a) 2016) 
 
FIGURE 33. Health care expenditures % of GDP in European Union (28) 2015 (OECD (a) 2016) 
2015 an important factor behind the increase of Norway’s health care spending share of GDP was 
the fall in oil prices (Statistics Norway 2015). In 2014 health care expenditure share of GDP was 
9,26 percent and 2015 it increased to 9,94 percent (figure 34).  
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FIGURE 34. Health care expenditures, % of GDP 2011 – 2015 (OECD (a) 2016) 
5.14 Pharmaceutical expenditures in Finland 
In Finland, 2015, total sales of pharmaceuticals were about 3 billion euros (figure 35) and its change 
from previous year was 4,5 percent. Total sales include prescription medicines in outpatient care, 
sales to hospitals and OTC- medicines in outpatient care (Over the Counter medicines). 
 
2015 the best-selling medicine groups were antineoplastic and immunomodulating agents (500 
million euros at wholesale prices), medicines affecting the nervous system (360 million euros) and 
medicines affecting the alimentary tract and metabolism (292 million euros). When measured in 
terms of consumption, the most commonly used medicinal groups in Finland were cardiovascular 
system medicines, alimentary tract and metabolism products and medicines affecting the nervous 
system. The consumption of medicines in the statistics is as defined daily doses (DDD), assumed 
average maintenance dose per day for a drug used for its main indication in adults). (Appendix 2; 
Fimea (f) 2016; Finnish medicines agency Fimea and social insurance institution 2016, 31; 
Metveinen et al. 2016; WHO 2016.)  
 
2014 sale of prescription medicines in outpatient care in Finland was 68 percent of total pharma-
ceutical sales (figure 36), 1 978 million euros. Sale of medicinal products has increased in recent 
years, generally 2 – 3 percent each year. Most has increased the cost of higher special rate of 
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reimbursement categories (100%) medical costs due to new and more expensive drug therapies. 
In 2015 1 378 million euros was paid as reimbursement payments under the Health Insurance 
Scheme. Reimbursement payments were up 5,5 percent from previous year, which was more than 
in the six preceding years. (Finnish medicines agency Fimea and social insurance institution 2015, 
31; Ruskoaho 2016, 4; HE 2016, 47.)  
 
In the period 2009 – 2014 the medicine reimbursement costs increased moderately by a maximum 
of 3,3 percent per annum having also occasional decreases. This was due to retrenchments, of 
which some were focused on pharmaceutical companies and pharmacies and some increased 
patient’s deductibles. For example, medicine’s generic reference price system was introduced on 
2009 and at the same time, generic substitution was expanded to include medicines protected by 
methods patent. However, recently the reference price system's ability to promote price competition 
between products under the system has faded. Several significant medicine groups prices under 
reference price system have started to increase, for example groups of statins, other cardiovascular 
medicines, antacids and antipsychotics. It seems that price competition is no longer functioning as 
it should and government has made some proposals how reference price system could be intensi-
fied. In 2016, basic rate of reimbursement was increased from 35 percent to 40 percent and for 
pharmaceutical companies were set one-time 6,9 million euro’s refund.  In 2015 reimbursement 
payments were increased by the introduction of new, more expensive medicines for example med-
icines used for treatment of various cancers, diabetes, multiple sclerosis and rheumatoid diseases. 
The increase can also be partly explained by the fact that purchasers stocked up on medicines in 
late 2015 in preparation for the new initial deductible limit, adopted in the beginning of 2016.  (Finn-
ish medicines agency Fimea and social insurance institution 2015, 31; Ruskoaho 2016, 4, 5, 29-
30; HE 2016, 12.) 
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FIGURE 35. Total sales of Pharmaceuticals 2000 – 2014 in million euros. Retail prices (inclusive 
of tax) were used for calculating sales of medicines in the outpatient selling and wholesale prices 
were used for sales of medicines sold to hospitals (Appendix 1; Finnish medicines agency Fimea 
and social insurance institution 2010 – 2016; National Agency for Medicines and Social Insurance 
Institution 2008 -2009; Matveinen et al 2016) 
2014 sales of prescription medicines were 68 percent and other medical durable goods was 2,8 
percent of total pharmaceutical sales (figure 36). Compared to previous year, prescription medicine 
expenditures decreased 0,2 percent.  Sales of prescription medicines, self-medication and other 
medical durable goods correspond 12,3 percent of health care expenditures (Matveinen et al. 2016, 
4). 
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FIGURE 36. Total sales of pharmaceuticals 2000 – 2014, % (Matveinen et al. 2016) 
The majority of total medicine sales 2015 are caused by antineoblastic and immunomodulating 
agents (500 million euros, ATC-code L) (figure 37) and not supprisingly six out of ten best selling 
medicines in Finland were in these group, Humira, Enbrel, Mabthera, Remicade, Herseptin and 
Avastin (all biological medicines). The medicines affecting nervous system (313 million euros, ATC-
code N, exluding nicotine) and alimentary tract and metabolism medicines (292 million euros, ATC-
code A) are also in top three in sales (figure 37). Sales in the group of anti-infectives for systemic 
use increased most, 36 million euros i.e. 25%. However the consumption of these products 
increased only by 4%, compared to previous year. In this group, the sales of human normal 
immunoglobulin increased the most, i.e. by 20 million euros and sales of antivirals for systemic use 
increased by 11 million euros. Increase of sales in the group of anti-infectives for systemic use was 
caused by new  approved therapeutic indications to immunoglobulins and was seen especially in 
sales to hospital because immunoglobulins are most often used in hospital setting (84% of sales).  
Antivirals for systemic use medicine sales increased due the introduction of new medicines 
indicated for the treatment of HIV infection and hepatitis C. The sales of antineoplastic and 
immunomodulating agents increased at similar rate compared to last few years, by 9%, i.e. 39 
million euros.  Under this class of medicines the highest growth was seen in the group of 
immunosuppressants (includes for example TNF-a inhibitors), 14% i.e. 27 million euros. The 
second highest growth was in the group of antineoplastic agents, 8% i.e. 15 million euros,  in which 
the costs of monoclonal antibodies increased the most, by almost EUR 9 million euros (Finnish 
medicines agency Fimea and social insurance institution 2016, 31, 35 - 36.) 
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FIGURE 37. In 2015, distribution of medicine sales between pharmacies and to hospitals per the 
ATC-code, at wholesale prices (million euros). ATC-codes A: Alimentary tract and metabolism, B: 
Blood and blood forming organs, C: Cardiovascular system, D: Dermatologicals, G: Genito urinary 
system and sex hormones, H: Systemic hormonal preparations, excl. sex hormones and insulins, 
J: Antiinfectives for systemic use, L: Antineoplastic and immunomodulating agents, M: Musculo-
skeletal system, N: Nervous system, P: Antiparasitic products, insecticides and repellents, R: Res-
piratory system, S: Sensory organs, V: Various (Appendix 2) 
As clearly seen from figure 38, the most commonly used medicine group in previous years has 
been cardiovascular medicines (ATC-code C) 556,35 DDD/inhabitants/day. The two other com-
monly used medicine groups in 2015 were medicines affecting the alimentary tract and metabolism 
(ATC-code A), 296,32 DDD/inhabitants/day and medicines affecting the nervous system (ATC-
code N), 259,53 DDD/inhabitants/day (figure 38).  
 
The group of medicines which is biggest in sales, the antineoplastic and immunomodulating agents 
(ATC-code L), is one of the lesser used medicine groups. In 2015, consumption of this group of 
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medicines was 18,59 DDD/1000 inhabitants/day and it has increased from 2013, when consump-
tion was 17,16 DDD/1000 inhabitants/day (figure 38).  
 
 
FIGURE 38. 2013 – 2015, consumption of medicines. ATC-codes A: Alimentary tract and metabo-
lism, B: Blood and blood forming organs, C: Cardiovascular system, G: Genito urinary system and 
sex hormones, H: Systemic hormonal preparations, excl. sex hormones and insulins, J: Anti-infec-
tive for systemic use, L: Antineoplastic and immunomodulating agents, M: Musculo-skeletal sys-
tem, N: Nervous system, R: Respiratory system, S: Sensory organs, V: Various (Fimea (d), 1, 9, 
12, 18, 20, 24, 26, 32, 34, 37, 44, 45, 49, 50, accessed 14 November 2016) 
5.14.1 Pharmaceutical expenditures in Finland compared to Nordic countries 
In relation to the overall economy, 2014 pharmaceutical expenditures accounts for 1,4 percent of 
GDP on average in European Union countries. However, the dispersion around this average is 
high: pharmaceutical expenditures accounts for less than 1 percent of GDP in Norway and Den-
mark, while it reaches over 2 percent of GDP in Greece and Hungary (figure 39). Share of GDP in 
Finland was little less than average in European Union, 1,2 percent, but highest in Nordic countries 
(figure 39, figure 40). In most Nordic countries, pharmaceutical expenditures share of GDP has 
been stable in recent years, except Iceland (figure 40). In Iceland share of GDP have decreased 
during period 2011 – 2014 (figure 40). Iceland along with Norway and Denmark was among the top 
three expenditures of health before global financial crisis and the collapse of Iceland’s three biggest 
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banks 2008. After that health expenditure as share of GDP dipped. Pharmaceutical products are 
mainly imported to Iceland and during the financial crisis prices of pharmaceutical products in-
creased sharply because of a currency collapse. Since 2010 cost-containment strategies have 
achieved reduction in pharmaceutical costs and prices have come down even consumption of phar-
maceutical products have increased. This was achieved partly by prescribing more generics and 
use of reference pricing and by changing the cost sharing mechanism. (Sigurgeirsdóttir et al 2014, 
44, 155.) 
 
 
FIGURE 39. Pharmaceutical expenditures in European Union (28), % of GDP 2014 (OECD (b) 
2016) 
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FIGURE 40. Pharmaceutical expenditures in Nordics, % of GDP 2011 - 2014 (OECD (b), 2016) 
2014 highest pharmaceutical expenditures share of health care expenditures was in Iceland 12,6 
percent, which though last few years has decreased from 15,1 and was 2014 almost same with 
Finland which was 12,3 percent (figure 41). Lowest share of pharmaceutical expenditures was in 
Denmark 6,7 percent (figure 41).  
 
In Denmark, pharmaceutical spending decreased in real terms between 2009 and 2012 and was 
particularly pronounced in 2011 and 2012. Partly this reduction can be explained by the growing 
market share of generics, related to the patent expiration for some high-volume and high-cost phar-
maceuticals, and policies to promote the use of generics. (OECD 2014, 2.) 
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FIGURE 41. Pharmaceutical expenditures, % of health care expenditures 2011 - 2014 (OECD (b) 
2016) 
Highest pharmaceutical expenditures with US dollars per capita was 2014 in Iceland 490 US$ and 
lowest in Denmark 325 US$ (figure 42). Denmark has substantially lower per capita expenditures 
than other Nordic countries, Sweden had 489 US$, Finland 476 US$ and Norway 457 US$ (figure 
42). 
 
 
FIGURE 42. Pharmaceutical expenditures in Nordics, US dollars/capita 2011 - 2014 (OECD (b) 
2016) 
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5.14.2 Sales of antineoplastic and immunomodulating agents in Nordic countries 
In 2015, ATC-group C medicines (cardiovascular system) were most used in all Nordic countries 
when measured in DDD/1000 inhabitants/day. Use of ATC-group L agents (antineoplastic and im-
munomodulating agents) were in similar level in all countries. Iceland 17, Denmark and Norway 18, 
Sweden and Finland 19 DDD/1000 inhabitants/day. (Figure 43.) 
 
 
FIGURE 43. Sales of pharmaceutical products in total in Nordic countries by ATC group, 2015. 
Only ATC groups with WHO DDDs assigned are included (Nomesco 2016, 135) 
Sales of antineoplastic agents have been growing in all Nordic countries from 2010 to 2015 (sales 
statistic from Iceland were not available for 2005). In 2015, highest sales were in Iceland, 107 
thousand euros per 1000/inhabitants, and lowest sales in Sweden 32 thousand euros per 1000/in-
habitants. Finland had, in 2015, comparable sales to Norway and Sweden (32 thousand euros per 
1000/inhabitants), 35 thousand euros per 1000/inhabitants. (Figure 44.) 
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FIGURE 44. Sales of antinoeplastic agents (ATC-group L01) in Nordic countries, Euro per 
1000/inhabitants at 2015 prices (Nomesco 2016, 158) 
Use of TNF-alpha inhibitors has increase from 2010 to 2015 in all Nordic countries. Iceland and 
Norway are using TNF-alpha inhibitors most 4,2 and 4,1 DDD/1000 inhabitants/day. In 2015, Fin-
land used the least TNF-alpha inhibitors, 2,4 DDD/1000 inhabitants/day, compared to other Nordic 
countries but Finland’s figure was quite comparable with Sweden and Denmark, 2,8 and 2,7 
DDD/1000 inhabitants/day. (Figure 45.)   
 
 
FIGURE 45. Use of tumor necrosis factor alpha inhibitors (L04AB) in Nordic countries, DDD/1000 
inhabitants/day (Nomesco 2016, 159) 
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5.14.3 Country example: pharmaceutical expenditures in Norway 
In Norway, graded price model and “preferred medicines” introduced in some medicine groups 
have limited the cost increase in the period 2010 – 2013. 2014 – 2015 increase was higher due to 
the approval of new very expensive medicines e.g. for HCV, cancer and multiple sclerosis. (Figure 
46.)  
 
 
Figure 46. Pharmaceutical expenditures in Norway, billion NOK (Sakshaug 2016,15) 
In 2015, antineoplastic and immunomodulating agents (ATC-code L) were the largest group in 
terms of costs and cost increase was 7 percent.  This group has had gradual increase share of 
total sales due to the increase of use of high cost medicines for treatment of cancer and increased 
sales of biological medicines (ATC group L04 i.e. immunosuppressant’s) for the treatment of e.g. 
rheumatoid arthritis. (Sakshaug 2016, 11, 13.) 
 
Sales of other antineoplastic agents has increased from 941 million NOK to 1255 million NOK be-
tween 2013 to 2015 (figure 47). Same time for example monoclonal antibody rituximab use has 
increased from 7 696 grams of active ingredient/year to 10 579 grams of active ingredient/year and 
trastuzumab from 3638 grams of active ingredient/year to 6038 grams of active ingredient/year. 
(Sakshaug 2016, 63.) 
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FIGURE 47. Sales of other antineoplastic agents (ATC-code L01X) in Norway 2013 – 2015, mil-
lion NOK (Sakshaug 2016, 61) 
Consumption of TNF-alpha inhibitors has increased in Norway from 3,3 DDD/1000 inhabitants/day 
to 4,1 DDD/1000 inhabitants/day between 2013 - 2015. Infliximab use has increased at same pe-
riod from 1,2 to 1,8 DDD/1000 inhabitants/day. (Figure 48.) 
 
 
FIGURE 48. Consumption of immunosuppressant’s in Norway 2013 - 2015 (Appendix 9) 
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Biosimilar infliximab was approved in Norway 2013. Biosimilar infliximab (Remsima) became avail-
able beginning of 2014 and as of April 2016, the biosimilar infliximab has garnered about 93 percent 
of market share. Dr. Kvien has said: “if you compare for rheumatoid arthritis, we could treat five 
patients with Remsima for the same cost as one patient with [Remicade]” (Collins 2016). The total 
number of infliximab prescriptions (the originator and the biosimilar combined) has leaped between 
2014 and end of 2015 from about 7000 to about 13 000. (Collins 2016; Dörner et al. 2016, 5; Welch 
2016.) 
5.14.4 Hospital pharmaceutical expenditures in Finland 
The growth of retail pharmaceutical spending has slowed down in recent years in most OECD 
countries, while spending on pharmaceuticals in hospital has generally increased (OECD 2015, 9). 
New hospital medicines are many times significantly expensive and one medicines annual cost can 
be up to tens of millions of euros. The medicine costs form a significant part of the total expenditures 
of the hospital districts. (Härkönen et al. (b) 2015, 46; Oksanen et al. 2011, 43.) 
 
In 2015 in Finland, medicine sales to hospitals were 561 million euros at wholesale prices and 
change from 2014 was 9 percent (figure 49). Medicine sales to hospitals were less than three 
percent of health care total expenditures in 2014. Although the hospital medicines share of total 
health expenditure is not substantial, the cost of medicines in hospitals has increased significantly 
in ten years (figure 49). The multiplication of specialty medicines offers a partial explanation of 
growth of hospital pharmacy spending, as those are often delivered in hospital setting rather than 
dispensed via pharmacies and are coming to the market with increasing high prices. (Finnish med-
icines agency Fimea and social insurance institution 2016, 31; OECD 2015, 32.) 
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FIGURE 49. Hospital pharmaceutical expenditures 2000 – 2014, million euros at wholesale 
prices. Possible hospital discounts are not included in the figures presented (Finnish medicines 
agency Fimea and social insurance institution 2010 – 2016; National Agency for Medicines and 
Social Insurance Institution 2008 -2009; Matveinen et al. 2016) 
In Finland, hospital’s sales share of total pharmaceutical sales has increased over the last ten 
years. 2015 the share of medicine sales to hospital was 19,0 percent, while in 2005 the proportion 
was 14,8 percent (figure 50).  
 
 
FIGURE 50. Share of hospital sales of total pharmaceutical sales, % (hospital discounts are not 
taken into account in calculations) (Appendix 1) 
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The three best-selling medicine groups in hospital setting in wholesale prices were antineoblastic 
and immunomodulating agents (ATC-code L), anti-infectives for systemic use (ATC-code J) and 
blood and blood forming organs (ATC-code B) (figure 51). Share of hospital sales of total medicine 
sales of antineoblastic and immunomodulating agents is 41 percent, representing the largest sales 
to hospitals in money vise, 206 million euros, of all ATC-groups. Anti-infectives for systemic use 
medicines hospital sales account 64 percent i.e. 117 million and of blood and blood formig organs 
38 percent i.e. 67 million of total sales in groups. (Figure 51, figure 52.)  
 
2015, antineoplastic and immunomodulating agents growth in sales was 8 % i.e. 15 million euros. 
Bigger growth was seen in the group of anti-infectives for systemic use, 29 % i.e. 26 million euros 
and in the group of blood and blood forming organs, which growth was 11 % i.e. 6 million euros in 
wholesale prices. (Appendix 2.) 
 
 
FIGURE 51. 2014 - 2015, distribution of medicine sales to hospitals per the ATC-code, at wholesale 
prices (million euros). ATC-codes A: Alimentary tract and metabolism, B: Blood and blood forming 
organs, C: Cardiovascular system, D: Dermatologicals, G: Genito urinary system and sex hor-
mones, H: Systemic hormonal preparations, excl. sex hormones and insulins, J: Antiinfectives for 
systemic use, L: Antineoplastic and immunomodulating agents, M: Musculoskeletal system, N: 
Nervous system, P: Antiparasitic products, insecticides and repellents, R: Respiratory system, S: 
Sensory organs, V: Various (Appendix 2) 
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Antineoblastic and immunomodulating agents (ATC-code L) are accounting the largest sales to 
hospitals in ATC classification level 1, as seen in figure 51. Under the ATC-code L, in the 
classification level 2, largets sales are in group of antineoplastic agents 140 million euros, 
accounting 73 percent of total antineoplastic agents sales (ATC-code L01). Second largest group 
in sales is immunosuppressants 58 million euros, accounting 26 percent of total 
immunosuppressants sales to hospitals (ATC-code L04). (Figure 52.) 
 
 
FIGURE 52. Antineoplastic and immunomodulating agent’s sales to hospitals, divided to ATC 
classification level 2. Share of sales to hospital are share of total sales in each ATC-group (Ap-
pendix 3) 
In the group of antineoplastic agents (ATC-code L01), the group of other antineoplastic agents 
(ATC-code L01X, classification level 3) have largest sales to hospital, 110 million euros from 140 
million euros. Sales in the group of other antineoplastic agents are mostly sales to hospitals, ac-
counting 71 percent of total sales. (Figure 53.) Other antineoplastic agents can be divided to clas-
sification level 4 group of medicines. In this group, monoclonal antibodies account clearly largest 
sales, 90 million euros, and were sold only to hospitals in 2015. (Figure 54.) The costs of monoclo-
nal antibodies increased the most, by almost 9 million euros, in the group of antineoplastic agents 
(Finnish medicines agency Fimea and social insurance institution 2016, 36).  
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FIGURE 53. Antineoplastic agent’s sales to hospitals, divided to ATC classification level 3. Share 
of sales to hospital are share of total sales in each ATC-group (Appendix 4) 
  
FIGURE 54. Other antineoplastic agent’s sales to hospitals, divided to ATC classification level 4. 
Share of sales to hospital are share of total sales in each ATC-group (Appendix 5) 
In the group of immunosuppressant’s (ATC-code L04), the group of TNF-alpha inhibitors (ATC-
code L04AB, classification level 4) have largest sales to hospitals, 40 million euros from 58 million 
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euros. Medicine sales in the group of TNF-alphas are mostly prescription medicines in outpatient 
care, accounting sales to hospitals of 29 percent. (Figure 55.) 
 
 
FIGURE 55. Immunosuppressant’s sales to hospitals, divided to ATC classification level 4. Share 
of sales to hospital are share of total sales in each ATC-group (Appendix 6) 
5.14.4.1 Cost of monoclonal antibodies in the hospitals in Finland 
Expenditures of monoclonal antibodies focused only to hospitals in 2015, i.e. 90 million euros in 
wholesale prices. Rituximab accounted largest sales 31 million euros and Trastuzumab and 
Bevacizumab little over 20 million euros. (Figure 56.) 
 
Total monoclonal antibody sales increased 10 percent compared to previous year (Appendix 7). 
Increase in sales was seen also with Trastuzumab and Bevacizumab, 3 and 13 percent (Rituximab 
sales 2014 were missing from the data used). Rituximab sales have increased 17 percent when 
compared to 2013 sales. 
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FIGURE 56. Monoclonal antibodies sales to hospitals in wholesale prices 2013 - 2015. Possible 
hospital discounts are not included in the figures presented (Appendix 7) 
At the present time, increase of consumption or prices and introduction of new therapeutic areas 
and possibly new innovative medicines of monoclonal antibodies, will increase hospitals medicinal 
costs solely. Though, pharmaceutical industry is focusing to innovate medicines not given in hos-
pital and iv-route, but subcutaneously or orally. This enables patients to take medicines by them-
selves at home and patient and/or national health insurance pay costs of these medicines, not 
hospital. 
5.14.4.2 Cost of TNF-alphas in the hospitals in Finland 
In 2015, TNF-alpha medicines (tumor necrosis factor alpha) total sales (outpatient care and hospital 
sales) were 137 million euros with wholesale prices, including sales of etanercept, infliximab, ada-
limumab, certolizumab pegol and golimumab (Appendix 6). Total TNF-alfa sales increased 7 per-
cent compared to 2014. Etanercept, infliximab and adalimumab sales of total TNF-alpha sales ac-
count 85 percent i.e. 116 million euros (Appendix 7). TNF-alfa inhibitors adalimumab, infliximab 
and etanercept are used for the treatment of rheumatoid arthritis, psoriasis, and inflammatory bowel 
diseases. Adalimumab is most sold TNF-alpha, 47 million euros (figure 59), but second in con-
sumption 0,68 DDD per 1000 inhabitants and per day (figure 58). When measured in terms of 
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consumption, the most commonly used TNF-alpha is Infliximab 0,89 DDD/1000 inhabitants/day 
(figure 58), but when compared in sales it is the second biggest, about 38 million euros (figure 59). 
Infliximab consumption increased from 0,77 to 0,89 DDD/inhabitants/day (figure 58) and sales 5 
percent compared to previous year. 
 
Infliximab is provided only in hospitals, while other TNF-alphas (etanercept and adalimumab) are 
prescription medicines in outpatient care (98 – 100 % of sales and consumption) (figure 57, Ap-
pendix 8). As seen in figure 57, etanercept has no hospital sales and adalimumab sales were 0,9 
million euros in 2015, and infliximab sales were 39,6 million euros. 
 
 
FIGURE 57. Immunosuppressant’s sales to hospitals in wholesale prices (million euros) 2014 - 
2015 (Appendix 7) 
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FIGURE 58. Etanercept, adalimumab and infliximab consumptions (outpatient care and hospital), 
DDD/inhabitants/day, 2013 - 2015 (Appendix 8) 
 
Figure 59. Immunosuppressant’s total sales (outpatient care and hospital) in wholesale prices (mil-
lion euros) 2014 - 2015 (Appendix 7) 
In September 2013, biosimilar versions of Remicade (Inflectra and Remsima) were granted mar-
keting authorization (European Medicines Agency (j) 2013; European Medicines Agency (k), 2013) 
in Finland and it can be speculated that maybe the increase of infliximab consumption seeing in 
figure 58 was possible after price competition in hospital tenders. 2011 and 2012 the consumption 
of infliximab was 0,62 and 0,68 DDD/1000 inh/day (Finnish Medicines Agency Fimea and Social 
Insurance Institution 2013, 230). 
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6 STUDY EXECUTION 
In the sixth chapter, the execution of qualitative study is presented. 
6.1 Material 
Questionnaire surveys were carried out in autumn 2016 and the target groups were chief gastro-
enterologists (n = 25), specialist gastroenterologists (11), chief rheumatologists (n = 22), specialist 
rheumatologists (2), chief oncologists (n = 23), specialist oncologists (3), chief physicians of internal 
medicine (12) medical directors of health care districts (n = 20), chief assessment physicians (n = 
4), heads of departments (n = 28) and chief pharmacists (n = 20) from five university and 16 central 
hospitals (Table 7). Ahvenanmaa was later excluded because of Swedish language. Two different 
questionnaire forms were made, one for chief pharmacists and one for other participants (Appendix 
11-12.) 
 
TABLE 7. The questionnaires were send to eleven different target groups and for 170 recipients 
Target group Number of emails sent, N 
Medical director of health care district 20 
Head of department 
Responsible of gastroenterology, rheumatology, oncology, internal medicine 
28 
Chief assessment physician 4 
Chief pharmacist 20 
Chief physician, internal medicine 12 
Chief physician, gastroenterology 25 
Specialists in gastroenterology 11 
Chief physician, rheumatology 22 
Specialist in rheumatology 2 
Chief Physician, oncology 23 
Specialists in oncology 3 
TOTAL 170 
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Two biosimilar products were included to questionnaire and the respondent were asked to choose 
a medicine, which is answered. Optional medical products were infliximab and filgrastim. The ques-
tionnaires were e-mailed to 170 recipients in total.  Filgrastim questionnaire analyses are not in-
cluded in this thesis due to the low response rate. Only one specialist oncology, two chief pharma-
cists and two heads of department returned the questionnaire. 
6.2 Data collection 
Respondents were under no obligation to complete and return the questionnaires if they did not 
wish to take part in the survey. Respondents could give their contact e-mail in the questionnaires 
to have link to published thesis. As some of the e-mail addresses of respondents were recorded in 
completed questionnaires, their anonymity had to be secured. Respondents names and e-mail ad-
dresses are not shared in any circumstances and their anonymity will be maintained.  
 
The questionnaires were accompanied by explanation letters (Appendix 10). The questionnaires 
were send first time 1st of October 2016 and again as remainder 21st – 25th of October 2016. The 
replies were requested to be sent to the given e-mail address no later than 31st of October 2016. 
6.2.1 Drafting of questionnaires 
In 2016, two Microsoft Word spreadsheet questionnaires were designed to gather information, 
opinions and future expectations about biosimilars. The questions used in this study were designed 
with the help of Professor, Department Head Tuulikki Sokka-Isler, Docent, Ph.D. Pekka Kurki and 
Hospital Chief Pharmacist. 
 
There were 30 questions to chief pharmacists and 28 to other target groups (Appendix 11 - 12). 
Both closed and open questions were used. Closed questions had multiple response options (2 – 
7) and some included also neutral answers (“I cannot say”). Also, open questions “why” and “other 
comments” were included to most of the questions, in case respondent wanted to comment the 
given answer or had alternative which was not given originally as on option. Few open questions 
were included to gather information when it was not ideal to give prepared response options, but 
instead to give the respondent an opportunity to express their own opinions on the matter without 
suggestive options. For example, switching biosimilar to biosimilar becomes relevant in future and 
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open questions were only possibility not to direct the responses, but to have opinion of the respond-
ent. The questionnaire was piloted by one physician and one chief pharmacist. Following the pilot 
implementation, some questions were discarded and the wording of others was clarified. 
6.2.2 Address list 
Questionnaires were send via e-mail to targeted groups. Names and e-mail addresses were gath-
ered from municipal web-pages, including hospital pages, publications, guidelines etc. Also, lot of 
names I was familiar via my work in medical industry and some were given by respondents, who 
felt there were not right contacts in their hospitals. Respondents send the questionnaire back to 
given e-mail. The respondent’s names will not be shared outside this thesis and their anonymity is 
secured. The thesis has not been made for or request of the pharmaceutical companies. 
6.3 Data analyzing 
Data collection of the survey was conducted by manually transferring answers to Microsoft Excel 
spreadsheets from word-based questionnaire sheets. The replies were documented according to 
the different target groups and to University and Central Hospital groups. The questions and an-
swers were translated into English. 
 
University Hospital and Central Hospital responses are not separated in this thesis, so that the 
respondents' anonymity is maintained. One senior ward physician response is also included to 
specialist gastroenterologists’ group of responses. Chief physician groups do include deputy chief 
physicians, chief of departments and chief specialists. In table 8, the English job titles are presented 
in Finnish. 
 
TABLE 8. Professional titles in Finnish 
Target group Target group in Finnish 
Medical director of health care district Sairaanhoitopiirin johtajaylilääkäri 
Head of department 
Responsible of gastroenterology, rheumatology, 
oncology, internal medicine 
Toimiala-, palvelualue-, vastuualue-, vastuuyksikkö-, tulos-
alue-, palveluyksikkö-, toimialuejohtaja 
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Chief assessment physician Arviointiylilääkäri 
Chief pharmacist Sairaala-apteekkari 
Chief physician, gastroenterology Gastroenterologian ylilääkäri 
Specialists in gastroenterology Gastroenterologian erikoislääkäri 
Chief Physician, rheumatology Reumatologian ylilääkäri 
Specialists in rheumatology Reumatologian erikoislääkäri 
Chief Physician, oncology Onkologian ylilääkäri 
Specialists in oncology Onkologian erikoislääkäri 
 
The number of recipients from biosimilar infliximab target groups who returned the questionnaire 
was 30 (18% of 144 recipients). The highest response rate is in the group of rheumatologists, 38 
%, and none of chief physicians of internal medicine replied the questionnaire. (Table 9.) It should 
also be noted that one of the hospitals decided that only chief pharmacist would answer the ques-
tionnaire on behalf of everybody. That might lower the response rates of other target groups. 
 
TABLE 9. Response rates of the biosimilar infliximab target groups 
Target group N Respondents, n Response rate, % 
Medical director of health care district 20 1 5 % 
Head of department, responsible of gastroenterology, 
rheumatology, oncology, internal medicine 
28 2 7 % 
Chief assessment physician 4 1 25 % 
Chief pharmacist 20 6 30 % 
Chief physician, internal medicine 12 0 0 % 
Chief physician, gastroenterology 25 7 28 % 
Specialists in gastroenterology 11 4 36 % 
Chief physician, rheumatology 22 9 41 % 
Specialist in rheumatology 2 0 0 % 
Gastroenterology, total 36 11 31 % 
Rheumatology, total 24 9 38 % 
TOTAL 144 30 21 % 
 
The response rate of the biosimilar infliximab target groups was really modest, only 5 % and just 
one specialist oncology returned the questionnaire and thus the analyzes are not included within 
this thesis. (Table 10.) 
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TABLE 10. Response rates of the biosimilar filgrastim target groups 
Target group N Respondents, n Response rate, % 
Medical director of health care district 20 0 0 % 
Head of department 28 2 7 % 
Chief assessment physician 4 0 0 % 
Chief pharmacist 20 2 10 % 
Chief Physician, oncology 23 0 0 % 
Specialists in oncology 3 1 33 % 
TOTAL 98 5 5 % 
 
When analyzing the results, it became clear, that questions should have been further processed 
and questionnaire should have included only one biosimilar product. Now there was possibilities to 
misunderstand questions, if the question was not read with proper thought in mind. As a web-based 
questionnaire, the number of responses could have been greater than by e-mail, and also the pro-
cessing of responses would have been faster than of Word-based query's. On the other hand, face-
to-face interviews could provide more comprehensive answers and clarifying questions could have 
been asked. 
 
Some of the figures in the replies are not directly comparable and the figures obtained must there-
fore be considered as indicative. For example, the calculations took a lot of time from the pharma-
cists and one of the respondents commented that some of the calculations were made with a mar-
ginal profit prices, not with purchase prices, as requested in the survey. Also, some figures were 
asked to give as estimates, because for example future savings cannot be calculated as exact 
figures. 
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7 RESULTS 
Responses of questionnaire are analyzed by customer groups and central hospital and university 
hospital replies are not analyzed separately. 
7.1 Position of biosimilar product in the hospital's pharmaceutical formulary 
Target groups were first asked what is the position of biosimilar product in their hospital’s pharma-
ceutical formulary at the current purchasing period and requested to rationalize why this is the case. 
7.1.1 Gastroenterologists 
All chief physicians of gastroenterology who responded the questionnaire (n=7), responded bio-
similar infliximab to be in pharmaceutical formulary the preferred option. One responded it to be 
also only infliximab product and other 6 responded that originator infliximab was also available. The 
same result was also seen in responses of specialists of gastroenterology (n=4). In this group four 
responded biosimilar infliximab to be the preferred option and one of them responded it to be also 
the only product and one responded that also originator infliximab was available. (Table 11.) 
  
TABLE 11. Biosimilar infliximab is the preferred option in pharmaceutical formulary 
Position of biosimilar infliximab in the 
hospital's pharmaceutical formulary at the 
current purchasing period 
Chief Physicians, n = 7 Specialist of  
Gastroenterology, n = 4  
Biosimilar infliximab is the preferred option 7 4 
Price. 
Main product chosen for the Ex-
pert Responsibility Area. 
Price and efficacy. 
Price 
Also, originator infliximab is available 6 1 
If patient prohibits switch. 
In use. 
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Change happens slowly when 
switching medication, some pa-
tients react with worsening of 
bowel-disease symptoms; pos-
sibility to continue treatment 
with the same product. 
Some patients want originator 
product. 
If biosimilar is inefficient or side 
effects occur. 
Only biosimilar infliximab in pharmaceutical 
formulary 
1 1 
 Was considered that there is 
no need for other. 
 
The biosimilar infliximab being the preferred option was most of the cases justified with price and 
one responded biosimilar to be main product chosen for the Expert Responsibility Area. Originator 
infliximab was available in case if patient prohibits switch, biosimilar proves to be inefficient or side 
effects occur and respondents saw it also as opportunity to return to originator infliximab if biosimilar 
infliximab treatment fails. One responded stated that some patients choose originator infliximab 
instead of biosimilar infliximab. 
 
Two respondents (one chief physician and one specialist) stated biosimilar infliximab to be only 
product in pharmaceutical formulary (no originator infliximab available), and one justified it with 
argument that it was considered that there is no need for originator. 
7.1.2 Rheumatologists 
All chief physicians from rheumatology replied the biosimilar infliximab to be the preferred option in 
the pharmaceutical formulary at the current purchasing period. Eight respondents told price to be 
the reason, and three of them also mentioned that biosimilar is demonstrated to be similar to the 
originator product. One of the respondents also pointed out that he / she had gathered personal 
experience of biosimilar infliximab. (Table 12.) 
 
Eight out of nine chief physicians replied that also originator infliximab is available, for example, in 
case if problems occur with the biosimilar product (lack of efficacy, adverse events) and if patient 
prohibits switch. It makes also possible to continue with originator infliximab if patient’s starting 
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point before switching has been very difficult and is only reasonably under control. In this kind of 
situation there is no desire to take the risk of switching. In addition, originator product in the phar-
maceutical formula makes it possible to return to originator infliximab if biosimilar infliximab treat-
ment fails. Also, one chief physician stated that pediatric rheumatology patients were not “forced” 
to switch and thus continued with originator infliximab. Remicade was also seen to be more desir-
able option for some patients, for example for pregnant womens. By keeping originator product in 
the pharmaceutical formulary, doctors’ autonomy was secured, and they could decide to continue 
treatments with originator infliximab or to switch to biosimilar one. 
 
TABLE 12. Biosimilar infliximab is the preferred option in pharmaceutical formulary 
Position of biosimilar in-
fliximab in the hospital's 
pharmaceutical formu-
lary at the current pur-
chasing period 
Chief physicians, n = 9 
Biosimilar infliximab is the 
preferred option 
9 
Price, studies have demonstrated biosimilar to be comparable to originator product. 
Studies and personal experiences have demonstrated that biosimilar is similar to the 
originator product in terms of efficacy and safety. 
The most affordable and is assumed to have similar effect as the reference product. 
Price advantage. 
Also, originator infliximab 
is available 
8 
With a few patients in a very difficult situation reasonably under control, there was no 
desire to take the risk of switching medicine, and the patient did not wish to change 
the medicine. 
If problems occur with the biosimilar product. 
Needed for some patients: 1. laboriously has been found a medicine that affects, 
Remicade, so treatment continued with the product in question. 2. pregnancy - Remi-
cade has nevertheless two decades of experience. 3. for stable patients whose treat-
ments were switched to biosimilar, but on objective outcome measures efficacy has 
collapsed, and their treatment was switched back to Remicade. 
If the biosimilar is not suitable or is not effective enough. 
No mandatory to switch treatment 
In case there is exceptional case. Pediatric rheumatology patients are not "forced" to 
switch. 
For some, is more suitable. 
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7.1.3 Medical director of health care district, head of department and chief assessment 
physician 
Two heads of departments answered the questionnaire. Both replied the biosimilar infliximab to be 
the preferred option in the pharmaceutical formulary at the current purchasing period and both told 
price to be the reason. The other of the respondents stated that the originator infliximab is also 
available, because some patients need it. 
 
Medical director of health care district replied that both originator and biosimilar infliximab are in 
the pharmaceutical formulary. Price was mentioned to be the reason why biosimilar has been cho-
sen and originator infliximab was chosen in order to maintain the doctors' autonomy. 
 
Chief assessment physician replied that the both originator and biosimilar infliximab are in the phar-
maceutical formulary. Originator was kept in order to ensure the transitional period and to have as 
one alternative. 
7.1.4 Chief pharmacists 
All chief pharmacists replied the biosimilar infliximab to be the primary option in the pharmaceutical 
formulary at the current purchasing period but also originator infliximab is available for specified 
patients. (Table 13.) 
 
Biosimilar infliximab is the preferred option because of the price. It has proven to be the most eco-
nomical choice in accordance with hospital tender criteria’s. One replied biosimilar infliximab to be 
main product chosen for the expert responsibility area. Fimea statement about interchangeability 
of biosimilars was also mentioned. 
 
Originator infliximab is available for specified patients like pediatric patients or patients who have 
used originator infliximab for a long period of time and have justified reason which prevents the 
switch. One chief pharmacist told that originator product can be used on a request for a named 
patient. 
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TABLE 13. Biosimilar infliximab is primary option in the pharmaceutical formulary, but also origina-
tor infliximab is available if needed 
Position of biosimilar infliximab in the hospi-
tal's pharmaceutical formulary at the current 
purchasing period 
Chief pharmacists, n = 6 
Biosimilar infliximab is the preferred option 6 
Per se, Fimea statement notes that it is possible to switch to bio-
similar. In accordance with hospital tender criteria’s, biosimilar is 
the most economical choice. 
Usage costs.  
Main product chosen for the Expert Responsibility Area. 
Price. 
Also, originator infliximab is available 6 
For those potential long-term users, who have a particular reason 
that the switch could not be done. 
On a request for a named patient. 
Opportunity to continue ongoing treatments with the same prod-
uct. 
For pediatric patients, whose treatment has been initiated with 
the originator infliximab and for patients for whom biosimilar in-
fliximab is not appropriate. 
For patients, whom originator infliximab has been in long-term 
use, and switch for biosimilar infliximab cannot be implemented. 
Pediatric patients. 
7.2 Studies of efficacy and safety 
Biosimilar application for marketing authorization must demonstrate that potential differences be-
tween the biosimilar and the originator product does not affect the efficacy or safety. 
7.2.1 Are biosimilar studies sufficiently comprehensive regarding of safety and efficacy 
One of the survey objectives was to identify if the biosimilar studies are seen to be sufficiently 
comprehensive regarding of efficacy and safety. 
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7.2.1.1 Gastroenterologists 
10 out of 11 (6/7 chief physicians and 4/4 specialist) responded biosimilar studies to be sufficiently 
comprehensive regarding of safety and efficacy. Efficacy and safety results were seen convincing 
enough, even if those were conducted mainly in rheumatology patients. Also, extrapolation of indi-
cations was mentioned in one answer and seen that results obtained from studies in RA and SpA 
can be extrapolated to IBD. (Table 14.) 
 
Only one respondent did think biosimilar studies are not sufficiently comprehensive regarding of 
efficacy and stated that for some patients biosimilar is not effective at all, even if biosimilar infliximab 
is being marketed to have similar efficacy as originator product. 
 
TABLE 14. Gastroenterologists opinion is that biosimilar studies are sufficiently comprehensive 
regarding the efficacy and safety 
Biosimilar studies are Chief physicians, n = 6 Specialist of gastroenterology, 
n = 4 
Sufficiently comprehensive 6 4 
Efficacy and safety results are convincing 
enough, even if conducted mainly in rheuma-
tology patients. 
Study in rheumatology. 
Proven safety and efficacy. 
I have received information about studies, 
mode of action and safety. 
Results obtained from studies in 
rheumatoid arthritis and SpA can 
be extrapolated to inflammatory 
bowel disease. 
Sufficient number of patients. 
Not sufficiently  
comprehensive 
1 
 
Marketed to have similar efficacy than origi-
nator product, but in reality, to some patients, 
biosimilar is not effective at all 
 
7.2.1.2 Rheumatologists 
All chief physicians from rheumatology responded the question. Eight out nine answered that stud-
ies are sufficiently comprehensive regarding of safety and efficacy, though one hesitates in his / 
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her answer, that research evidence does not exist to all indications, and only little research evi-
dence and long term follow-up is available. Other reasons were for example, that biosimilar studies 
meet requirements of the EU, there is confidence to regulatory authorities in this matter and studies 
are seen to have enough power to demonstrate the biosimilarity. (Table 15.) 
 
One respondent answered studies not to be sufficient enough, because long-term outcomes are 
not known. 
 
TABLE 15. Head physicians in Rheumatology think, that biosimilar studies are sufficiently compre-
hensive 
Biosimilar studies are Chief physicians, n = 9 
Sufficiently  
comprehensive 
8 
Meet the requirements of the EU. 
I trust the regulatory authorities. 
In principle, yes, but there is no research evidence for all indications, and only little 
research evidence, and long term follow-up, is available. 
In terms of efficacy, studies made for originator product are sufficient; in terms of 
safety, studies required in the authorization procedure are sufficient. 
Equality is adequately addressed. 
If the biosimilar has all the corresponding originator properties and structure, less 
extensive clinical tests are sufficient. 
Not sufficiently  
comprehensive 
1 
Maybe not. The long-term outcomes are not known. 
7.2.1.3 Medical director of health care district, head of department and chief assessment 
physician 
Medical director, heads of department and chief assessment physicians replied biosimilar studies 
to be sufficiently comprehensive regarding of safety and efficacy. 
7.2.1.4 Chief pharmacists 
All chief pharmacists replied biosimilar studies to be sufficiently comprehensive regarding of safety 
and efficacy. One chief pharmacist replied that medicinal products will not get authorization unless 
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the standardized conditions are not met and other one thinks that pharmaceutical regulatory au-
thorities have strict requirements for studies of biosimilars. (Table 16.) 
 
TABLE 16. All chief pharmacists think, that biosimilar studies are sufficiently comprehensive 
Biosimilar studies are Chief pharmacists, n = 6 
Sufficiently comprehensive 6 
The supervising authority grants the marketing authorization for medicinal products. 
To obtain the marketing authorization, regulatory authority will assess quality, effi-
cacy and safety, as well as appropriateness in all approved indications. Medicinal 
product will not get authorization unless the standardized conditions are met. 
The pharmaceutical regulatory authorities have stringent criteria. 
7.2.2 Sources of biosimilar information 
The questionnaire surveyed from which sources biosimilar information is obtained. 
7.2.2.1 Gastroenterologists 
Questionnaire showed that respondents have received information about biosimilars often from 
many different sources (table 17). The study respondents have all (n=11) received information 
about biosimilars from pharmaceutical companies. Nine of the eleven respondents have received 
info also from regulatory authorities (6 of the 7 chief physicians and 3 of the 4 specialists) and eight 
of all respondents have gotten information also from colleagues (chief physicians 5/7 and special-
ists 3/4). 
 
TABLE 17. Information about biosimilars is received mostly from pharmaceutical companies and 
regulatory authorities 
Where have you received information 
about biosimilar products 
Chief Physicians, n = 7 Specialist of gastroenterology,  
n = 4 
Pharmaceutical companies 7 4 
Regulatory authorities 6 3 
From colleagues 5 3 
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From elsewhere? 5 
FROM: 
Scientific publications. 
Congresses. 
Meetings 
Training sessions 
3 
FROM: 
Medical journals and congresses. 
EMEA, journals, the literature of 
the field. 
 
Other sources of information have been publications (was mentioned most frequently), congresses, 
meetings and training sessions. Also, one mentioned EMEA as information source. 
7.2.2.2 Rheumatologists 
Questionnaire showed that respondents received information about biosimilars from multiple 
sources (table 18). The study respondents have all received information about biosimilars from 
pharmaceutical companies and almost as many, eight out of nine, has received information also 
from regulatory authorities. Seven respondents have received info also from colleagues and same 
number has gotten information from other sources. Other sources of biosimilar information have 
been journals and literature, congresses, and presentations. One also mentioned that he/she has 
had biosimilar in trial use and one has been involved in some way in EU's development work. 
 
TABLE 18. Information about biosimilars is received from mostly from pharmaceutical companies 
and regulatory authorities 
Where have you received information about biosimilar 
products 
Chief Physicians, n = 9 
Pharmaceutical companies 9 
Regulatory authorities 8 
From colleagues 7 
From elsewhere? 7 
Been involved in EU’s development work. 
Literature. 
From published studies. 
Biosimilar has been in trial use. 
The congresses lectures.  
Congresses, journals, presentations. 
Rheumatology journals. 
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7.2.2.3 Medical director of health care district, head of department and chief assessment 
physician 
Questionnaire showed that also respondents in this group have received information about biosim-
ilars from multiple sources (table 19). Just one of the head of department replied source to be only 
regulatory authorities. The other head of department has received information from regulatory au-
thorities, pharmaceutical companies, and educational meetings. Both medical director and chief 
assessment physician mentioned regulatory authorities, colleagues, and pharmaceutical compa-
nies as information sources. Chief assessment physician has gathered information also from sci-
entific publications and educational meetings. 
 
TABLE 19. Biosimilar information has been obtained mostly from the regulatory authorities 
Where have you received information about biosimilar 
products 
Number of answers, n = 4 
Pharmaceutical companies 3 
Regulatory authorities 4 
From colleagues 2 
From elsewhere? 2 
Scientific publications.  
Educational meetings. 
7.2.2.4 Chief pharmacists 
Questionnaire showed that chief pharmacists have received information about biosimilars from 
multiple sources, usually at least from pharmaceutical companies, regulatory authorities, and col-
leagues (table 20). Just one chief pharmacists replied source to be only regulatory authorities. 
Three chief pharmacists have gathered information also from professional publications, literature 
and pharmaceutical databases. 
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TABLE 20. Biosimilar information has been obtained mostly from the regulatory authorities and 
pharmaceutical companies 
Where have you received information about biosimilar products Chief pharmacists, n = 6 
Pharmaceutical companies 5 
Regulatory authorities 6 
From colleagues 4 
From elsewhere? 3 
Pharmaceutical databases. 
Professional publications. 
Literature. 
7.2.3 Need for additional information about biosimilars 
The survey was intended to identify the need for information of the biosimilar products, and the 
topics on which additional information is required. 
7.2.3.1 Gastroenterologists 
All chief physicians had the opinion that they do not need additional information about biosimilars. 
One specialist (1/4) felt she/he needs information about long-term outcomes and comparison such 
as Nor-Switch. All other specialists (3/4) had same opinion as chief physicians, no need for more 
information. (Table 21.) 
 
TABLE 21. Most of the respondents do not see a need for additional information about biosimilars 
Do you need more information 
about biosimilars 
Chief Physicians, n = 7 
Specialist of gastroenterology, n = 4 
Yes 
 
1 
 Long-term outcomes, comparison such as 
Nor-Switch. 
No 7 3 
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7.2.3.2 Rheumatologists 
Three out of nine respondents would like to have information of new upcoming biosimilars and 
when those are coming. One requires also long-term results of switches and stated, that she/he is 
already been longing for more details on how switches have succeeded in practice. (Table 22.) 
 
However, the majority of respondents did not feel they need more information about the biosimilars. 
 
Table 22. Some of the respondents are interested of upcoming biosimilars 
Do you need more information 
about biosimilars 
Need information for, n = 9 
Yes 3 
When will there be new biosimilar products introduced.  
Long-term results, and at the beginning I would have liked more information 
on how the switches have succeeded in practice. 
Of the many upcoming biosimilar products. 
No 6 
7.2.3.3 Medical director of health care district, head of department and chief assessment 
physician 
Medical director, heads of department and chief assessment physicians did not feel they need more 
information of the biosimilars. 
7.2.3.4 Chief pharmacists 
Two out of six respondents would like to have information about biosimilars, one for safety and 
another one whenever new information is published or regulatory authorities inform of the biosimi-
lars. However, most respondents did not feel they need more information of the matter. (Table 23.) 
 
TABLE 23. Some would like to have more information about biosimilars, for example, about safety 
Do you need more information about biosimilars Need information for, n = 6 
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Yes 2 
Safety. 
Always, if new information is published or regulatory authori-
ties inform on the matter. 
No 4 
7.3 Switching from infliximab originator to its biosimilar 
In some hospitals, patients treated with originator infliximab were switched to its biosimilars. 
7.3.1 Preparations before switching originator infliximab to biosimilar 
Questionnaire aimed to determine whether the hospital made preparations before switching origi-
nator infliximab to biosimilar infliximab. For example, in the Statement of The Finnish Society for 
Rheumatology is recommended to measure drug trough concentration and anti‐drug antibodies 
before switching. 
7.3.1.1 Gastroenterologists 
Most of the respondents (nine out of eleven) stated that switching did cause separate arrangements 
(table 24) and the reported arrangements have been either “guiding the patient what biosimilar is” 
or “educating personnel about what biosimilar is”. Six out of eleven respondents indicated that both 
arrangements were implemented in their hospitals.  
 
Only three out of eleven reported that switching did not cause separate arrangements. However, 
one of these three respondents did nevertheless also inform that drug trough concentration and 
antibodies were determined before switching and patient and personnel education was given and 
other one informed that personnel were educated. 
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TABLE 24. Only few felt that switching did not cause separate arrangements 
 Chief Physicians, 
 n = 7 
Specialist of gastroenterology,  
n = 4 
How switches were prepared? Number of answers Number of answers 
Switches did not cause separate arrangements 2 1 
Determining drug trough concentration and an-
tibodies before switching 
2 2 
By guiding the patient about what biosimilar is 4 4 
By educating personnel about what biosimilar is 4 4 
 
Four respondents (2 chief physicians and 2 specialists) informed determination of drug trough con-
centration and antibodies before switching. None of the responses did not inform determination of 
antibody and drug concertation was made solely, but also education for patient and/or personnel 
was given.  
7.3.1.2 Rheumatologists 
Most chief physicians (seven out of nine) stated, that certain arrangements were made before pa-
tients who have been treated with originator infliximab were switched to its biosimilar. Seven out of 
nine of the respondents reported that both arrangements “guiding the patient what biosimilar is” 
and “educating personnel about what biosimilar is” were implemented in their hospitals. Only two 
out of nine reported that switching did not cause separate arrangements. However, one of those 
two respondents did nevertheless also inform that personnel education was given and other one 
informed that treatments of all patients were switched from originator infliximab to its biosimilar. 
(Table 25.) 
 
Four respondents informed determination of drug trough concentration and antibodies before 
switching. None of the responses did not inform determination of antibody and drug concertation 
was made solely, but also personnel had been educated and patients had been informed about 
biosimilars.  
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Two chief rheumatologists had identified more precisely patients, whose treatments are to be 
switched from originator infliximab to biosimilar infliximab. One chief rheumatology defined, that 
patients had to be stable with the originator infliximab and they should have patient’s approval. 
Another had set an age limit of at least 18 years. 
 
Two chief physicians told that the all patients treated with originator infliximab, were systematically 
switched to its biosimilar. In these cases, one clinic had educated personnel and patients about 
biosimilars and one told that there were no special arrangements made. 
 
TABLE 25. Before switching, personnel and patients were educated and informed about biosimilars 
How switches were prepared? Number of answers, n = 9 
Switches did not cause separate arrangements 2 
Determining drug trough concentration and antibodies be-
fore switching 
4 
By guiding the patient about what biosimilar is 7 
By educating personnel about what biosimilar is 8 
By identifying patients who can be switched 3 
Basically, treatment of all patients was switched if sit-
uation was stable with the treatment of originator 
product and the patient did not refuse.  
Not less than 18 years of age. 
Switches were made systematically for all patients on 
originator infliximab treatment. 
Otherwise, how? 1 
All patients treated with originator infliximab were 
switched. 
 
7.3.1.3 Medical director of health care district, head of department and chief assessment 
physician 
Both heads of department reported that switching did not cause separate arrangements. However, 
one of these two respondents did also inform that both arrangements “guiding the patient what 
biosimilar is” and “educating personnel about what biosimilar is”, were made. The other mentioned, 
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in addition what is mentioned above, that clinic had identified more precisely patients,’ whose treat-
ments were going to be switched from originator infliximab to biosimilar infliximab. Though, he did 
not specify precisely which types of patients were selected. (Table 26.) 
 
Medical director of health care district informed that several arrangements were made prior the 
treatments were switched from originator infliximab to biosimilar infliximab. Both, patients and per-
sonnel were educated about biosimilars, and drug trough concentration and antibodies were deter-
mined before switching. 
  
Chief assessment physician replied that switching did not cause separate arrangements. However, 
she/he also informed that both arrangements, guiding the patients what biosimilar is and educating 
personnel, were made and drug trough concentration and antibodies were determined. 
 
None of the responses did not inform determination of antibody and drug concertation was made 
solely, but also personnel had been educated and patients had been informed about biosimilars.  
 
TABLE 26. Prior the switching of treatments, personnel and patients received information about 
biosimilars 
How switches were prepared? Number of answers 
Switches did not cause separate arrangements 3 
Determining antibody and drug concentrations before switching 2 
By directing the patient about what biosimilar is 4 
By educating personnel about what biosimilar is 4 
By identifying patients who can be switched 1 
7.3.1.4 Chief pharmacists 
Most chief pharmacists (four out of six) reported that switching did not cause separate arrange-
ments. However, three of them replied that personnel were educated about biosimilars, and one 
of them told that also patients were informed and one replied that also antibody and drug concer-
tation were determined. One respondent notified biosimilar infliximab was reviewed in the man-
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agement teams and the other told that medical expert and pharmaceutical advisory board han-
dling was made, as part of hospital tendering. Only one chief pharmacist argued that any sepa-
rate arrangements were made. (Table 27.) 
 
One chief pharmacist replied that both arrangements “guiding the patient what biosimilar is” and 
“educating personnel about what biosimilar is” were implemented in their hospital. Also, drug trough 
concentration and antibodies prior the switching were determined, to be able to identify patients 
which could be switched. 
 
One stated that he/she has no information, because switches were done in polyclinics. 
 
TABLE 27. Most chief pharmacists replied that, prior the switching of treatments, personnel re-
ceived educated about biosimilars 
How switches were prepared? Number of answers, n = 6 
Switches did not cause separate arrangements 4 
Determining antibody and drug concentrations before switching 2 
By directing the patient about what biosimilar is 2 
By educating personnel about what biosimilar is 4 
By identifying patients who can be switched 1 
Antibody and drug concentrations 
Otherwise, how? 3 
 Biosimilar infliximab was reviewed in the 
management teams.  
Medical expert and pharmaceutical advisory 
board handling, as part of hospital tendering. 
There is no information: switches are done in 
polyclinics. 
7.3.2 Has the switching the treatment from originator infliximab to its biosimilar, affected 
the safety and/or efficacy? 
The concern has been, that switching of the treatment form originator infliximab to its biosimilar 
could affect the safety and/or efficacy of the treatment. The aim of the questionnaire was to inves-
tigate, if the switching of the treatment from originator infliximab to its biosimilar has affected the 
efficacy and/or safety, and to find out what these effects have been. 
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7.3.2.1 Gastroenterologists 
All specialist gastroenterologists answered that switching of the treatment did not affect the efficacy 
or safety and one commented that there have not been so far problems related to switching. One 
chief physician out of seven had observed allergic reactions in some patients and intestinal symp-
toms had returned for some patients. Two chief physicians could not say, if the switching had af-
fected the treatment, however one of them commented that there is research on going but the 
impression is that it has not impact. Other chief physicians (four out of seven) commented that they 
had not observed switching to affect safety and efficacy. (Table 28.) 
 
TABLE 28. The switching had not impact on safety and/or efficacy, according to most chief gastro-
enterologists 
 
Chief Physicians, n = 7 
Specialist of gastroenterology, 
n = 4 
Has the switching of the treatment af-
fected the efficacy and/or safety of the 
treatment? 
Number of answers Number of answers 
Yes 1 
 
Some patients have had allergic 
reactions, for some patients’ in-
testinal symptoms have re-
turned 
No 4 4 
Cannot say 2 
 
Other comments Research on going, but the im-
pression is that there is no im-
pact on the efficacy or safety 
No problems so far related to 
the switching 
7.3.2.2 Rheumatologists 
Most chief rheumatologists (seven out of nine) answered that they had not observed that the switch-
ing the treatment would have affected the efficacy or safety, though one had observed an individual 
patient to have poor response to biosimilar infliximab treatment. One chief physician experienced, 
that for some patients, the switching the treatment has possibly affect the efficacy and safety, be-
cause when treated with biosimilar infliximab, for some patients’ subjective efficacy had worsened, 
and also antibodies were detected. However, the physician pointed out that samples were not taken 
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from all patients before switching and as a result of this, it is not possible to draw definite conclu-
sions that switching patients from originator infliximab to biosimilar infliximab has actually affected 
their treatment. (Table 29.) 
 
One chief physician could not say, if the switching had affected the treatments, however he/she 
commented that they have research on going. 
 
TABLE 29. Most chief rheumatologists felt that the switching of the treatment did not have effect 
safety and the efficacy 
Has the switching of the treatment affected the effi-
cacy and/or safety of the treatment? 
Number of answers, n = 9 
Yes 1 
Possibly in some patients, subjective efficacy was 
worsened, and some of them, also antibodies were 
detected. Unfortunately, samples had not been taken 
from all before switching of treatment, so some ques-
tions were left open. 
No 7 
Cannot say 1 
Other comments Research on going. 
A single patient with poorer efficacy. 
7.3.2.3 Medical director of health care district, head of department and chief assessment 
physician 
Medical director, chief assessment physician and one of the heads of department answered that 
the switching of the treatment from originator infliximab to its biosimilar had no effect on the efficacy 
or safety. One head of department could not say if the switches have affected the treatment, but 
did not specify the answer. 
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7.3.2.4 Chief pharmacists 
Half of chief pharmacist, could not say if the switching of the treatment from originator infliximab to 
its biosimilar has affected the safety and/or efficacy, even though one replied that side effects re-
lated to biosimilar infliximab has not occurred. One of them commented that the switching did 
mainly not affect the treatment, but some individual cases the antibodies were detected and pa-
tients’ treatments were switched back to the originator infliximab. There was also another chief 
pharmacist, who commented that the switching the treatments affected safety in some patients, 
because adverse events occurred when treated with biosimilar infliximab. Those patients’ treat-
ments were switched back to originator infliximab. (Table 30.) 
 
Two out of six respondents did not think the switching the treatments affected the safety and/or 
efficacy. 
 
TABLE 30. The treatment of some patients has been switched back to originator infliximab 
Has the switching of the treatment affected the efficacy 
and/or safety of the treatment? 
Number of answers, n = 6 
Yes 1 
The treatment of some patients has been 
switched back to the originator infliximab be-
cause of side effects. 
No 2 
Cannot say 3 
Other comments Biosimilar-related adverse events have not 
occurred. 
Mainly did not affect. Some individual cases 
in which the antibodies were detected, pa-
tients’ treatments were switched back to the 
originator infliximab. 
7.3.3 Follow-up, after the switching from originator infliximab to its biosimilar 
Efficacy and safety of biologics medicines are monitored many ways routinely, for example via 
assessments by clinicians, self-assessments by patients, and laboratory tests.  
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Because all biological medicinal products are immunogenic, it is recommended for example in the 
Statement of The Finnish Society for Rheumatology, that “drug trough concentration and anti‐drug 
antibodies are measured at time, especially in patients who experience adverse effects or second-
ary treatment failure”. (The Finnish Society for Rheumatology, 2015.) 
 
One aim of the questionnaire was to determine whether some follow-up was made after the treat-
ments were switched from originator infliximab to its biosimilar, and what issues were monitored. 
7.3.3.1 Gastroenterologists 
Majority, seven out of eleven, of gastroenterologists answered that there has not been any special 
follow-up made of the switches. One specialist out of four told that follow-up after switching was 
made by determining drug trough concentration and antibodies in certain intervals. (Table 31.) 
 
Of chief physicians, four out of seven answered that there was no special follow-up made. However, 
one these respondents did also comment that drug trough concentration and antibodies were de-
termined when necessary. Also, one commented that some patients have been switched back to 
originator infliximab. One chief physician determined drug trough concentration and antibodies, but 
did now specify it in more detail. He/she also made follow-up via symptom queries. Two out of 
seven chief physicians answer that follow-up is made by determining a drug trough concentration 
and antibodies when necessary. (Table 31.) 
 
TABLE 31. Follow-up of the switches is made in some clinics 
Is follow-up made of the switches? Chief Physicians, n = 7 Specialist of gastroenterology, 
n = 4 
No special follow-up 4 3 
Drug trough concentration and antibodies 
determined in certain interval 
 
1 
Drug trough concentration and antibodies 
determined when necessary 
3 
 
Otherwise, how? 2 
 
Symptom queries.  
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Switched back to origina-
tor product. 
7.3.3.2 Rheumatologists 
Most chief rheumatologists (seven out of nine) measured drug trough concentration and antibodies, 
to follow-up of the switches. Usually measurements were not done in certain intervals. Five out of 
nine respondents made measurements only when necessary, one respondent did measurements 
in certain intervals and also if considered necessary and one has done follow-up measurements in 
certain intervals. In addition to what the above-mentioned, one monitors also clinically the efficacy 
of the treatment, and the tolerability of the medicine. One chief physician pointed out that follow-up 
of efficacy and safety of medicines are part of routines. (Table 32.) 
 
Four of the respondents tracked the causes of the treatment interruptions, and one told that there 
is an intention to prepare a summary of the results. 
 
Only three respondents out of nine told, that there is no special follow-up done, however one of 
them had answered that also drug trough concentration and antibodies were measured if seen 
necessary and one chief physician also pointed out, that even though there is no special follow-up 
done, the switched patients have the same follow-up than patients treated with any biological med-
icine. 
 
TABLE 32. Most chief rheumatologists have done some follow-up 
Is follow-up made of the switches? Number of answers, n = 9 
No special follow-up 3 
Drug trough concentration and antibodies de-
termined in certain interval 
2 
Drug trough concentration and antibodies de-
termined when necessary 
6 
By tracking the causes of treatment interruption 4 
Otherwise, how? 2 
Follow-up of efficacy and safety of medicines are part of routine. 
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By monitoring clinically the efficacy of the treatment, and the tol-
erability of the medicine. 
Other comments? The normal follow-up, as when patient is treated with any biolog-
ical medicine.  
Summary of the results has not yet been made. 
7.3.3.3 Medical director of health care district, head of department and chief assessment 
physician 
Medical director replied that follow-up is done of the switches by measuring the drug trough con-
centration and antibodies in certain intervals and by following the causes of the treatment interrup-
tions.  
 
Only one of the heads of department replied that there is no special follow-up done. The other head 
of department and chief assessment physician both answered that drug trough concentration and 
antibodies were measured if seen necessary. (Table 33.) 
 
TABLE 33. Usually drug trough concentration and antibodies were determined 
Is follow-up made of the switches? Number of answers 
No special follow-up 1 
Drug trough concentration and antibodies determined in certain interval 1 
Drug trough concentration and antibodies determined when necessary 2 
By tracking the causes of treatment interruption 1 
7.3.3.4 Chief pharmacists 
Most chief pharmacists replied that no special follow-up was done. Two of them commented that 
patients treated with biosimilar infliximab have the normal monitoring related to biological medicines 
and biosimilar does not change this comprehensive follow-up. One chief pharmacists had no infor-
mation if any special follow-up was made and another one reported that it should be queried from 
the treating physicians. (Table 34.) 
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One chief pharmacists replied that, in one hospitals, pharmaceutical advisory board has done the 
cost monitoring. 
 
TABLE 34. Biosimilar infliximab patients are followed as any other patient treated with biological 
medicines 
Is follow-up made of the switches? Number of answers, n = 6 
No special follow-up 4 
Otherwise, how? 2 
The normal monitoring of drug therapy. 
No information. 
Other comments? All patients receiving Infliximab are patients, whose dis-
ease and its progression/healing are monitored quite com-
prehensively in any case. Biosimilar does not bring any 
changes to this comprehensive follow-up. 
Pharmaceutical advisory board has done cost monitoring. 
Should be asked from physicians who treats the patients. 
7.4 Switching biosimilar to biosimilar (same active substance) 
Biosimilar competition is increasing due to fact that, in future, originator biosimilar will have several 
biosimilar versions in the market. Thus, switching between biosimilars (same active substance) 
might be reality in near future.  
 
It should be noted, that biosimilar product might be marketed with different trade names even if the 
same manufacturer. For example, biosimilar infliximab is being marketed in Europe as Remsima 
and Inflectra, both manufactured and developed by Celltrion. In EU, third biosimilar infliximab Flix-
abi, manufactured by Biogen, has received marketing authorization in May 2016, and thus is chang-
ing the switching situation between infliximabs. 
7.4.1 Are biosimilars interchangeable (switching biosimilar to biosimilar)? 
Target groups were asked, do they think biosimilars are interchangeable (same active substance 
and originator product) in hospital. 
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7.4.1.1 Gastroenterologists 
Most of the respondents (nine out of eleven) do think that biosimilars with same active substance 
are interchangeable in hospital, but some stated that only in under certain conditions. One chief 
physician stated that there must be sufficient evidence obtained on the equivalence, and other that 
efficacy and safety must be demonstrated. When there were doubts (two out of eleven replies), the 
thoughts were that not enough is known yet and much depends on the structural and functional 
similarity of molecules, the quality of the production technological processes and possible changes 
in those. (Table 35.) 
 
One chief physicians answered both yes and know. In option “yes”, he justified the switching with 
the same quality requirements, but saw that it might be that all patients should be evaluated in case 
there are obstacles against the switching, for example patients who have developed antibodies, 
allergic patients, patients who use other immunosuppressive medicines. In option “no” he argued 
against the switching by saying, that in practice, biosimilars are not as similar as promised com-
pared to originator products. 
 
TABLE 35. Most of the gastroenterologists think that, in hospitals, biosimilars are interchangeable 
under certain conditions 
 
Chief Physicians, n = 7 
Specialist of gastroenterology, 
n = 4 
Are biosimilar products (with 
same active substance) inter-
changeable in hospitals? 
Number of answers Number of answers 
Yes 7 2 
After the sufficient evidence has been 
obtained on the equivalence. 
Quality requirements are same, it 
might be that all patients should be 
evaluated if barriers to switch; pa-
tients who developed antibodies, al-
lergic patients, patients who use other 
immunosuppressive medicines etc. 
If proven efficacy and safety. 
Have the same efficacy. 
Efficacy appears to be similar to 
originator product. 
The results can be extrapolated 
from other indications. 
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No 1 
 
In practice are not as similar as prom-
ised compared to originator product 
 
Cannot say 
 
2 
 I'm not sure, switching from biosim-
ilar to other is not necessarily good 
thing. However, we do not know 
enough yet. 
Probably are, but much depends 
on the structural and functional 
similarity of molecules, the quality 
of the production technological pro-
cesses and possible changes in 
those. 
7.4.1.2 Rheumatologists 
Five out of nine respondents did not see problems when switching between biosimilars with same 
active substance in hospitals. They justified their answers of the switches by saying that biosimilars 
are approved by the pharmaceutical regulatory authorities, those are adequately studied and there 
are safety requirements which biosimilars must fulfill. (Table 36.) 
 
Still almost half of the respondents (four out of nine) were not sure if biosimilars with same active 
substance are interchangeable. One chief physician was concerned about, if biosimilars come from 
a large number of different manufacturers, whether differences occur in the quality, and thus also 
in the efficacy of the biosimilars. One respondent did not recommend repeated switches of the 
medicines, because it makes more difficult to follow-up the treatment and also the documentation 
would be more difficult. Though, the switches were not expected to affect the treatment otherwise. 
 
One chief physician could not say, whether biosimilars are interchangeable and asks if there are 
comparability studies made between biosimilars. 
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TABLE 36. Almost half of the respondents have concerns when switching between biosimilars 
Are biosimilar products (with same active sub-
stance) interchangeable in hospitals? 
Number of answers, n = 9 
Yes 5 
Are approved by the regulatory authorities.  
Are been adequately studied. 
If studied, such as the authorization procedure requires. 
The safety requirements. 
Cannot say 4 
If the same manufacturer, then should be the same product, 
but if a large number of different manufacturers, then suspi-
cion, whether differences occur in quality of the products, and 
thus also in the efficacy. 
Each of the biosimilar product and its related studies must be 
evaluated separately. 
The constant back and forth or repeated switching of the treat-
ment should probably try to be avoided. It makes difficult to 
follow-up the treatment. Will not likely otherwise affect treat-
ment. Documentation is going to be more difficult. 
Is there a comparison between the biosimilars? 
7.4.1.3 Medical director of health care district, head of department and chief assessment 
physician 
Chief assessment physician and medical director did not see problems of switching between bio-
similars with same active substance in hospital care. (Table 37.) 
 
One head of department was not sure if all biosimilars with same active substance are interchange-
able. She/he argued that some biosimilars, like filgrastims, which are used for a short period of 
time, are interchangeable, but with medicines used for long time, respondent was more cautious. 
 
Another head of department considers that clinicians cannot know if biosimilar can be switched to 
biosimilar, and in his/her opinion, this should be the responsibility of the pharmaceutical regulatory 
authorities. 
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TABLE 37. Regulatory authorities should be responsible of determining if biosimilars with same 
active substance are interchangeable 
Are biosimilar products (with same active  
substance) interchangeable in hospitals? 
Number of answers 
Yes 2 
No 1 
Some of them are, for example, filgrastim, which is used for 
a short period of time. Those, which are used for a long time, 
should be contemplated. 
Cannot say 1 
Practical operator cannot know, this must be the responsibil-
ity of the pharmaceutical regulatory authorities. 
7.4.1.4 Chief pharmacists 
All chief pharmacist think that biosimilar products, which have same active substance, are inter-
changeable in hospitals. There seems to be trust to the regulatory authorities and one commented 
that the Finnish supervising authority has taken a favorable position about the switching. Though, 
some thought that possibly there should be similar approach to the matter that was implemented 
with infliximab. (Table 38.) 
 
TABLE 38. Biosimilar products with same active substance are seen to be interchangeable in hos-
pitals 
Are biosimilar products (with same active  
substance) interchangeable in hospitals? 
Number of answers, n = 6 
Yes 6 
In Finland, supervising authority has taken a favorable position 
about the switching. 
The biosimilar is similar enough and the experiences about in-
fliximab are positive. 
With certain restrictions, like was done with Infliximab. 
The quality requirements are the same, each patient will prob-
ably need to be individually assessed whether there are spe-
cial groups of patients, who have barriers to the switching. 
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Meets the requirements of the regulatory authorities. 
 
7.4.2 Thinks to consider when switching between biosimilars with same active substance 
“Because each new batch of a biologic is a different product, switching a patient between biosimi-
lars for the same reference product is “no more risky” than switching a patient from the reference 
product to one of the biosimilars” (Brennan (b) 2017). 
 
One interest of the questionnaire was to find out what should be considered when switching a 
patient between biosimilars with same active substance. 
7.4.2.1 Gastroenterologists 
Eight out of the eleven respondents answered the question concerning what should be taken in to 
the consideration when switching between biosimilars. (Table 39.) 
 
Three specialist gastroenterologists responded the question and one of them had opinion that pos-
sible allergic reactions and formation of antibodies should be monitored, other would possibly 
measure drug concentrations and monitor immunization and third pointed out that there has to be 
sufficient documentations about the products. 
 
Five chief physicians answered the question and one pointed out that switching should not be done 
during the induction phase, though later switching would be ok. Other chief physician pondered if 
switching should be done blinded to be able to remove the subjective knowledge experienced by 
patients. Third chief physician thinks that price should be taken in to consideration and two of the 
chief pharmacists thought that patients should be informed about the switching. One pointed out 
the research-based information about the products. 
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TABLE 39. Different issues were raised when considering the switching biosimilar to biosimilar with 
same active substance 
 
Chief Physicians, n=5 Specialist of gastroenterology, n=3 
What should be taken in to 
consideration when switch-
ing between biosimilars 
(same active substance)? 
No switching during the induction 
phase, later switching is ok. 
Possibly should be done blinded, to 
be able to remove the subjective 
knowledge experienced by a pa-
tient. On the other hand, whether it 
is ethically right not to tell the pa-
tient if the medicine is changing? I 
do not know! 
Price. Inform patient. 
There is a research-based infor-
mation about the product (effi-
cacy/safety). 
To monitor possible allergic reactions 
and the formation of antibodies, in 
particular if as a result of switch treat-
ment is interrupted or the break is 
prolonged for one reason or another. 
Possibly measure concentrations and 
monitor immunization. 
There is sufficient documentation 
about the product. 
7.4.2.2 Rheumatologists 
Seven chief rheumatologists out of the nine responding the questionnaire answered the question 
about what should be taken in to the consideration when switching biosimilar to biosimilar with 
same active substance. (Table 40.) 
 
One chief pharmacist answered that there is really not anything what should be taken in to consid-
eration and one could not say what it could be. 
 
One chief physician saw that information activities are important and other one thought that indica-
tions and co-medications are important to take into account. Also, the Finnish Society of Rheuma-
tology has made position paper about biosimilar use and this was mentioned in one of the answer. 
 
Two of the respondents wanted to follow and document the switches more specifically, and one of 
them replied that the results of the monitoring should also be reported for example to the register 
of biological treatment.  
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TABLE 40. Switching biosimilar to biosimilar with same active substance should be closely moni-
tored 
 Chief physicians, n=7 
What should be taken 
in to consideration 
when switching be-
tween biosimilars 
(same active sub-
stance)? 
Not really anything. 
Careful monitoring, the efficacy before and after, systematically to follow-up before and 
after the switch the possible side effects, drug trough concentration and antibodies, to 
report the results for example to the register of biological treatment. 
I agree to what the Finnish Society for Rheumatology is saying in its position paper about 
use of biosimilars. 
Indications and co-medication. 
To document the switch and to monitor possible changes in efficacy and tolerability. 
Information activities. 
Could not say what it could be. 
 
7.4.2.3 Medical director of health care district, head of department and chief assessment 
physician 
Only chief assessment physician answered the question about what should be taken in to the con-
sideration when switching biosimilar to biosimilar with same active substance. Respondent’s opin-
ion is that acquisition periods should be long enough, so that switches do not occur too frequent 
and drug safety has to be taken into account. 
7.4.2.4 Chief pharmacists 
The question about what should be taken in to the consideration when switching biosimilar to bio-
similar which has same active substance gave various answers from chief pharmacists. One thinks 
that patients treated with biological medicines are monitored comprehensively anyway and biosim-
ilars do not bring any extra following to group of patients treated with infliximab’s. When using 
biological medicines, humans are administered a foreign protein, whether it be the originator or 
biosimilar product. Whenever a foreign protein is administered to humans, the risk to develop anti-
bodies increases. This risk is not in itself higher between various biological medicinal products. 
(Table 41.) 
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Also, product trainings and information about biosimilars as well as closer monitoring of antibodies 
at the beginning and safety should be taken in to account when switching between biosimilars. One 
good remark was that sharing of the information should be objective. 
 
TABLE 41. When switching biosimilar to biosimilar with same active substance, sharing of the in-
formation should be objective 
 
Number of answers, n = 6 
What should be taken 
in to consideration 
when switching be-
tween biosimilars 
(same active sub-
stance)? 
Patients treated with biological medicines are monitored comprehensively anyway. Bi-
osimilars do not cause anything special extra to the group treated with infliximab. When 
using biological medicines, humans are administered a foreign protein, whether it be 
the originator or biosimilar product. Whenever a foreign protein is administered to hu-
mans, the risk to develop antibodies increases. This risk is not in itself higher between 
various biological medicinal products. Biologic drugs are produced in living cells, and 
purified through a variety of processes. There may have differences in the purification 
residues, because the production plants are the living cells and proteins are result of 
their metabolism. In the biological world, nothing is exactly the identical, not even the 
monoclonal cell culture metabolism. 
Normal practice when changing one medicine for another. 
Sharing information should be objective. 
Product trainings, information. 
Safety. 
At the beginning, the formation of antibodies should be monitored more closely. 
 
7.4.3 Obstacles which slow down the wider usage of biosimilar products 
Questionnaire participants were asked which are the obstacles slowing down the wider usage of 
the biosimilar products. 
7.4.3.1 Gastroenterologists 
Two respondents of specialist gastroenterologists answered question about obstacles slowing 
down the wider usage of the biosimilar products and two did not. One answered that there are 
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necessarily any obstacles and another thought that there are no obstacles at the moment as bio-
similar infliximab has dominance in the market. (Table 42.) 
 
Six out of seven chief physicians answered question and two of them saw attitude as an obstacle 
and another mentioned also prejudices. As an obstacle were also seen the too rarely performed 
tendering’s of the medicines, the long term patents and evidence of the efficacy. One mentioned 
that indications of biosimilar products should be kept sufficiently tight. 
  
TABLE 42. Gastroenterologists think that there is several obstacles influencing to the greater use 
of biosimilar products 
 
Chief Physicians, n = 6 Specialist of gastroenterology, n = 2 
What are the obsta-
cles for the greater 
use of biosimilars? 
Indications must be kept sufficiently tight 
(price, benefits, disadvantages). 
Too rarely performed tendering of medi-
cines. 
Evidence of efficacy. 
Long term patents. 
Attitude. 
The attitudes and prejudices. 
Biosimilar infliximab has dominance, so 
I think there is no obstacles at the mo-
ment. 
Not necessarily have any. 
7.4.3.2 Rheumatologists 
Eight of the nine respondents answered the question, that aimed to find out, which things slow 
down the wider usage of biosimilars. (Table 43.) 
 
Most of the respondents (six out of eight) saw multiple obstacles slowing down the wider usage of 
biosimilars. Patients and doctors have still prejudices of the biosimilar products, some might not 
have experience with biosimilars and one reason is also the pressure from the company that has 
manufactured the original product. There is also speculation, whether the quality of the products 
can be guaranteed, if biosimilars are manufactured in many different countries where cultural prac-
tices differ. This puts lot of pressure to the pharmaceutical regulatory authorities, which have to be 
able to ensure quality of the products. The repeated switches are also seen as a potential threat to 
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achieve the best possible care. Access to information of the new biosimilars must also be guaran-
teed. Each physician prescribing biological medicinal products, needs a lot of information of each 
new biosimilar coming to the market. In addition, it is a challenge to get the prescriber to change 
the practice, because it is easier to stick to the original product, which physician already knows 
 
Two chief physicians out of eight think that at the moment, there are not so many known obstacles 
for wider use of the biosimilars. 
  
TABLE 43. Rheumatologists see many obstacles which slow down the wider usage of biosimilars 
 
Arguments, n = 8 
What are the obstacles for the 
greater use of biosimilars? 
Prejudices and uncertainties, the pressure from company which has developed 
the drug. 
Patients and doctors have prejudices. 
The quality must be guaranteed. Probably the biosimilars are manufactured 
and will be manufactured in many different countries, having different sorts of 
cultural practices. The pharmaceutical regulatory authorities (such as the 
EMEA) have a great responsibility on what kind of products will be approved. 
Each physician prescribing biological medicinal products, needs a lot of infor-
mation of each biosimilar he/she is using. It is easier to stick to the originator 
medicine, which physician knows. 
Inexperience. 
Treatment should be clear, documented and reliably implemented. Repeated 
switches can complicate this. 
There are not many known obstacles. 
There are still so few. 
7.4.3.3 Medical director of health care district, head of department and chief assessment 
physician 
One of the heads of department, medical director and chief assessment physician replied the ques-
tion about obstacles for wider usage of biosimilars. One reason which has slowed down the use of 
biosimilars is pharmaceutical industry’s strong anti-marketing. Also, prescribers might have fears, 
misconceptions, and insufficient biosimilar knowledge Some of the originator products have now 
“improved” versions of themselves on the market and as a result of that, those versions might be 
seen as better options than the biosimilars. (Table 44.) 
  
156 
 
TABLE 44. One obstacle slowing down the wider usage of the biosimilars, is the pharmaceutical 
industry’s strong anti-marketing against biosimilars 
 
Number of answers, n = 3 
What are the obstacles for the 
greater use of biosimilars? 
Prescriber's fears and misconceptions, insufficient knowledge of biosimilar. 
From the originator product has come an option, that is better than the bio-
similar. 
The pharmaceutical industry's strong anti-marketing. 
7.4.3.4 Chief pharmacists 
Five of the six respondents answered the question, that aimed to find out, which things slow down 
the wider usage of biosimilars. (Table 45.) 
 
The reasons slowing down the use of biosimilars are insufficient biosimilar knowledge, originator 
companies’ product development and prejudices, as well as originator companies' effective mar-
keting systems. Clinicians have been reluctant to use biosimilars, however, the resistance of phy-
sicians is not so intense than it used to be. Also, safety was seen to be one of the reasons slowing 
down the wider use of biosimilars.  
  
TABLE 45. Lack of knowledge and prejudices, for example, are obstacles for wider usage of 
biosimilars 
 Number of answers, n = 5 
What are the obstacles for the 
greater use of biosimilars? 
Attitudes, originator companies' product development. 
If there are barriers, lack of information. 
Prejudices. 
Safety, clinicians’ resistance (is no longer so intense than before). 
Originator companies' effective marketing system. 
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7.5 Price competition 
When biosimilar product enters to the market, it is assumed to cause price competition. The first 
biosimilar filgrastim received a marketing authorization in Europe in September 2008 and Infliximab 
in September 2013. 
7.5.1 Estimated price differences 
The questionnaire participants were asked, what they estimated price difference to be between 
biosimilar and originator infliximab, before the first biosimilar infliximab entered to the market. 
7.5.1.1 Gastroenterologists 
Nine out of eleven (6/7 chief physicians and 3/4 specialists) respondents answered the question 
what were their estimates of price difference between biosimilar infliximab and originator infliximab, 
before the first biosimilar infliximab entered to the market. (Table 46.) 
 
The estimated price differences varied quite a lot, between 25 – 80 %. Chief gastroenterologists 
had estimated that the price difference could have been 30 - 60%, and they had based their pre-
sumptions of the price difference mostly purely to the guesses. One justified his/her estimate by 
previous experience in competitive tendering, other one told that the originator research is expen-
sive and one based his/her estimate to what he/she had heard. One specialist's estimated price 
difference was based on to the information received from pharmaceutical companies. 
 
TABLE 46. The estimated price difference varied between 25 to 80 % 
 
Chief Physicians, n = 6 
Specialist of gastroenterology,  
n= 3 
 
Estimated 
price  
difference 
Arguments Estimated 
price  
difference 
Arguments 
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Before the biosimi-
lar infliximab en-
tered to market, you 
estimated price dif-
ference between bi-
osimilar infliximab 
and its originator in-
fliximab to be 
50% 
35% 
60% 
40%  
30%  
 
Guess. 
Previous experience in competi-
tive tendering. 
The originator research is ex-
pensive; research information.  
On the basis of I have heard 
and memory. 
Estimate 
Assumption. 
50 - 80% 
30% 
25% 
Based on information 
received from phar-
maceutical compa-
nies. 
Guess  
7.5.1.2 Rheumatologists 
The estimated price differences of originator infliximab and its biosimilar varied only little, between 
30 – 50 %. Most chief physicians (six out of nine) had estimated that the price difference could 
have been 30 %, and one of them had purely speculated the price difference and another had 
thought that 30 % is a significant enough and had not expect it to be more radical. One chief phy-
sician had based his/her estimate to what was general supposition and one physician had had 
expert evaluations in use and had assumed that the price difference could have been 30% and 
pointed out that challenging manufacturing processes do affect the pricing. One had trusted the 
competition and had assumed the price difference could have been little more, 40 %. Also, 50 % 
price difference was mentioned twice, and one told it to be a speculative. (Table 47.) 
 
TABLE 47. The price difference was estimated to be 30 – 50 % 
 
Estimated 
price  
difference 
Arguments, n = 9 
Before the biosimilar infliximab en-
tered to market, you estimated price 
difference between biosimilar inflix-
imab and its originator infliximab to 
be 
50% 
40% 
30% 
Competition. 
Estimate. 
General supposition. 
Guess. 
Expert evaluations, challenging manufacturing process. 
Thought that it would be significant, but assumed that the 
price difference would not be more radical. 
To the best of my recollection. 
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7.5.1.3 Medical director of health care district, head of department and chief assessment 
physician 
Chief assessment physician and two heads of department replied the question about estimated 
price difference between biosimilar infliximab and originator infliximab (before biosimilar infliximab 
came on the market). The other head of department had estimated the price difference to be 30 %, 
and another 50 %. Chief assessment physician had speculated, that the price difference could have 
been 50 %. 
7.5.1.4 Chief pharmacists 
Five of the six respondents answered the question. The estimated price differences of originator 
infliximab and its biosimilar varied between 30 – 60 %. One chief pharmacist based his/her the 
presumption of 40% price difference to the speculations of how much the new entrants wanted to 
penetrate the market. Two of the respondents did estimate the price difference could have been 
30%, and one of them based his/her estimate to the discussions in professional journals. Two chief 
pharmacists had assumed the price difference could have been as high as 60%. One replied that 
when more options of same product enters the market, the competition will start, as in the any 
market area. Chief pharmacist commented that there is no possibility to ponder beforehand what 
will happen to one individual product’s price, since hospital has in use several thousands of different 
medicinal products, when taking into account the different dosages, pack sizes and forms of med-
icines. (Table 48.) 
 
TABLE 48. The estimated price difference was estimated to be 30 – 60 % 
 
Estimated price 
difference 
Arguments, n = 5 
Before the biosimilar infliximab 
entered to market, you estimated 
price difference between biosim-
ilar infliximab and its originator 
infliximab to be 
60% 
40% 
30% 
 
Does not possibility to think about the possible 
changes in prices, when the market of an individual 
product changes. When more options of the same 
product enter the market, the competition will start, 
as in any market area. 
Discussions in professional journals. 
On research information. 
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To a feeling, how much the new entrants wanted 
to penetrate the market 
7.5.2 Price difference when biosimilar product was selected to pharmaceutical formulary 
The questionnaire participants were asked to reveal the price difference between the biosimilar and 
originator infliximab, when biosimilar infliximab was selected to the pharmaceutical formulary at the 
first time. Also, the year when this happened was requested to give. 
7.5.2.1 Gastroenterologists 
Not all respondents answered this question. Six out of seven chief gastroenterologists and three 
out of four specialists answered. One chief physician advised to inquire from the pharmacy, and 
one specialist did not know the answer. (Table 49.) 
 
In the answers given, the price difference (calculated on the purchase prices) between originator 
and biosimilar infliximab varied quite much, between 20 – 70%.  The first time when biosimilar 
infliximab was selected to the pharmaceutical formulary, varied from 2014 to 2016. 
 
TABLE 49. The year when biosimilar was selected to the pharmaceutical formulary varied from 
2014 to 2016, and the price difference between originator and biosimilar infliximab varied between 
20 – 70 % 
 
Chief Physicians, n = 6 Specialist of gastroenterology, n = 3 
 
Price  
difference, 
% 
Biosimilar was  
selected to pharmaceuti-
cal formulary (year) 
Price  
difference, 
% 
Biosimilar was  
selected to pharmaceu-
tical formulary (year) 
Price difference (cal-
culated on the pur-
chase price) between 
biosimilar infliximab 
and its originator in-
fliximab, after bio-
similar was selected 
65% 
57% 
20% 
70% 
40% 
2016 
2015 
2015 
2014 
2015 
Advised to inquire from the 
pharmacy. 
65% 
70% as far 
as could 
recollect 
2016 
2015 
Did not know 
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to pharmaceutical 
formulary 
7.5.2.2 Rheumatologists 
The price difference (calculated on the purchase price) between originator and biosimilar infliximab, 
when biosimilar was selected to pharmaceutical formulary for the first time, varied quite much, 
between 30 – 80 %. In four responses, price difference varied between 70 – 80%, and in five 
responses the difference was 30 – 50 %. Two of the respondents mentioned that also the originator 
infliximab had lowered the price and one of them had used the “original price” of the originator 
product in calculations. One chief rheumatology commented, that essential is the price difference 
to the originator product before biosimilar came on the market. In the tenders, the price difference 
is not that important. (Table 50.) 
 
Biosimilar infliximab has been selected to the hospitals’ pharmaceutical formulary between 2014 – 
2016. 
 
TABLE 50. The year when biosimilar was selected to pharmaceutical formulary varied from 2014 
to 2016, and the price difference between originator and biosimilar infliximab varied between 30 – 
80 % 
 
Price difference, % 
n = 9 
Biosimilar was selected to phar-
maceutical formulary (year) 
Price difference (calculated 
on the purchase price) be-
tween biosimilar infliximab 
and its originator infliximab, 
after biosimilar was se-
lected to pharmaceutical 
formulary 
50% 
80% 
40% 
70% 
70 % of the original price of the originator 
product 
30% 
2016 
2014 
2015 
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Other comments I understood, that 80% of the price of the 
originator, although the originator dropped 
the price also X %. 
The originator dropped the price also due 
to the competition.  In my view, essential 
is the price difference to the originator 
product before biosimilar came on the 
market. In the tenders, the price difference 
is not that important. 
 
7.5.2.3 Medical director of health care district, head of department and chief assessment 
physician 
Medical director and one of the head of the department replied the question about the price differ-
ence (calculated on the purchase price) between originator and biosimilar infliximab, when biosim-
ilar was selected to pharmaceutical formulary for the first time. Head of the department replied that 
the price difference is 60 % and medical director 43 %. 
7.5.2.4 Chief pharmacists 
The price difference (calculated on the purchase price) between originator and biosimilar infliximab, 
when biosimilar was selected to pharmaceutical formulary for the first time, varied between 50 to 
57% in the four replies and in two responses difference was 40 – 43 %. (Table 51.) 
 
The year when biosimilar infliximab was selected to the hospital’s pharmaceutical formulary varied 
from 2014 to 2016. 
 
TABLE 51.The year when biosimilar was selected to the pharmaceutical formulary varied from 2014 
to 2016, and the price difference between originator and biosimilar infliximab varied between 40 – 
57 % 
 
Price difference, % 
n = 6 
Biosimilar was selected to pharma-
ceutical formulary (year) 
Price difference (calculated on the purchase 
price) between biosimilar infliximab and its 
57% 
50% 
2016 
2015 
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originator infliximab, after biosimilar was se-
lected to pharmaceutical formulary 
43% 
40% 
2014 
 
7.5.3 Has biosimilar infliximab affected the price of the originator infliximab? 
The survey participants were asked to reveal if the purchase price of originator infliximab was 
changed after the biosimilar infliximab for first time participated in the hospital tendering, compared 
to the purchase price of the originator infliximab offered in the previous hospital tendering. 
7.5.3.1 Gastroenterologists 
Six out of seven chief gastroenterologists and three out of four specialist gastroenterologists an-
swered the question. Of these responses, one chief physician refused to answer, one gave an 
estimate and one specialist did not know the answer. (Table 52.) 
 
Four chief physicians told that purchase price of the originator product was reduced when biosimilar 
infliximab participated the hospital tendering for the first time and the price was compared to previ-
ous hospital tendering purchase price. The price decrease varied from 20 % to 30 % (35% was told 
to be an estimate). One answered that the originator Infliximab purchase price was not change. 
 
Two specialists (2/4) told that the originator infliximab price was reduced, but one did not know how 
much of the purchase price of originator infliximab has changed and other one answered 50 %. 
 
TABLE 52. The originator infliximab purchase price decreased, when biosimilar infliximab partici-
pated hospital tendering first time 
 Chief Physicians, n = 6 Specialist of gastroenterology, n = 3 
When biosimilar entered the 
hospital tendering for the first 
time, did the originator 
product's purchase price 
change, when compared to 
the previous purchase price? 
Number of 
answers 
Price change, % Number of 
answers 
Price change, % 
Reduced  4 30%  2 50% 
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20% 
35%, estimate  
Did not remember how 
much 
Did not change 1 
 
    
Other comments? 1 Did not want to 
comment  
 1 Did not know 
 
7.5.3.2 Rheumatologists 
All chief rheumatologists replied to the question. Of these respondents one did not know if the price 
of the originator infliximab has changed. (Table 53.) 
 
Six chief physicians told, that the purchase price of the originator product was reduced, when bio-
similar infliximab participated hospital tendering for the first time and the price was compared to the 
previous hospital tendering purchase price. Two responded the price reduction be 30 % and 40 %, 
one did not know the exact price reduction, and two of the respondents did not give figures. One 
chief physician replied that the originator infliximab purchase price was not changed. 
 
TABLE 53. When the biosimilar infliximab participated hospital tendering for the first time, also the 
originator infliximab purchase price decreased 
When biosimilar entered the hospital tendering 
for the first time, did the originator product's pur-
chase price change, when compared to the pre-
vious purchase price? 
Number of answers, 
n = 9 
Price change, % 
Reduced 6 40% 
30% 
Did not change 1   
Other comments? 2 Did not know 
Did not know the exact difference. 
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7.5.3.3 Medical director of health care district, head of department and chief assessment 
physician 
Medical director and one head of department replied the question. Head of department told that 
the purchase price of the originator product was reduced when biosimilar infliximab participated 
hospital tendering for the first time and the price was compared to the previous hospital tendering 
purchase price. Medical director answered that the originator product price had lowered during the 
previous acquisition period and the same price was offered to the current procurement season. 
However, none of the respondents did not reveal the exact price reduction of the originator product. 
7.5.3.4 Chief pharmacists 
Two chief pharmacists replied that the purchase price of the originator product was lowered by 30% 
when biosimilar infliximab participated hospital tendering for the first time and the price was com-
pared to the previous hospital tendering purchase price. (Table 54.) 
 
Three replied that originator infliximab purchase price had not changed and one of them com-
mented that the price had decreased already during the previous acquisition period after the new 
competitive tendering had been opened during the procurement period. Another commented that 
new competitive tendering was opened during the procurement period 2014 – 2015, but originator 
infliximab had lowered the price already in 2013. When competitive tendering was opened for 2014-
2015 period, company having the originator product offered the same price again and also two 
companies with biosimilar product participated. 
 
TABLE 54. At least in one hospital, originator infliximab price was lowered before biosimilar inflixi-
mab participated tender process for the first time 
When biosimilar entered the com-
petitive tendering for the first time, 
did the originator product's pur-
chase price change, when compared 
to the previous purchase price? 
Number of answers, n = 5 Price change, % 
Reduced 2 30% 
No 3   
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Other comments? A new competitive tendering was made between the 
procurement period 2014 - 2015 (the possibility is 
recognized in the invitation to tender). Already in 
2013, for the period 2014 to 2015, the originator 
company gave a discount. Originator company gave 
the same price again when competitive tendering 
was opened in between 2014-2015 period and also 
two biosimilar providers participated. The other bio-
similar's offer was overall more economical and was 
chosen for 2015. 
Price decreased during the previous acquisition pe-
riod, after new competitive tendering was made dur-
ing the current procurement period. 
  
 
7.6 Cost savings 
The introduction of biosimilars is expected to reduce prices and to generate medicinal cost savings 
for the hospitals.  
7.6.1 For which patients’ biosimilar infliximab treatments were initiated? 
One aim of the questionnaire was to find out, how medicinal cost savings were attempted to be 
achieved by using biosimilar infliximab. 
7.6.1.1 Gastroenterologists 
All chief physicians, and three out of four specialists, replied the question. (Table 55.) 
 
One specialist gastroenterology replied, that the medicinal cost savings were attempted to be 
achieved by initiating biosimilar infliximab for new patients and by switching chosen patient groups, 
treated with infliximab originator, to biosimilar infliximab. Another two respondents told that all pa-
tients treated with originator infliximab were switched to its biosimilar. 
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Two out of seven chief physicians replied, that the medicinal cost savings were attempted to be 
achieved by switching all patients treated with originator infliximab to biosimilar infliximab. One chief 
physician who had switched the treatment only for the chosen patient groups commented, that 
skeptical patients were not switched. One replied that the savings were attempted to be achieved 
by initiating biosimilar infliximab to new patients and also by switching the treatment for chosen 
patient groups. The patients whom were not switched, were highly allergic patients and for whom 
had been difficulties to find the suitable medicines. Three out of seven chief gastroenterologists 
had all initiated biosimilar infliximab for the new patients and also all the patients treated with orig-
inator infliximab were switched to its biosimilar. 
  
No one answered that the savings would have been attempted to be achieved only by initiating 
biosimilar infliximab for the new patients. 
   
TABLE 55. Most often, the medicinal cost savings were attempted to be achieved by switching all 
patients treated with the originator infliximab to its biosimilar and also by initiating biosimilar inflixi-
mab for the new patients 
 
Chief Physicians, n = 7 
Specialist of gastroenterology, 
n = 3 
How drug cost savings were attempted 
to be achieved by using biosimilars? 
Number of answers Number of answers 
By initiating biosimilar for new patients 4 1 
By switching all patients from originator 
product to biosimilar product 
5 2 
By switching chosen patient groups from 
originator product to biosimilar product 
2 1 
Highly allergic patients who also 
otherwise have been difficult to 
find suitable medicines. 
Skeptical patients. 
Specific patients. 
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7.6.1.2 Rheumatologists 
Four chief rheumatologists replied that drug cost savings were attempted to be achieved by initiat-
ing biosimilar infliximab for new patients and by switching all patients treated with the originator 
infliximab to its biosimilar. (Table 56.) 
 
Three replied that savings were attempted to be achieved by initiating biosimilar infliximab for new 
patients and by switching chosen patient groups treated with the originator infliximab to the biosim-
ilar infliximab. In all cases, pediatric patients were excluded from the switches and in another case, 
also patients who had refused of the switch despite given information, were excluded. At least in 
one hospital, pediatricians have initiated the infliximab treatments with biosimilar infliximab instead 
of the originator infliximab. 
 
Two of the respondents told that all patients treated with originator infliximab were switched to the 
biosimilar infliximab. 
 
No one answered that savings would have been attempted to achieved only by initiating biosimilar 
infliximab treatments for new patients. 
 
TABLE 56. Pediatric patients were not switched, but at least in one hospital, pediatricians initiated 
the infliximab treatments with biosimilar infliximab 
How cost-savings were attempted to be achieved by using 
biosimilars? 
Number of answers, n= 9 
By initiating for new patients 7 
By switching all patients from originator product to biosimilar 
product 
6 
By switching chosen patient groups from originator product to 
biosimilar product 
3 
Pediatric patients were apparently not switched, 
and also if the patient refused, despite the infor-
mation given. 
Young patients. 
Pediatricians decided not to switch the originator 
products of pediatric patients, but the new treat-
ments were initiated with biosimilar. 
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7.6.1.3 Medical director of health care district, head of department and chief assessment 
physician 
Both, medical director, and chief assessment physician replied that medicinal cost savings were 
attempted to be achieved by initiating biosimilar infliximab for new patients and by switching the 
chosen patient groups treated with the originator infliximab to the biosimilar infliximab. Pediatric 
patients and reluctant patients were not switched. 
 
Two heads of department replied that savings was attempted to be achieved by switching chosen 
patients treated with originator infliximab to the biosimilar infliximab. One respondent did not specify 
patients which were not switched and other one told the most difficult patients were excluded of the 
switches. 
7.6.1.4 Chief pharmacists 
Three chief pharmacists replied that medicinal cost savings were attempted to be achieved by 
initiating biosimilar infliximab for new patients and by switching chosen patient groups treated with 
originator infliximab to the biosimilar infliximab. One of them commented that pediatric patients 
were not switched and another commented that rheuma, psoriasis and IBD-patients were excluded 
and one did not specify. (Table 59.) 
 
Only one respondent told that treatments of all patients were switched to biosimilar infliximab and 
one commented that medicinal cost savings were attempted to be achieved by switching chosen 
patient groups, treated with originator infliximab, to its biosimilar. The pediatric patients were ex-
cluded of the switches. 
 
No one answered that savings would have been attempted to achieved only by initiating biosimilar 
infliximab for new patients. 
 
There was also commented that beforehand there cannot be set any certain saving targets or dis-
count percentage goals. The Health Care Act and the Act on Specialized Medical Care stipulates 
that the hospital concerned must provide to patients the known effective treatment. By initiating the 
usage of the selected biosimilar, it was possible to lower the growth pressure of the medicine costs. 
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Encouraged by the hospital's medical director, the target was set to switch, as widely as possible, 
to the use of biosimilar infliximab. The same target was set for the period 2016-2017. 
 
TABLE 57. Most often, medicinal cost savings were attempted to be achieved by switching chosen 
patient groups treated with originator infliximab to its biosimilar and also by initiating biosimilar in-
fliximab for new patients 
How cost-savings were attempted to be 
achieved by using biosimilars? 
Number of answers, n = 6 
By initiating for new patients 3 
By switching all patients from originator 
product to biosimilar product 
1 
By switching chosen patient groups from 
originator product to biosimilar product 
4 
Pediatrics. 
Rheuma, Psoriasis, IBD. 
Other comments? By starting to use the selected biosimilar, it was possible to reduce 
the growth pressure of medicine costs. Encouraged by the hospital's 
medical director, the target was set to shift, as widely as possible, 
for the use of biosimilar. The same target was set for the period 
2016-2017. 
7.6.2 Were the medicinal cost savings achieved? 
If the drug cost savings were attempted to be achieved by using biosimilar infliximab, were the 
medicinal cost saving goals achieved? 
7.6.2.1 Gastroenterologists 
All chief gastroenterologists, and two out of four specialist gastroenterologists responded the ques-
tion. Most respondents (seven out of nine) felt, that cost savings were achieved by using biosimilar 
infliximab, and the factors which helped the realization of cost savings were that infusions were 
cheaper than before and originator infliximab treatments of all patients from were switched to bio-
similar infliximab. (Table 60.) 
Two chief physicians felt that the cost savings were achieved only partly. One explained that for 
some patients’ the higher doses had to be used, for some patients more frequent doses were given 
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because of exacerbations, and exacerbations of intestinal inflammatory disease appeared to in-
crease despite of all medications. Other one stated that the usage of infliximab has increased com-
pared to the past. 
No one answered that the drug cost savings were not achieved by using a biosimilar infliximab. 
 
TABLE 58. Most of the respondents felt, that the cost savings were achieved by using biosimilar 
infliximab 
 Chief Physicians, n = 7 Specialist of gastroenterology,  
n = 2 
Are the cost savings realized? Number of answers Number of answers 
Yes 5 2 
All patients switched from originator 
product biosimilar. 
Each infusion is cheaper than before. 
 
Partly 2 
 
Some of the patients use higher 
doses, more frequent doses are given 
because of exacerbations, and exac-
erbations of intestinal inflammatory 
disease appears to increase despite of 
all medications. 
Increased use of infliximab compared 
to the past. 
 
7.6.2.2 Rheumatologists 
All but one chief rheumatology felt, that cost savings were achieved by using biosimilar infliximab. 
The factors which helped the realization of cost savings were, that biosimilar infliximab was used 
with same indications that originator infliximab was used, all adult patients treated with originator 
infliximab were switched to biosimilar infliximab, and new infliximab treatments were initiated with 
lower price biosimilar infliximab. (Table 61.) 
 
All but one chief physicians felt, that cost savings were achieved by using biosimilar infliximab. The 
factors that helped to achieve the cost savings were, that biosimilar infliximab was used with same 
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indications that originator infliximab was used, all adult patients treated with the originator infliximab 
were switched to the biosimilar infliximab, and new infliximab treatments were initiated with the 
more affordable biosimilar infliximab. 
 
No one answered that the drug cost savings were not achieved by using a biosimilar Infliximab. 
 
TABLE 59. Most chief rheumatologists felt, that cost savings were achieved by using a biosimilar 
infliximab 
Are the cost savings realized? Number of answers, n = 9 
Yes 8 
Same indications. 
Principally, the treatment of all patients was switched to biosimilar inflixi-
mab. 
Lower price made possible to achieve savings, because adult patients 
were switched to biosimilar infliximab and all new infliximab treatments 
were initiated with biosimilar. 
Partly 1 
All patients were not switched, some patients had to be switched back to 
originator infliximab. Though, cost savings were achieved by initiating bio-
similar infliximab for new patients. 
7.6.2.3 Medical director of health care district, head of department and chief assessment 
physician 
Medical director, chief assessment physician and both heads of department estimated that cost 
savings were achieved. The factors helping in the realization of cost savings were, new infliximab 
treatments were initiated with lower price biosimilar infliximab, the switching was done actively and 
biosimilar infliximab is considerably cheaper compared to originator infliximab. 
7.6.2.4 Chief pharmacists 
Four chief pharmacists commented, that cost savings were achieved by using biosimilar infliximab. 
The factors that helped to achieve the cost savings were, that after hesitation, also originator inflix-
imab treatments were switched to biosimilar, and not only initiated biosimilar infliximab treatments 
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for new patients. In one hospital, it is recommended that originator product may only be used in 
exceptional cases. (Table 62.) 
 
One chief pharmacist felt that cost savings were achieved only partly, but did not explain what was 
the reason. 
 
There was also one comment in which was explained why total medicinal costs will not reduce. It 
said that even if through tendering is achieved more favorable net price level the new innovations 
are usually more costly than previous ones and for this reason, usually as a whole, medicinal costs 
do not reduce. Competition and competitive tendering restrain the growth of medicinal costs, but 
do not eliminate it. 
 
TABLE 60. Most chief pharmacists commented that cost savings were achieved by using biosimilar 
infliximab 
Are the cost savings realized? Number of answers, n = 6 
Yes 4 
Originator product may only be used in exceptional cases. 
After hesitation, also originator infliximab treatments switched to biosimilar. 
Partly 1 
Other comments? Through competitive tendering is achieved as a whole more favorable net 
price. New innovations are usually more costly than previous ones. For this 
reason, usually as a whole, drug costs are not reduced. Competition and 
competitive tendering in itself restrain the growth of medical costs, but do not 
eliminate it. 
7.6.3 How much was saved by using biosimilar infliximab? 
If the drug cost savings were achieved by using the biosimilar infliximab, how much were the cost 
savings? 
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7.6.3.1 Gastroenterologists 
Only one out of four specialist gastroenterologists answered the question and he/she told that there 
was no drug cost savings achieved 2015, but this could be explained by the fact that biosimilar 
infliximab was chosen to hospital’s pharmaceutical formulary for the first time one year later, 2016. 
(Table 63.) 
 
Five out of seven chief gastroenterologists, answered the question. One chief physician answered 
that there was no drug cost savings achieved 2015, but as with specialist, this could be explained 
by the fact that the biosimilar infliximab was chosen to hospital’s pharmaceutical formula first time 
2016. Other estimates of the savings varied from 40 000€ to 700 000€. 
 
TABLE 61. Estimated drug cost savings achieved by using biosimilar infliximab were up to 700 
000€ 
 
Chief Physicians, n = 5 
Specialist of gastroenterology, 
 n = 1 
Your estimate of the cost savings, 
that were achieved with use of bio-
similar product in 2015. (€) 
0€  
40 000€ 
50 000€  
300 000€  
700 000€ 
0€ 
7.6.3.2 Rheumatologists 
Only six out of nine chief rheumatologists replied the question. The five chief physicians’ estimated 
cost savings varied from 50 000€ to over 500 000€. One chief rheumatology answered that there 
was no drug cost savings achieved 2015, but as with specialist of gastroenterology, this could be 
explained by the fact that biosimilar infliximab was chosen to the hospital’s pharmaceutical formu-
lary first time in 2016. (Table 64.) 
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TABLE 62. Estimated drug cost savings achieved by using biosimilar infliximab were up to 
500 000€ 
 
Estimated cost savings, € 
 n = 6 
Your estimate of the cost savings, that were achieved with 
use of biosimilar product. 
As far as I have understood over 500 000€. 
300 000€  
200 000€ 
50 000€ 
0€ (switching started beginning of 2016) 
7.6.3.3 Medical director of health care district, head of department and chief assessment 
physician 
Medical director estimated the cost savings be 1,8 million euros and head of department 50 000€. 
Chief assessment physician and other head of department did not answer the question. 
7.6.3.4 Chief pharmacists 
five out of six chief pharmacists replied the question and estimated cost savings varied from 140 
000 € to 950 000 €. One chief pharmacist did not reply to the question, but this could be ex-plained 
by the fact that biosimilar infliximab was chosen to hospital’s pharmaceutical formulary first time in 
2016. (Table 65.) 
 
TABLE 63. Estimated drug cost savings achieved by using biosimilar infliximab were up to 950 
000€ 
 
Estimated cost savings, € 
 n = 5 
Your estimate of the cost savings, that were achieved with 
use of biosimilar product. 
950 000 
335 000 
313 000 
300 000 
140 000 
  
176 
7.6.4 How the released funds, which were achieved by using a biosimilar infliximab, were 
spent? 
If the drug cost savings were achieved by using the biosimilar infliximab, how the money saved 
was spent? 
7.6.4.1 Gastroenterologists 
All chief physicians and three out of four specialists responded the question. (Table 66.) 
 
The majority of chief physicians (six out of seven) commented that the medicinal cost savings, 
which were achieved by using biosimilar infliximab, were used hospital’s cost of medicines man-
agement. One told in addition, that the cost savings did enable commissioning of new medicinal 
products to the pharmaceutical formulary and it made also possible to treat more patients with the 
biosimilar infliximab. In one hospital, drug cost savings were used to treat more patients with bio-
similar infliximab. 
 
One specialist did not know how money saved was spent. One answered that drug cost savings 
were used to the hepatitis C medications and also to the management of cost of medicines. One 
told that savings was used to the operating area and hospital budgets in generally. 
 
TABLE 64. Drug cost savings, achieved by using biosimilar infliximab, were used to manage the 
cost of medicines 
 Number of answers 
If medicine cost savings were achieved for 
the hospital with use of biosimilar product, 
where the released funds were used? 
Chief Physicians, n = 7 Specialist of gastroenterology, n = 3 
Made possible to treat more patients with the 
product in question 
2 
 
Enabled commissioning of new medicinal 
products to the pharmaceutical formulary. 
1 
 
To manage the cost of medicines 6 1 
Other, what? 
 
3 
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 I do not know. 
For hepatitis C medications. 
To the operating area and hospital 
budget generally. 
7.6.4.2 Rheumatologists 
Most chief rheumatologists (eight out of nine) told that cost savings achieved by using biosimilar 
infliximab, were used to manage the cost of medicines. Only three replied that the management of 
drug costs was the only target. Five answered also, that the cost savings enabled commissioning 
of the new medicinal products to the pharmaceutical formulary and/or made possible to treat more 
patients with the infliximab. In one hospital, addition the above mentioned, the money saved was 
used to hiring personnel and for equipment procurement. (Table 67.) 
 
Only one chief physician replied, that no substitute was received. 
 
TABLE 65. Cost savings, achieved by using biosimilar infliximab, were used to manage the cost of 
medicines 
If medicine cost savings were achieved for the hospital with 
use of biosimilar product, where the released funds were 
used? 
Number of answers, n = 9 
Made possible to treat more patients with the product in question 3 
Enabled commissioning of new medicinal products to the pharma-
ceutical formulary 
4 
To manage the cost of medicines 8 
To hire personnel 1 
Other, what? 2 
For equipment procurement. 
We did not get any substitute. 
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7.6.4.3 Medical director of health care district, head of department and chief assessment 
physician 
Medical director and one head of department replied that cost savings, achieved by using biosimilar 
infliximab, were used to manage the hospital’s cost of medicines. Chief assessment physician and 
other head of department mentioned also, that the cost savings enabled commissioning of new 
medicinal products to the pharmaceutical formulary. 
7.6.4.4 Chief pharmacists 
Most chief pharmacists (four out of six) told that cost savings, which were achieved by using bio-
similar infliximab, were used to manage the hospital's cost of medicines. Only one responded that 
the management of drug costs was the only focus. Three of them mentioned also, that the cost 
savings enabled commissioning of the new medicinal products to the pharmaceutical formulary and 
made possible to treat more patients with infliximab. In one hospital, the cost savings enabled 
commissioning of new medicinal products to the pharmaceutical formulary and was also used to 
manage the hospital's cost of medicines. (Table 68.) 
 
One chief pharmacist pointed out that in the budget, the euros earmarked for medicines, cannot be 
used to recruit staff, or vice versa. 
 
TABLE 66. Cost savings, achieved by using biosimilar infliximab, were used to manage the cost of 
medicines 
If medicine cost savings were achieved for the hospital with 
use of biosimilar product, where the released funds were 
used? 
Number of answers, n = 6 
Made possible to treat more patients with the product in question 3 
Enabled commissioning of new medicinal products to the phar-
maceutical formulary 
4 
In order to manage the cost of medicines 5 
Other, what? 1 
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In the budget, the euros earmarked for medi-
cines, cannot be used to recruit staff, or vice 
versa. 
7.6.5 Biosimilar infliximab share of the total use of infliximab 
The aim was to survey, how much was biosimilar infliximab usage share of the total use of infliximab 
products (ATC -code L04AB02), in 2015. Infliximab was counted in milligrams. 
7.6.5.1 Gastroenterologists 
One specialist gastroenterology answered the question. He/she told that the share of biosimilar 
infliximab was 30% of the total usage of infliximab products. (Table 69.) 
 
Almost all chief gastroenterologists, who had returned the questionnaire, answered the question 
(six out of seven). The lowest biosimilar share was 40 %, and highest 100%. Four out of seven told 
that the biosimilar infliximab share was 95 % - 100 %. One chief physician did not answer the 
question, but this hospital had no biosimilar infliximab in hospital’s pharmaceutical formulary in 
2015. 
 
TABLE 67. Biosimilar infliximab share (%) varied quite much, from 30 to 100 % 
 Chief Physicians, n = 6 Specialist of gastroenterology, 
n = 1  
Percentage of, % 
Biosimilar infliximab share of the total use 
of infliximab products, ATC-code L04AB02 
(infliximab mg). 
100% 
95% 
98% 
50% 
40% 
30 % 
7.6.5.2 Rheumatologists 
Four chief rheumatologists replied that the share of the biosimilar infliximab of the total use of in-
fliximab products was 90% (one answer was probably 2016 year's figure) and two told it to be 95%, 
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in 2015. The lowest biosimilar share was 80 % and it might be also 2016 year's figure, since in this 
hospital, biosimilar infliximab was chosen to the pharmaceutical formulary in the beginning of 2016. 
Actually, one chief physician mentioned this in his/her reply, by saying that infliximab share was 
90% but not until 2016. In that hospital, pediatric patients continued using originator infliximab. One 
chief rheumatology did not know the answer. (Table 70.) 
 
TABLE 68. Biosimilar infliximab share (%) varied from 80 to 95 % 
 
Percentage of, % 
n = 9 
Biosimilar infliximab share of the total use of infliximab 
products, ATC-code L04AB02 (infliximab mg). 
95% 
90% 
80% 
Do not know 
90% (I think not until 2016, only the pediatric pa-
tients continued with the originator infliximab) 
7.6.5.3 Medical director of health care district, head of department and chief assessment 
physician 
One head of department did not answer the question. One head of department and chief assess-
ment physician replied the biosimilar infliximab share of the total use of infliximab products be 90% 
and medical director, told it to be 73% in 2015. 
7.6.5.4 Chief pharmacists 
Five chief pharmacists answered the question. One did not answer, due the fact that biosimilar 
infliximab was chosen to pharmaceutical formulary in 2016 for the first time. (Table 71.) 
 
The highest biosimilar infliximab share in 2015 was in hospital where it was chosen to pharmaceu-
tical formulary already 2014, 71 %. Others had chosen biosimilar in 2015 for the first time and the 
biosimilar infliximab share of the total use of infliximab varied between 4 – 48 %. 
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TABLE 69. Biosimilar infliximab share (%) varied from 4 to 71 % 
 
Percentage of, % 
 n = 5 
Biosimilar infliximab share of the total use of infliximab 
products, ATC-code L04AB02 (infliximab mg). 
71% 
48% 
40% 
30% 
4% 
Other comments? The product was switched middle of the year. 
7.7 Future biosimilars 
Several biological products are expected to be exposed to biosimilar competition over the next 
years. Competition in the market is also growing, because new biosimilar products will enter the 
market for biological products already facing biosimilar competition. 
7.7.1 Pricing of biosimilars in hospitals in the future 
The survey examines what the biosimilar products' prices are expected be in hospitals in the future. 
7.7.1.1 Gastroenterologists 
Three out of four specialist gastroenterologists responded the question, and two of them answered 
that in hospitals biosimilars are going to be cheaper than the originator products. One specialist 
gastroenterology expects that originator products do participate price competition and will be as 
affordable as biosimilar products. One specialist expects biosimilar to be 20 – 30 % cheaper than 
originator product, and the other assumes that in the beginning the price difference is bigger and 
in long term the biosimilar will be 20 – 50% cheaper. (Table 72.) 
 
All chief gastroenterologists answered this question and they all expect the biosimilars be cheaper 
than the originator products. In future, most chief physicians (five out of seven) do expect biosimi-
lars to be at least 50% cheaper, and the answers varied in range of 20 - 65 %. However, two 
answered not only that biosimilars are going to be cheaper, but after the biosimilars have received 
  
182 
marketing authorization, the originator products will also participate the price competition and will 
be as affordable as the biosimilars. 
 
No one expects the originator products be cheaper than the biosimilars. 
 
TABLE 70. In hospitals, biosimilars are expected to be cheaper than originator products 
 Chief Physicians, n = 7 Specialist of gastroenterology, 
n = 3 
What you expect biosimilar prod-
uct’s pricing in hospitals to be in 
the future 
Number of 
answers 
Price difference, 
% 
Number of 
answers 
Price difference, 
% 
Biosimilar products are cheaper than 
the originator products 
7 65% 
60% 
50% 
30% 
20% 
2 20 - 30% 
At the beginning 
the difference is 
greater, in the 
long term 20 - 
50% 
After the biosimilar product has re-
ceived marketing authorization, the 
originator product participates price 
competition and is as affordable as bi-
osimilar products 
2 
 
1 
 
7.7.1.2 Rheumatologists 
In hospital, all chief rheumatologists expect biosimilars to be cheaper than the originator products, 
and the answers varied in range of 30 - 60 %.  Three chief physicians expect the price difference 
to be 50 %, three 30 %, two 40 % and one between 30 – 60% (biosimilar cheaper option). However, 
five answered not only that biosimilar are going to be cheaper, but also, after biosimilar receives 
marketing authorization, originator products will participate price competition and are going to be 
as affordable as biosimilars.  One commented that the originator product tends in price competition 
to remain on the same level than the biosimilar, but biosimilars generally might be a little cheaper 
than the originator products. He thinks competition is going to be steady and the originator products 
will learn to cope in this competitive situation. (Table 73.) 
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One respondent thinks biosimilars are going to be the cheapest option and originator products' 
prices will not lower their prices. Other chief physician expects that the products are included to the 
price band.  
 
In future in hospitals, no one expects originator products be cheaper than biosimilars. 
 
TABLE 71. In hospitals, biosimilars are expected to be cheaper than originator products, but also 
originator products are expected to participate price competition 
What you expect biosimilar products pricing 
to be in the future (hospital) 
Number of answers, 
 n = 9 
Price difference, % 
Biosimilar products are cheaper than the origi-
nator products 
9 50% 
40% 
30% 
30-60% 
After the biosimilar product has received market-
ing authorization, the originator product partici-
pates price competition and is as affordable as 
biosimilar products 
5 
 
Originator product's price does not decrease 1 
 
Other comments? Is going to be included to the price band. 
The originator product tends in price competition to remain on 
the same level than the biosimilar, but it is probably difficult, so 
biosimilars generally might be a little cheaper than the origina-
tor products. The competition is steady and the originator prod-
ucts will learn to cope in competition. 
7.7.1.3 Medical director of health care district, head of department and chief assessment 
physician 
Both heads of department, chief assessment physician and medical director expect biosimilars to 
be cheaper than the originator products in hospitals, and the answers varied between 30 - 40 %.  
One head of department also anticipates that after biosimilar has received marketing authorization, 
originator products will participate price competition and are going to be as affordable as biosimi-
lars.  
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The other head of department answered, somewhat inconsistently, that biosimilars will be cheaper 
than originator products, but also originator products are going to be cheaper than biosimilars, and 
price difference would be 25 %. 
7.7.1.4 Chief pharmacists 
In hospitals, five chief pharmacists expect biosimilars to be cheaper than the originator products, 
and the price difference varied in range of 20 - 60 %. One commented that it may be that the 
originator products gives small discounts and the effort to direct the use to the dosage forms which 
have longer patents is very active. Also, one answered not only that biosimilar are going to be 
cheaper, but also, after biosimilar receives marketing authorization, originator products will partici-
pate price competition and are going to be as affordable as biosimilars. (Table 74.) 
 
One chief pharmacist commented that all alternatives provided are in principle possible. It depends 
on the market situation in the EU and whether the biosimilar will enter Finnish market among the 
first EU countries or has it already been marketed in other EU countries. Often, but not always, the 
biosimilar offers a cheaper price than the originator product. The first round of the competition the 
discounts are often from 10 to 30%, in the longer run sometimes up to 70% can be achieved. 
 
TABLE 72. In hospitals, biosimilars are expected to be cheaper than originator products 
What you expect biosimilar products 
pricing to be in the future (hospital) 
Number of answers, n = 6 Price difference, % 
Biosimilar products are cheaper than the 
originator products 
5 60 
50 
40 
20-30 
After the biosimilar product has received 
marketing authorization, the originator 
product participates price competition and 
is as affordable as biosimilar products 
1 
 
Other comments? 2 
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All alternatives provided are in principle possi-
ble. Depends on the market situation in the EU 
and whether the biosimilar will enter Finnish 
market among the first EU countries or has it 
already been marketed in other EU countries. 
Often, but not always, the biosimilar offers a 
cheaper price than the originator product. The 
first round of the competition the discounts are 
often from 10 to 30%, in the longer run some-
times up to 70% can be achieved. 
It may be that the originator products give small 
discounts. The effort to direct the use to the 
dosage forms which have longer patents is 
very active. 
 
7.7.2 Biosimilar competition induced drug cost saving in future 
In the questionnaire was asked to assess how much during the next five years, biosimilars price 
competition would help to achieve cost saving in hospitals for drug purchases. 
7.7.2.1 Gastroenterologists 
Of specialist gastroenterologists, one out of four answered to question about cost savings for drug 
purchases. He/she guessed that biosimilars caused price competition can help to achieve 10 million 
euros’ savings to the hospital during the next five years. (Table 75.) 
 
Six out of seven chief gastroenterologists answered the question and their estimated cost savings 
varied from 100 000 to 5 million euros during the next five years. Their estimates were based on 
consumption knowledge, current price trend and that more biosimilar products are coming availa-
ble. 
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TABLE 73. Biosimilars are expected to cause significant drug cost savings for hospitals during next 
five years 
 
Chief Physicians, n = 6 
Specialist of gastroenterology, 
n = 1 
 
Cost savings, € Arguments Cost savings, € Arguments 
How much, within the next 
five years, you estimate bio-
similar products price com-
petition to cause medicinal 
cost savings for drug pur-
chases in your hospital? 
5 million 
2 million 
1,5 million 
700 000 
500 000 
100 000 
We know the con-
sumption. 
The current price 
trend. 
More biosimilar prod-
ucts coming in to use. 
10 million Guess 
7.7.2.2 Rheumatologists 
Seven out of nine chief physicians replied the question about how much biosimilar price competition 
could cause medicinal cost savings for hospital drug purchases within the next five years and esti-
mated cost savings varied from 100 00 to 10 million euros. Their estimates were based on expected 
price advantage and know number of patients and the knowledge what has been saved previously. 
One commented that estimate is difficult to assess, because a large part of the biological medicines 
in Rheumatology are already outpatient care products, and not administered or funded by the hos-
pital. He/she thinks that probably in five years even more drugs will be administered subcutane-
ously in outpatient care (part originator products, part biosimilars) and hospital costs are reduced 
for this reason also. (Table 76.) 
 
One chief physician estimates savings in hospital to be 1 million euros/year, including savings about 
0,5 million euros from rheumatology and 0,5 million euros form other specialties. 
 
TABLE 74. Biosimilars are estimated to cause several millions cost savings for hospitals during 
next five years 
 
Cost savings, € Arguments, n = 7 
How much, within the next five 
years, you estimate biosimilar 
products price competition to 
10 million 
5 million 
1,5 million 
A rough estimate. 
In rheumatology 0,5 million/year and other specialties could 
have the same amount/year. 
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cause medicinal cost savings 
for drug purchases in your 
hospital? 
1,2 million 
1 million 
250000 
100 000 
 
Previous savings 
Price advantage and number of patients. 
Very difficult to assess. A large part of the biological medi-
cines in Rheumatology are already outpatient care products, 
and not administered or funded by the hospital. Probably in 
five years more drugs will be administered in subcutaneous 
in outpatient care (part originator products, part biosimilars) 
and hospital costs are reducing for this reason also. 
7.7.2.3 Medical director of health care district, head of department and chief assessment 
physician 
One head of department and medical director commented that biosimilar price competition could 
cause medicinal cost savings in hospital for drug purchases within the next five years and estimated 
cost savings varied from 500 000 to 7,5 million euros. Medical director based the estimated saving 
to the price difference which he/she mentioned earlier in the questionnaire. 
 
Chief assessment physician and the other head of department did not reply the question.  
7.7.2.4 Chief pharmacists 
Five out of six chief pharmacists replied the question about how much biosimilar price competition 
could cause medicinal cost savings in hospital for drug purchases within the next five years and 
estimated cost savings varied from 490 000 to 5 million euros. One estimate was based on what 
has happened with mAb already existing. (Table 77.) 
 
One commented that several monoclonal antibody product patents are going to expire within the 
next five years and savings, which could be achieved, are dependent on how quickly biosimilar 
products get marketing authorizations after patents have expired and competition is possible. In 
their hospital, the medical budget for the next five years is a few hundred million euros. In this 
perspective, the decrease in the net price caused by a single biosimilar is small in percentages, 
even though millions in euros. 
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TABLE 75. Biosimilars are estimated to cause several millions cost savings per hospital during next 
five years 
 
Cost savings, € Arguments, n = 5 
How much, within the next five 
years, you estimate biosimilar 
products price competition to 
cause medicinal cost savings for 
drug purchases in your hospital? 
3-5 million 
3,0 million 
2-3 million 
1,5 million 
490 000€ 
 
Several monoclonal antibody product patents are go-
ing to expire within the next five years. It depends on 
how quickly biosimilar products get marketing au-
thorizations after the patents expire, after which the 
competition begins. The budget for the next five 
years is a few hundred million euros. In this perspec-
tive, the decrease in the net price caused by a single 
biosimilar is small in percentages, even though mil-
lions of euros. 
Based on what has happened with mab already ex-
isting. 
7.7.3 Next biosimilar product which will impact hospital medicinal costs 
Respondents were asked to indicate, which biosimilar products will next significantly impact the 
drug costs in their hospital and how much hospital’s cost savings could be per year. 
7.7.3.1 Gastroenterologists 
None of the specialist gastroenterologists answered the question. Six out of seven chief physicians 
answered and most of them (four out of seven) did comment that the next biosimilar in gastroen-
terology will be adalimumab, but they also commented, that it will not affect to hospital’s drug costs 
(patients inject themselves at home). One estimated that adalimumab biosimilar could help to 
achieve cost savings 20 000€ per year in his/her hospital and based his/her estimate on experience 
gained on infliximab and for adalimumab use. (Table 78.) 
 
One chief physician expects Remsima to be the next biosimilar, which affects most to hospital’s 
drug costs, about 22 000 € per year. He/she comments that the amount is only guess, but savings 
will be more than at the moment. 
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Trastuzumab was mentioned once and estimated cost savings, what hospital could achieve, is 200 
000 € per year. 
 
TABLE 76. Chief physicians expect next biosimilar in gastroenterology to be adalimumab, but it will 
not affect hospital's drug costs 
 
Product,  
n = 6 
Estimated cost 
savings, € 
Cost saving estimate is based on 
Biosimilar product, which you ex-
pect to affect significantly your 
hospital's medicine costs? 
Trastuzumab 
Adalimumab 
Remsima 
 
200 000 
20 000 
22 000 
The experience with infliximab, and 
the use of adalimumab. 
Only guessing, but more than now 
(Remsima). 
Other comments? In gastroenterology, adalimumab, but it does not cause costs to hospital. 
Do not know, Humira is self-inject medication and not paid by hospital. 
7.7.3.2 Rheumatologists 
Eight out of nine chief physicians expect the next biosimilar, affecting significantly hospital’s medi-
cine costs, be rituximab. One commented that etanercept and adalimumab are outpatient care 
products and biosimilars of those products will not directly affect hospital's cost of medicines. Esti-
mated costs saving for hospital varied between 20 000 € to 300 000 €/year and estimates were 
based on prior use of the product and to number of users. (Table 79.) 
 
One chief physician expects next biosimilar, which affects most to hospital’s drug costs, be possibly 
some medicine for cancer. 
 
TABLE 77. Chief physicians in rheumatology expect next biosimilar affecting significantly hospital’s 
medicine costs to be rituximab 
 
Product,  
n = 9 
Estimated cost 
savings, € 
Cost saving estimate is based on 
Biosimilar product, which you ex-
pect to affect significantly your 
hospital's medicine costs? 
Rituximab  300 000 
150 000 
100 000 
20 000 
On prior use. 
Number of users. 
About 100 treatments x X€. 
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Other comments? Some cancer drug? 
Etanercept and adalimumab are outpatient care products and biosimilars of 
those products will not directly affect hospital's cost of medicines. 
7.7.3.3 Medical director of health care district, head of department and chief assessment 
physician 
Both heads of department expect the next biosimilar, affecting significantly hospital’s medicine 
costs, be rituximab. One of them assumes cost savings to be 50 000 euros per year (in purchase 
price). The head of department based the answer to the current use of medicine. 
 
Chief assessment physician commented the next biosimilar will be trastuzumab and medical direc-
tor thinks that iv-forms of trastuzumab and rituximab biosimilars have significant affect to hospital’s 
medicine costs. Medical director estimated that the biosimilars mentioned could provide 30 % sav-
ings based on the current consumption (last 12 months). This would mean savings of 430 000 
euros per year (in purchase price). 
7.7.3.4 Chief pharmacists 
Four out of six chief pharmacists replied the question about next biosimilar, affecting significantly 
hospital’s medicinal costs. This biosimilar is expected to be either rituximab or trastuzumab. (Table 
80.) 
 
One commented that if both, rituximab and trastuzumab will have biosimilar or even several per 
molecule in the market in 2017 and will come before the submission of tenders, the discounts may 
be at best 30 to 50 %. Unless authorized biosimilars come to market, price changes are not ex-
pected. 
 
Estimated costs saving for hospital varied between 200 000 € to 1-2 million € per year and one 
based the estimate on current consumption of the product and to estimated discount. 
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TABLE 78. Chief pharmacists expect next biosimilar affecting significantly hospital’s medicine costs 
to be rituximab or trastuzumab 
 
Product,  
n = 4 
Estimated cost 
savings, € 
Cost saving estimate is based on 
Biosimilar product, 
which you expect to 
affect significantly 
your hospital's med-
icine costs? 
Rituximab  
Trastuzumab 
1-2 million 
300 000 
200 000 
If both will have biosimilar or even several 
per molecule in 2017 in the market and 
come before the submission of tenders, the 
discounts may be at best 30 to 50%. Unless 
authorized biosimilars come to market, 
price changes are not expected. 
Consumption, estimated discount.  
7.8 Costs of medicines in hospitals 
Spending on pharmaceuticals in hospitals have generally increased and are challenging hospital 
budgets. The medicine costs form a significant part of the total expenditures of the hospital districts. 
7.8.1 Total hospital's medical costs 
The questionnaire aimed to find out, how much the total medicinal costs were in hospitals (in pur-
chase prices) in 2015. This question was only targeted for chief pharmacists. 
7.8.1.1 Chief pharmacists 
The total hospital medicinal costs in 2015, when calculated in purchase prices, were between 9,5 
to 44,2 million euros. One chief pharmacists pointed out that there might be some differences, what 
are calculated in to medicinal costs. There might be for example, blood and blood products, radio-
active medicines and/or medicinal gases included. Therefore, the given amounts are not neces-
sarily directly comparable to each other. (Table 81.) 
 
  
192 
TABLE 79. In 2015, the total hospital’s medicinal costs were between 9,5 to 44,2 million euros, 
calculated in purchase prices 
 Costs at purchase prices, million € 
n = 6 
In 2015, the total hospital’s medical 
costs at purchase prices. 
44,2 
23,1 
13 
11,6 
10,3 
9,5 
7.8.2 How the costs of medicines have changed in hospitals 
The survey aimed to find out how the last five years the cost of medicines has changed in hospital. 
7.8.2.1 Gastroenterologists 
Two out for four specialist gastroenterologists and six out of seven chief physicians answered the 
question. All responded that cost of medicines has increased the past five years. One specialist 
gastroenterology answered that drug costs have increased by 18 % and three chief gastroenterol-
ogists think it has increased by 13 - 40 %. (Table 82.) 
 
All chief physicians told the cause of increased drug costs are the new expensive medicines, which 
have entered the market. 
 
TABLE 80. Hospital drug costs have increased the past five years 
 
Chief Physicians, n = 6 
Specialist of gastroenterology, 
n = 2 
 
Increased, % Arguments Increased, % 
During the past five 
years, the hospital 
medicine costs have 
13 % 
20 % 
40 % 
New expensive highly selective 
drugs have entered the market.  
A lot of new, expensive medicines. 
New drugs. 
18 % 
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Expensive new treatments enter 
continuously. 
7.8.2.2 Rheumatologists 
All chief rheumatologists responded, that the cost of medicines has increased the past five years 
and in five replies cost increase has been between 20 to 35 %. Four chief physicians did not give 
percentage. (Table 83.) 
  
All replied the cause of increased drug costs to be the new expensive medicines. Two specified 
medicines to be biological medicines and one pointed out that also the use of existing biological 
drugs has increased. 
 
TABLE 81. Hospital drug costs have increased the past five years 
 
Increased, % Arguments, n = 9 
During the past five years, the 
hospital medicine costs have 
20% 
25% 
30% 
35%  
Consumption and prices have increased. 
Biological medicines. 
Likely, because for example for the treatment of infectious 
diseases and oncology, is coming new, expensive, and 
more effective drugs.  
New medicines (biologic). 
New treatment options, new drugs are expensive. 
Expensive new drugs have been introduced. The use of ex-
isting biological drugs has increased. 
New expensive drugs. 
7.8.2.3 Medical director of health care district, head of department and chief assessment 
physician 
Chief assessment physician and medical director responded the cost of medicines has increased 
the past five years.  The cause of increased drug costs is seen to be the new expensive medicines 
for example for cancer, mAbs and medicines for rare diseases. They replied that the increase has 
been 2,3 % and 2 %.  
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One head of department did not reply the question about change of the cost of medicines and the 
other one answered that the cost of medicine have not changed. The head of department stated 
that new medicines are entering the market, but at same time prices of older medicines are de-
creasing. 
7.8.2.4 Chief pharmacists 
All chief pharmacists replied, that the cost of medicines has increased the past five years and 
increase varied between 9,6 to 27,7 %. One commented that increase has been about 5 percent 
per year. (Table 84.) 
  
All replied the cause to increased medicinal costs to be the new expensive medicines. One speci-
fied medicines to be for cancer and hepatitis C. Also in university hospital medicines for life-threat-
ening infections and for complications of bone marrow transplants have increased the costs. 
 
TABLE 82. Hospital drug costs have increased the past five years between 9,6 to 27,7 % 
 
Increased % Arguments, n = 6 
During the past five years, the hos-
pital medicine costs have 
27,7% 
20% 
15% 
12% 
9,6%  
New cancer treatments as well as new medicines for 
hepatitis C and in university hospitals treatments for life-
threatening infections and treatments for complications 
of bone marrow transplants. 
New expensive treatments. 
About 5% per year. 
7.8.3 Hospital medicine costs share of total hospital expenditure 
In the questionnaire was asked, how much the hospital medicine costs accounted of total hospital 
expenditure in 2015. 
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7.8.3.1 Gastroenterologists 
Only three out of seven chief gastroenterologists answered the question and none of the specialists 
replied. Two out of the three respondents told the hospital medicine costs accounted of total hos-
pital expenditure, in 2015, 20 %. One of them told he/she estimated the percentage. One replied 
hospital medicine costs accounted for 4,8 % of total hospital expenditure. (Table 85.) 
 
TABLE 83. Hospital medicine costs were estimated to account up to 20 % of total hospital expendi-
ture in 2015 
 
Percentage, % 
The hospital medicine costs as a percentage of total hospital expendi-
ture in 2015? The total costs are the operating costs, that is, they do 
not take into account the investment costs. 
Estimate 20% 
20%, 
4,8% 
7.8.3.2 Rheumatologists 
Only six out of nine chief rheumatologists answered the question. Two respondents told the hospital 
medicine costs accounted for 5% of total hospital expenditure, in 2015. One told he/she guessed 
the percentage to be about 10% and highest share mentioned was 30%. (Table 86.) 
 
TABLE 84. Hospital medicine costs were estimated to account up to 30 % of total hospital expendi-
ture in 2015 
 
Percentage, % 
The hospital medicine costs as a percentage of total hospital expendi-
ture in 2015? The total costs are the operating costs, that is, they do 
not take into account the investment costs. 
5% 
Maybe 10% 
15% 
30% 
Do not know 
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7.8.3.3 Medical director of health care district, head of department and chief assessment 
physician 
Chief assessment physician and both heads of department did not reply the question of how much 
the hospital medicine costs accounted of the total hospital expenditure in 2015. Medical director 
had calculated, that the hospital medicine costs accounted for 4,7 % of the total hospital expendi-
ture. 
7.8.3.4 Chief pharmacists 
Four out of six chief pharmacists answered the question. The hospital medicinal costs as a per-
centage of total hospital expenditure in 2015 varied between 4,5 to 12,8 percent. The total costs 
are the operating costs, that is, they do not take into account the investment costs. One chief phar-
macist pointed out that external service purchases are not taken into account. There might be dif-
ferences what external service there are in each hospital. (Table 87.) 
 
TABLE 85. Hospital medicine costs accounted up to 12,8 % of total hospital expenditure in 2015 
 
Percentage, % 
The hospital medicine costs as a percentage of total hospital 
expenditure in 2015? The total costs are the operating costs, 
that is, they do not take into account the investment costs. 
12,8% 
9,8% 
6%  
4,5% 
7.8.4 Share of hospital’s biological medicinal costs of the total medicinal expenditures 
In the questionnaire were asked, how much the hospital’s biological medicinal costs accounted of 
the total medicinal expenditures in 2015 and has the share of biological medicinal products in-
creased in past five years. These questions were only presented to chief pharmacists. The calcu-
lation supposed to include products that are included under the ATC codes: A10A (insulins), B03XA 
(anemia), H01AC (somatropins), J06 (immunoglobulins), L03AA (cytokines), L03AB (interferons), 
L04AA (immunosuppressants, excluding -06, -10, -13, -27, -29, -31, -32), L04AB (tumor necrosis 
factor alpha inhibitors), L04AC (interleukin inhibitors), L01XC (Monoclonal antibodies). 
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7.8.4.1 Chief pharmacists 
Five out of six chief pharmacists replied the question about how much the hospital’s biological 
medicinal costs accounted of the total medicinal expenditures in 2015. In table 90 is presented 
which ATC-codes were included to calculations. The highest calculated share of biological medic-
inal products was 42 percent and lowest 27 percent. (Table 88.) 
 
TABLE 86. The hospital’s biological medicinal costs accounted 27 to 42 percent of the total medic-
inal expenditure in 2015 
 Percentage, % 
Percentage of biological medicinal products of the total cost of hospital 
medicines in 2015. The calculation should include products that are in-
cluded under the following ATC codes: A10A (insulins), B03XA (ane-
mia), H01AC (somatropins), J06 (immunoglobulins), L03AA (cytokines), 
L03AB (interferons), L04AA (immunosuppressants, excluding -06, -10, -
13, -27, -29, -31, -32), L04AB (tumor necrosis factor alpha inhibitors), 
L04AC (interleukin inhibitors), L01XC (Monoclonal antibodies). 
42% 
37%, 
34,6% 
31,3% 
27 % 
 
Three out of five chief pharmacists replied that the share of biological medicinal products has grown 
of the total cost of hospital medicines in past five years. One calculated that the share of biologics 
mentioned in question has grown 1,4 percent, another 38 percent and one did not give any per-
centage. One of them commented, that the new indications are the reason for this. One chief phar-
macists told that share of biological medicines mentioned was exactly same in 2015 than it was 
2011. Another chief pharmacist commented that biological medicine share of the total cost of hos-
pital medicines has not increased meaningfully, being 2011 27,6 % compared to 27 % in 2015. 
This was explained with the fact, that also, the costs of other ATC-groups' medicines have in-
creased. In euros, the cost of biological medicines has increased about 2 million euros. (Table 89.) 
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TABLE 87. The share of biological medicinal products of the total cost of hospital medicines has 
not necessarily grown, because costs of other medicine-groups have increased same time 
Has the share of biological medicinal products grown of 
the total cost of hospital medicines in past five years? 
ATC codes: A10A (insulins), B03XA (anemia), H01AC 
(somatropins), J06 (immunoglobulins), L03AA (cyto-
kines), L03AB (interferons), L04AA (immunosuppres-
sants, excluding -06, -10, -13, -27, -29, -31, -32), L04AB 
(tumor necrosis factor alpha inhibitors), L04AC (inter-
leukin inhibitors), L01XC (Monoclonal antibodies) 
Number of answers, 
n = 5 
Percentage, % 
Yes 3 38 % 
1,4% 
New indications. 
No 2 
Biological medicine share of the total cost of hospital 
medicines has not increased meaningfully. Was 
2011 27,6 % compared to 27 % in 2015. New expen-
sive medicines have been introduced to the treat-
ment of cancer, as well as new medicines in the B-, 
M- and N-groups and the macular degeneration 
medicines in S-group. These have raised the cost in 
terms of other ATC groups. C The cost of medicines 
in the ATC groups mentioned in question, have in-
creased by 2 million euros, when comparing year 
2011 to year 2015. 
Biological medicinal products share of the total med-
ication costs in 2011 and 2015 is the same. 
7.9 Biosimilars for patients in outpatient care 
Biosimilar infliximab is a hospital product and was first biosimilar monoclonal antibody approved by 
the EMA. The first biosimilar monoclonal antibody among other things raised questions on the im-
munogenicity and efficacy of the product compared to originator infliximab. The questionnaire ex-
plored the respondents’ biosimilar readiness in outpatient care. 
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7.9.1 Willingness to prescribe biosimilars for patients in outpatient care? 
The questionnaire explored the willingness to prescribe upcoming biosimilars (authorized for use) 
for patients in outpatient care. 
7.9.1.1 Gastroenterologists 
Three out of four specialist gastroenterologists answered the question about their willingness to 
prescribe up-coming biosimilars (authorized for use) for patients in outpatient care. They all were 
ready to prescribe, and one justified it to be economically sensible. (Table 90.) 
 
All chief gastroenterologists gave response and six of them were ready to prescribe biosimilar prod-
ucts for outpatient care patients and one was reluctant. The justifications for prescribing were re-
duction of costs, cost savings, and expectations that biosimilars are going to be more affordable. 
One chief physician not willing to prescribe biosimilars for outpatient care patient justified his/her 
decision by telling that patients should be monitored in hospitals. 
 
None of the respondents were not using biosimilars in outpatient care at the time. 
 
TABLE 88. Most of the gastroenterologist were willing to prescribe biosimilars for outpatient care 
patient 
If you treat patients in an outpatient 
setting, would you prescribe up-
coming (authorized for use) biosim-
ilar products for patients in outpa-
tient care? 
Chief Physicians, n = 7 Specialist of gastroenterology,  
n = 3 
Yes 6 3 
To reduce costs. 
Cost savings. 
Finland economize.  
Price. 
More affordable. 
Economic sense 
No 1 - 
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Patients should be monitored in 
the hospital 
- 
7.9.1.2 Rheumatologists 
Eight chief rheumatologists gave response and seven of them were ready to prescribe biosimilar 
products for outpatient care patients, and one could not provide response at the moment, because 
she/he need more information about future biosimilars. The justifications for prescribing biosimilars 
were cost savings (for society), right price-quality ratio, biosimilars are inexpensive and more pa-
tients could be treated with the same amount of money. One chief physician stated that the costs 
do not play a large role only for the society, but also for patients. (Table 91.) 
 
None of the respondents were not using biosimilars in outpatient care at the time. 
 
TABLE 89. Most chief rheumatologists were willing to prescribe biosimilars for outpatient care pa-
tient 
If you treat patients in an outpatient setting, 
would you prescribe new (marketing author-
ized) biosimilar products for patients in outpa-
tient care? 
Arguments, n = 8 
Yes 7 
Right price-quality ratio. 
Are inexpensive. 
Ok, if efficacy and safety has been demonstrated, costs have 
a big role in both the patient and to society. 
Cost savings. 
The cost savings for society, or more patients can be treated 
with the same amount of money. 
The nation's advantage. 
Other comments? 1 
Do not know yet. 
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7.9.1.3 Medical director of health care district, head of department and chief assessment 
physician 
Chief assessment physician did not reply the question of willingness prescribing biosimilars for 
patients in outpatient care. Both heads of department and medical director were willing to prescribe 
biosimilar products for outpatient care patients. The justifications for prescribing biosimilars were 
cost savings and price of the biosimilar medicines. 
 
One of the heads of department is using biosimilar epoetin and filgrastim in outpatient care. 
7.10 Hospital's the three most expensive biological medicines in 2015 
The questionnaire aimed to find out which were the hospital's three most expensive biological med-
icines in 2015. Amounts were calculated at purchasing prices. This question was only presented to 
chief pharmacists. 
7.10.1 Chief pharmacists 
Five out of six chief pharmacists replied the question and three of them commented that the hos-
pital’s most expensive biological medicine at purchase price was rituximab, varying from 0,8 to 1,4 
million euros. Second most expensive biological medicine was usually trastuzumab, accounting 0,5 
to 1,9 million euros. Infliximab was mentioned in three replies as third position, accounting 0,5 to 
0,8 million at purchase price. Only one chief pharmacist did not mentioned infliximab in the list of 
three most expensive biological medicines and only one had listed it as most expensive. (Table 
92.) 
 
Rituximab was mentioned in all answers, infliximab and trastuzumab in four answers and bevaci-
zumab in two answers. 
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TABLE 90. The most expensive biological medicine was usually rituximab (at a purchase price). 
The amounts have been rounded to the nearest hundred thousand 
The hospital's three most expensive (at a purchase 
price) biological medicines in 2015. 
Biological 
medicine 
Amount, million € 
1.  Rituximab 
Infliximab 
Bevacizumab 
0,8; 0,8; 1,4 
2,2 
1 
2.  Trastuzumab 
Rituximab 
0,5; 0,6; 0,9; 1,9  
1 
3.  Infliximab 
Rituximab 
Bevacizumab 
0,5; 0,8; 0,8  
1,8 
0,5 
 
The cost share of infliximab of total cost of medicines in different hospitals varied between 4 to 6 
percent, being 5 percent in hospital where it was mentioned as the most expensive biological med-
icine. Also cost share of trastuzumab was between 4 to 6 percent, rituximab accounted between 4 
to 8 percent and bevasizumab 5 to 8 percent in hospitals. (Table 95.) 
 
TABLE 91. The cost share of most expensive biological medicines of total cost of medicines (at 
purchase price) in hospitals. Calculated from figures obtained from replies of chief pharmacists 
Biological medicinal product Share, % 
Infliximab 4 - 6 
Trastuzumab 4 - 6 
Rituximab 4 - 8 
Bevasizumab 5 - 8 
 
The cost share of three most expensive biological medicines accounted in the highest 22 percent 
and in lowest 13 percent of total cost of medicines in hospitals. (Table 96.) 
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TABLE 92. Cost share of three most expensive biological medicines in hospitals varied between 
13 to 22 % of total cost of medicines. Calculated from figures obtained from replies of chief phar-
macists 
Hospital Cost share of three most expensive bio-
logical medicines in different hospitals, % 
A 13 
B 14 
C 22 
D 19  
E 18 
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8 SUMMARY OF THE RESULTS 
The author's own assumption was that the biosimilars have already established their position 
amongst specialists in question, although the user experience has not yet accumulated from a long 
period of time. The maximum experience with biosimilar infliximab has accumulated in Finland 
since September 2013, when biosimilar infliximab received its marketing authorization.  
 
In the case of biosimilar infliximab, hardly anyone expected the price competition to be so aggres-
sive as what it turned out. Hospitals' tendering periods influenced the introduction of biosimilar 
infliximab, because infliximab is fully a hospital product. After the biosimilar infliximab received a 
marketing authorization, some of the hospitals opened a new tendering during the valid acquisition 
period. The responses also indicate, that company having originator infliximab started the price 
competition even before biosimilar infliximab was able to participate tendering competition for the 
first time, by decreasing its price during the previous acquisition period.  
 
When the respondents compared the originator infliximab purchase price after the biosimilar first 
time participated in the hospital tendering, to the purchase price offered in the previous tendering, 
they reported that price of originator product had decreased by 20 - 40 %. Biosimilars responded 
to price competition, and based on the results obtained from chief pharmacists’ questionnaires, the 
price difference between originator and biosimilar infliximab was 40 to 57%. In other responses, 
the price difference varied between 20% and 80%. Biosimilar infliximab has been selected to hos-
pitals’ pharmaceutical formulary between 2014 - 2016, depending on whether the tendering pro-
cess was re-opened during the valid acquisition period, or whether was the tendering made in 
according the normal tendering. Hospitals can re-open tenders if the market situation changes sub-
stantially (the possibility is recognized in the invitation to tender) and in this case, biosimilar inflixi-
mab fulfilled the criteria. Before the biosimilar infliximab entered the market, chief gastroenterologist 
estimated the price difference between originator and biosimilar infliximab to be 30 – 60 %. The 
estimates from chief rheumatologists and hospital chief pharmacists were very much in line with 
gastroenterologists. 
 
Biosimilar infliximab is, at the current acquisition period, the preferred option in the hospitals’ phar-
maceutical formulary and only one responded that biosimilar infliximab is solely selected to hospi-
tal’s pharmaceutical formulary. The price was most commonly the reason, why biosimilar infliximab 
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was chosen as a primary option, but also studies in which similarity was demonstrated and Fimea's 
statement on biosimilars, came up in the responses. One rheumatology had also gained personal 
experience of biosimilar infliximab. Some replied that also originator infliximab is chosen, because 
of various reasons. Originator was available to be able to continue treatment with pediatric patients, 
with patients who prohibited the switch and with patients whose treatment was poorly controlled. 
Also, respondents wanted to have originator infliximab in pharmaceutical formulary, in case bio-
similar proves to be inefficient or side effects occur. Medical director pointed out, that originator 
infliximab was chosen to formulary in order to maintain the doctor’s autonomy. 
 
Biosimilar application for marketing authorization must demonstrate that potential differences be-
tween the biosimilar and the originator product does not affect the efficacy or safety. In most replies, 
biosimilar studies were seen to be comprehensive enough regarding of safety and efficacy. The 
comments of gastroenterologists revealed, that the studies demanded for marketing authorization 
were conducted with rheumatology patients, but this was not considered a problem. There was 
some hesitation among rheumatologists about lack of long term follow-up. One of the gastroenter-
ologists stated that biosimilar infliximab is being marketed to have similar efficacy as originator, but 
in reality, for some patients biosimilar is not effective at all.  
 
Respondents have received information about biosimilars often from many different sources, and 
most of them felt, that there is no need for additional information. In general, information is received 
at least from pharmaceutical companies and from regulatory authorities, and this did not vary be-
tween groups. Almost the same number had received information also from colleagues and other 
sources. Other sources mentioned were congresses, professional journals and meetings. One re-
spondent had also been involved in EU’s development work. Those who would like to have more 
information, would like to have information of the long-term outcomes, the switches and new up-
coming biosimilars. In the answers of the hospital chief pharmacists, information is wanted about 
the safety of biosimilars and whenever new information is published or the regulatory authorities 
inform of the biosimilars. It would have been interesting to separate pharmaceutical companies to 
biosimilar marketers and originator product-focused companies and to find out whether or not the 
biosimilar marketers were also actively sharing information and in what format compared to origi-
nator-focused companies. 
  
In hospitals, treatments are switched from originator infliximab to its biosimilar. Based on the sur-
vey, hospitals prepared for switches usually by educating personnel and by guiding the patients 
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about biosimilars. Some of the respondents who informed that special arrangements were not 
done, had also done actions mentioned above. Some replied that drug trough concertation and 
antibodies were detected before switching. None responded that this was made solely, but always 
education for personnel and/or patient guiding was done also. For example, in the Statement of 
The Finnish Society for Rheumatology is recommended to measure drug trough concentration and 
anti‐drug antibodies before switching to a biosimilar. This statement was published in June 2015. 
Some of the rheumatologists mentioned that infliximab treatment was switched only from chosen 
patient groups and the criteria were age over 18 years, patients had to be stable with originator 
infliximab and the switch should have patients’ approval. In some cases, treatment of all patients 
was switched, but in subsequent responses pediatric patients were often told to be excluded. It 
should be noted, that physicians treating pediatric patients were not included in this survey. It would 
be interesting to study introduction of biosimilars in pediatric indications. Chief Pharmacists re-
sponded that biosimilar infliximab was in one hospital reviewed in the management teams (johtory-
hmissä) and in one hospital the pharmaceutical advisory board handling (lääkeneuvottelukun-
takäsittely) was made as part of hospital tendering. 
 
The responses of rheumatologists and gastroenterologists were very similar concerning the effects 
of switches. Most of them experienced, that switching from originator to biosimilar infliximab had 
not affected the efficacy or safety. Some of them commented that at the moment they could not 
say if switching had any effect, but there was research on going. One gastroenterology had ob-
served allergic reactions in some patients and two chief pharmacists commented that patients have 
been switched back to originator infliximab. Switching back has been done, because of side effects 
and because antibodies were detected. Medical Director and Chief Assessment Physician re-
sponded that switching had no effect on the efficacy and safety. One pondered that in some pa-
tients, subjective efficacy was worse, and for some of them also antibodies were detected, but 
unfortunately samples were not taken from all patients prior the switch and conclusions cannot be 
drawn. It would also be interesting to study, has the educating of patients and personnel affected 
the success of the switches and from where patients got the biosimilar information. Another inter-
esting topic would be to find out, whether the switching from the original preparation to biosimilars 
has affected antibody formation. 
 
Maybe a little unexpectedly majority of the respondents answered that there has not been any 
special follow-up made about switched patients. However, this can be explained by the fact that 
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the patients in question are already closely monitored. Most often the follow-up was made by de-
termining drug trough concentration and antibodies when seen necessary. Only some replied that 
drug trough concentration and antibodies were determined in certain intervals. Rheumatologists 
have followed the reasons for the discontinuation of treatment. One commented that there is inten-
tion to prepare a summary of the reasons of interruption. Medical director replied that follow-up is 
done of the switches by measuring the drug trough concentration and antibodies in certain intervals 
and by following the causes of the treatment interruptions. One hospital Chief Pharmacist replied 
that pharmaceutical advisory board had done cost monitoring. 
 
Biosimilar competition is increasing due to fact that, in future, originator biosimilar will have several 
biosimilar versions in market. Thus, switching between biosimilars (same active substance) might 
be reality in near future. Majority of gastroenterologists’ opinion is that biosimilars with same active 
substance are interchangeable (switching biosimilar to biosimilar) in hospital care. Chief Pharma-
cists are on the same line with gastroenterologists and they justified their opinion for example by 
commenting that in Finland, supervising authority has taken a favorable position about switching. 
There was some pondering that maybe there should be a similar approach than with infliximab to 
the matter, and patients should be evaluated, in case there are patients who should not be 
switched. Rheumatologists, on the other hand, are more cautious in their responses. Almost half 
of chief rheumatologists were not sure if biosimilars with same active substance are interchangea-
ble. The concerns were for example repeated switches, which would also make treatment follow-
up more difficult. Chief assessment physician and medical director did not see problem of switching 
between biosimilars in hospital care and head of department considered that this should be the 
responsibility of the pharmaceutical regulatory authorities. Things to consider, when switching from 
biosimilar to biosimilar, usually were related to antibodies, efficacy and side effects. 
 
When asked which things have slowed down the introduction of biosimilars, most frequently the 
replies were attitudes and the prejudices or lack of knowledge of physicians, but the attitudes of 
the patients were also mentioned. It would be interesting to find out what kind of position the patient 
organizations have taken to the biosimilars, from where these organizations have received their 
information, and how do they share the it. Some of the responses also highlighted the originator 
companies’ effective marketing organization and that pharmaceutical industry has had strong anti-
marketing of biosimilars. As a number of innovative pharmaceutical companies have also begun to 
develop and market biosimilars, one of the interesting research topics would be to find out how the 
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biosimilar marketing has changed and how companies that have both originator and biosimilar 
products (possibly even for the same patient groups), have organized the marketing. 
 
When biosimilar product enters the market, it is expected to reduce prices and thus enable cost 
savings for hospitals. According to questionnaire, most of the hospitals have attempted to achieved 
medicinal cost savings by initiating biosimilar infliximab for new patients and by switching patients 
treated with originator infliximab to biosimilar infliximab. Some replied that, for example, pediatric 
patients and skeptical patient were not switched. At least in one clinic also pediatricians have initi-
ated infliximab treatments with biosimilar infliximab. No one answered that savings would have 
been attempted to achieved only by initiating biosimilar infliximab for new patients. Majority of the 
respondents felt that cost savings were achieved by using biosimilar infliximab. Those who com-
mented that cost savings realized only partly, told that infliximab consumption had increased, some 
of the patients were using higher and more frequent doses and some patients were switched back 
to originator infliximab. One chief pharmacist commented that through competitive tendering is 
achieved as a whole more favorable net price. The new innovations are usually more costly than 
previous ones and for this reason, usually as a whole, drug costs are not reduced. He / she com-
mented that competition and competitive tendering in itself restrain the growth of medical costs, but 
do not eliminate it. Gastroenterologists' and rheumatologists' estimates of the cost savings, 
achieved by using biosimilar infliximab in 2015, ranged from € 40,000 to € 700,000. Some replied 
that cost saving were not achieved, but this was by the fact that biosimilar infliximab was selected 
to hospital’s pharmaceutical formula first time in 2016. Hospital chief pharmacists’ estimates of 
achieved cost savings varied between 140 000 to 950 000 €. The magnitude of the savings is in-
fluenced by the size of the hospital and the amount of infliximab used. When investigated, how the 
cost savings achieved by using biosimilar infliximab were used, most often the response was, that 
it was used to hospital medicinal cost management. In chief pharmacists' responses were also 
emphasized the possibility of commissioning of new medicinal products to the pharmaceutical for-
mulary. In one reply cost savings were used to the operation area and hospital budget generally. 
One chief pharmacists commented that in the budget, the euros earmarked for medicines cannot 
be used to recruit staff or vice versa. Based on the answers from chief pharmacists, the share of 
biosimilar infliximab of the total use of infliximab (calculated on mg) was at highest 71 % and lowest 
at 4 %. The year, when biosimilar was selected to pharmaceutical formulary, and whether all pa-
tients’ or only specified patients’ treatments were switched, has affected the magnitude of biosimilar 
share. 
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Several biological medicinal products are expected to be exposed to biosimilar competition over 
the next years. In the future in hospitals, majority of the respondents expect biosimilar products to 
be 20 to 60% cheaper than the originator products. After biosimilars receive marketing authoriza-
tion, some of the respondents expect originator products to participate price competition and be as 
affordable as biosimilar products. Only one replied that the originator product price will not de-
crease. One chief rheumatologists commented, that the originator product strives in price compe-
tition to remain on the same level than the biosimilar, but assumes that the biosimilar generally will 
be a little cheaper than the originator product. One chief pharmacist thinks that the pricing depends 
on the market situation in the EU and whether the biosimilar will enter Finnish market among the 
first EU countries or has it already been marketed in other EU countries. He / she stated that often, 
but not always, the biosimilar offers a cheaper price than the originator product. In the first round 
of the competition the discounts are often from 10 to 30% and in the longer run sometimes up to 
70% can be achieved. Also, another chief pharmacist commented that the effort to direct the use 
to the dosage forms which have longer patents is very active. 
 
Rheumatologists' and gastroenterologists', as well as medicinal director’s estimates of how much 
biosimilar price competition could cause medicinal cost savings to the hospital over the next five 
years, varied from 0.1 to 10 million euros. Their estimates were based on current consumptions 
and price trend. One chief rheumatology commented that a large part of the biological medicines 
in Rheumatology are already outpatient care products, and not administered or funded by the hos-
pital. He / she thinks that probably in five years more drugs will be administered in subcutaneous 
in outpatient care (part originator products, part biosimilars) and hospital costs are reducing for this 
reason also. Hospital chief pharmacists' saving estimates varies between 0,49 – 5 million euros. 
One of them commented that several monoclonal antibody product patents are going to expire 
within the next five years and savings depends on how quickly biosimilar products get marketing 
authorizations after the patents expire. In this hospital, the budget for the next five years is a few 
hundred million euros. Chief pharmacist commented that in this perspective, the decrease in the 
net price caused by a single biosimilar is small in percentages, even though millions of euros. 
 
Biosimilar products, which are next expected significantly to affect drug costs in hospitals, are ritux-
imab and trastuzumab. With these biosimilar products hospitals could achieve medicinal costs sav-
ings from 0,1 to 2 million euros per year. One Chief Pharmacist comments that price changes are 
not expected, if authorized biosimilar products will not enter to market. 
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Spending on pharmaceuticals in hospitals have generally increased and are challenging hospital 
budgets. In Finland, total hospital medicinal costs in 2015, when calculated in purchase prices, 
were between 9,5 to 44,2 million euros. All chief pharmacists replied that the cost of medicines has 
increased the past five years, and the increase varied between 9,6 – 27,7 %. The new expensive 
medicines are told to be the cause of this. Also, was mentioned, that the use of existing biological 
medicines has increased. Chief pharmacists replied that hospital medicines costs account for 4,5 
to 12,8 % of total hospital expenditure (operating costs excluding investment costs). Estimates 
made by gastroenterologists and rheumatologists were generally considerably higher than the cal-
culations of chief pharmacists. The external service purchases were not taken into account in cal-
culations and there might be some differences, what external services there are in each hospital. 
The biological medicinal products accounted up to 42 percent of the hospital’s total medicinal ex-
penditure in 2015.  One chief pharmacist commented that the costs of other ATC-groups' medicines 
have increased also and that’s why the share of biological medicines has not increased meaning-
fully. In this hospital, the cost of biological medicines had increased in euros about 2 million in past 
five years. Chief pharmacists were also asked which were the three most expensive biological 
medicines at purchase price in 2015 in their hospitals. The most expensive biological medicine was 
most often rituximab, accounting from 0,8 to 1,4 million euros. Second most expensive biological 
medicine was usually trastuzumab, accounting from 0,5 to 1,9 million euros and in third place was 
most often infliximab, accounting from 0,5 to 0,8 million euros. When calculating the cost share of 
these medicines of the total cost of medicines, rituximab’s share varied between 4 – 8 % and 
trastuzumab’s and infliximab’s between 4 – 6 %. The cost share of three most expensive biological 
medicines accounted in the highest 22 percent and in lowest 13 percent of total cost of medicines 
in hospitals. 
 
Most of the gastroenterologists and rheumatologists are willing to prescribe up-coming biosimilars 
for patients in outpatient care and they justified it by cost savings, economic reasons and saw it 
also as possibility to treat more patients with the same amount of money. 
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9 CONCLUSION 
Cost of medicines has increased in the past years and there is pressure, not only in Finland, but 
globally, to find ways how increase of the medicine costs is managed so that in the future all patients 
are still able to have the best treatment available with reasonable price. 
 
The results of this study suggest that biosimilars are seen as opportunity to manage the hospitals’ 
cost of medicines. The biosimilars which are expected to influence hospitals’ medicinal costs most 
in next five years are rituximab and trastuzumab. Biosimilar caused price competition is expected 
to result up to several million savings per hospital in next coming years. In December 2016, Celltrion 
received initial authorization for its biosimilar rituximab, CT-P10 (reference product MabThera) and 
it is interesting to see how this will affect product’s tender pricing in hospitals. Will the price decrease 
be as has huge as it was with infliximab and will the competition of pricing start before biosimilar 
rituximab actually is on the market?  
 
Another question is biosimilar medicines in outpatient care. Amgen received initial authorization for 
its biosimilar adalimumab, ABP501 (reference product Humira), in January 2017 and it is interesting 
to see, when this biosimilar will enter Finnish market and how does the company having the origi-
nator product react. For example, biosimilar etanercept has not reimbursement in Finland, even if 
it had marketing authorization in EU already in January 2016. At same time, biosimilar etanercept 
has taken already big market shares in Norway and Denmark.  
 
In Finland, the New Health Insurance Act involves price regulation concerning biosimilars. In order 
to increase the use of and price competition between biological medicines and biosimilars, the 
suggested reimbursable price for the first biosimilar entering the reimbursement system cannot 
exceed 70 percent of the list price of the original biologic. Also, the list price of the reference med-
icine will be re-examined, after the biosimilar is launched. 
 
Author’s impression is that there still seems to be need for information about biosimilars, especially 
data about switches is missing.  Also, always when new biosimilar enters the market, it should be 
introduced with proper data about safety, efficacy and similarity to the originator product. 
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PHARMACEUTICAL EXPENDITURES IN FINLAND 2000 – 2015 APPENDIX 1 
 
Year 
Total sales on pharmaceuticals, 
million € 
Hospital sales, 
million € 
Share of hospital sales, 
% 
2000 1646 222 13,5    
2001 1842 253 13,7    
2002 2026 288 14,2    
2003 2137 302 14,1    
2004 2288 325 14,2    
2005 2435 360 14,8    
2006 2361 379 16,1    
2007 2 500 408 16,3    
2008 2 664 438 16,4    
2009 2 629 434 16,5    
2010 2 619 444 17,0    
2011 2 682 479 17,9    
2012 2 740 475 17,3    
2013 2 824 497 17,6    
2014 2 831 514 18,2    
2015 2 958 561 19,0    
 
Hospital discounts are not taken into account in calculations. Retail prices (inclusive of tax) were 
used for calculating sales of medicines in the outpatient selling and wholesale prices were used for 
sales of medicines sold to hospitals. (Finnish medicines agency Fimea and social insurance insti-
tution 2010 – 2016; National agency for medicines and social insurance institution 2008 – 2009; 
Matveinen et al 2016, liitetaulukko 5a.) 
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DISTRIBUTION OF MEDICINES SALES  APPENDIX 2 
 
   
 
2015 
  
Total 
sales, 
2014 
Hospital 
sales, 
2014 
2014 
ATC-
code 
Medicinal agent 
Total 
sales, € 
Hos-
pital 
% 
Hospital 
sales, € 
Phar-
macy 
% 
Pharmacy 
sales, € 
Change 
% 
Change 
% 
Total 
sales, € 
Hos-
pital 
% 
Hospital 
sales, € 
P 
Antiparasitic 
products, insec-
ticides and re-
pellents 
5,2  3,9 0,2    96,1    5,0    - 1,3    - 19,8    5,3    4,8    0,3    
V Various 28,2  90,0 25,4    10,0    2,8    4,0    6,0    27,1    88,3    24,0    
D Dermatologicals 38,6  4,9 1,9    95,1    36,7    1,3    1,3    38,1   4,9    1,9    
H 
Systemic hormo-
nal preparations 
42,2  21,6 9,1    78,4    33,1    2,9    - 2,5    41,0    22,8    9,4    
S Sensory organs 46,6  31,7 14,8    68,3    31,8    9,4    39,3    42,6    24,9    10,6    
M 
Musculo-skeletal 
system 
97,4  14,4 14,0    85,6    83,4    - 0,9    - 19,4    98,3    17,7    17,4   
G 
Genito urinary 
system and sex 
hormone 
111,5  4,7 5 240    95,3    106 239    0,2    0,2    111 267    4,7    5 230    
R 
Respiratory sys-
tem 
143,6  4,7 6,8    95,3    136,9   - 3,1    8,4    148,2   4,2    6,2   
B 
Blood and blood 
forming organs 
177,4  37,5 66,5   62,5    110,9    9,4    10,6    162,1    37    60,2    
J 
Antiinfectives for 
systemic use 
182,1  64,1 116,7    35,9    65 ,4    25,0    29,2    145,8    62,0    90,4   
C 
Cardiovascular 
system 
202,8  8,5 17,2    91,5    185,6    6,3    0,4    190,8    9,0    17,2   
A 
Alimentary tract 
and metabolism 
292,1  8,7 25,4    91,3    266,7    5,1    - 0,7    278,1    9    25,6    
N Nervous system 313,0  16,4 51,4    83,6    261,7    - 3,4    - 7,4    324,0    17,1    55,4 
L 
Antineoplastic 
and immuno-
modulating 
agents 
500,2  41,2 206,1 58,8    294,1    8,6    8,0    460,7    41,4    190,7    
 
Distribution of medicines sales between pharmacies and hospitals per the ATC-code in 2015, at 
wholesale prices (million euros). Hospital and pharmacy sales and change percentages are calcu-
lated values. Wholesales of nervous system medicines (ATC-code N) do not include nicotine sales. 
Hospital discounts are not taken into account in calculations. (Finnish medicines agency Fimea and 
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social insurance institution 2016, 52-53, 176, 190, 196, 212, 215, 223, 226, 237, 246, 254, 274, 
276, 287, 291; Finnish medicines agency Fimea and social insurance institution 2014, 51-52.) 
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ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS, HOSPITAL SALES    APPENDIX 3 
 
ATC-
code 
Medicinal agent 
Total sales, 
million € 
Hospital share of sales, 
% 
Hospital sales, 
million € 
L 
Antineoplastic and 
immunomodulating 
agents 500,2 41 % 206,1 
L01 Antineoplastic agents 192,4 73 % 140,5 
L02 Endocrine therapy 35,3 4 % 1,4 
L03 Immunostimulants 49,0 12 % 5,9 
L04 
Immunosuppres-
sants 223,4 26 % 58,1 
 
In 2015, Hospital sales (at wholesale prices) of antineoplastic and immunomodulating agents, di-
vided to classification level 2. Hospital and pharmacy sales are calculated values. Hospital dis-
counts are not taken into account in calculations. (Finnish medicines agency Fimea and social 
insurance institution 2016, 237.) 
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ANTINEOPLASTIC AGENTS, CLASSIFICATION LEVEL 3          APPENDIX 4 
 
ATC-
code 
Medicinal agent 
Total sales, 
million € 
Hospital share 
of sales, % 
Hospital sales, 
million € 
L01 Antineoplastic agents 192,4 73 % 140,5 
L01A Alkylating agents 6,0 68 % 4,1 
L01B Antimetabolites 17,9 71 % 12,7 
L01C Plant alkaloids and other 
natural products 
8,9 85 % 7,5 
L01D Cytotoxic antibiotics and 
related substances 
5,4 100 % 5,4 
L01X Other antineoplastic 
agents 
154,3 71 % 109,5 
 
In 2015, Hospital sales (at wholesale prices) of antineoplastic agents, divided to classification level 
3. Hospital and pharmacy sales are calculated values. Hospital discounts are not taken into account 
in calculations. (Finnish medicines agency Fimea and social insurance institution 2016, 238-239.) 
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OTHER ANTINEOPLASTIC AGENTS, CLASSIFICATION LEVEL 4  APPENDIX 5 
 
ATC-
code 
Medicinal agent Total sales, 
million € 
Hospital share 
of sales, % 
Hospital sales, 
million € 
L01X Other antineoplastic 
agents 
154,3 71 % 109,5 
L01XA Platinum compounds 0,6 100 % 0,6 
L01XC Monoclonal antibodies 90,0 100 % 90,0 
L01XD Sensitizers used in pho-
todynamic /radiation 
therapy 
0,9 99 % 0,9 
 
In 2015, Hospital sales (at wholesale prices) of other antineoplastic agents, divided to classification 
level 4. Hospital and pharmacy sales are calculated values. Hospital discounts are not taken into 
account in calculations. (Finnish medicines agency Fimea and social insurance institution 2016, 
239.) 
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IMMUNOSUPPRESSANTS, CLASSIFICATION LEVEL 4 APPENDIX 6 
 
ATC-
code 
Medicinal agent 
Total sales, 
million € 
Hospital share 
of sales, % 
Hospital sales, 
million € 
L04 Immunosuppressants 223,4 26 % 58,1 
L04A Immunosuppressants 223,4 26 % 58,1 
L04AA 
Selectice immunosup-
pressants 38,4 33 % 12,7 
L04B 
Tumor necrosis factro al-
pha (TNF-a) inhibitors 136,7 29 % 39,6 
L04AC Interleukin inhibitors 13,7 32 % 4,4 
L04AD Calcineurin inhibitors 12,2 5 % 0,6 
L04AX 
Other immunosuppres-
sants 22,4 10 % 2 ,2 
 
In 2015, Hospital sales (at wholesale prices) of immunosuppressants, divided to classification level 
4. Hospital and pharmacy sales are calculated values. Hospital discounts are not taken into account 
in calculations. (Finnish medicines agency Fimea and social insurance institution 2016, 237, 244-
245.) 
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MONOCLONAL ANTIBODIES, CLASSIFICATION LEVEL 5 APPENDIX 7 
 
  
2015 2014 2013 
ATC-code Medicinal 
agent 
Total 
sales, 
million € 
Hospital 
share of 
sales, % 
Hospital 
sales, 
million € 
Total 
sales, 
million € 
Hospital 
share of 
sales, % 
Hospital 
sales, 
million € 
Total 
sales, 
million € 
Hospital 
share of 
sales, % 
Hospital 
sales, 
million € 
L01XC Monoclonal 
antibodies 
90,0 100 90,0 81,4 100 81,4 73,8 99 73,1 
L01XC02 Rituximab 31,4 100    31,4    - - - 26,9 100    26,9 
L01XC03 Trastuzumab 22,5 100 22,5 21,7 100 21,7 20,4 100 20,4 
L01XC06 Cetuximab 1,6 100 1,6 1,7 100 1,7  -   -   -  
L01XC07 Bevaci-
zumab 
21,0 100 21,0 18,8 99 18,6 18,3 99 18,2 
L04AB TNF-alpha 
inhibitors 
136,7 29 39,6 127,4 29 36,9 102,1 31 31,7 
L04AB01 Etanercept 31,7 0 0 30,1 0 0 28,5 0 0 
L04AB02 Infliximab 37,7 100 37,7 35,8 100 35,8 30,2 100 30,2 
L04AB04 Adalimumab 46,5 2 0,9 44,8 2 0,9 43,3 3 1,3 
 
In 2015, Hospital sales (at wholesale prices) of monoclonal antibodies, divided to classification level 
5. Hospital and pharmacy sales are calculated values. Hospital discounts are not taken into account 
in calculations. (Finnish medicines agency Fimea and social insurance institution 2016, 239, 244.) 
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PHARMACEUTICAL CONSUMPTION IN FINLAND 2013 – 2015 APPENDIX 8 
 
  
2015 2014 2013 
ATC-code Medicinal agent DDD/  
1000 inh/ 
day 
Hospital 
share, % 
DDD/ 
1000 inh/  
day 
Hospital 
share, % 
DDD/  
1000 inh/ 
day 
Hospital 
share, 
% 
L04AB01 Etanercept 
(DDD 7 mg) 
0,49 0 0,47 0 0,44 0 
L04AB04 Adalimumab 
(DDD 2,9 mg) 
0,68 2 0,65 2 0,63 3 
L04AB02 Infliximab  
(DDD 3,75 mg) 
0,89 100 0,77 100 0,71 100 
 
Pharmaceutical consumption in Finland 2013 – 2015 as DDD per 1000 inhabitants per day. Sales 
to hospitals as a proportion (%) of consumption. (Finnish medicines agency Fimea and social in-
surance institution 2016, 244; Finnish medicines agency Fimea and social insurance institution 
2013, 230.) 
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PHARMACEUTICAL CONSUMPTION IN NORWAY 2013 – 2015  APPENDIX 9 
 
ATC-code Medicinal agent 2015, 
DDD/1000 inh 
/ day 
2014, 
DDD/1000 inh 
/ day 
2013, 
DDD/1000 inh 
/day 
L04A Immunosuppressants 11,3 10,6 9,8 
L04AB TNF-alpha inhibitors 4,1 3,7 3,3 
L04AB01 Etanercept (7mg) 0,8 0,8 0,9 
L04AB02 Infliximab (3,75mg) 1,8 1,4 1,2 
L04AB04 Adalimumab (2,9mg) 0,7 0,8 0,8 
 
Pharmaceutical consumption in Norway 2013 – 2015 as DDD per 1000 inhabitants per day. The 
figures are given as the number of DDDs/1000 inhabitants/day, calculated as follows: (DDD/1000 
inhabitants/year)/365. (Sakshaug 2016, 9, 66.) 
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COVER LETTER, CHIEF PHARMACISTS APPENDIX 10 (1/8) 
 
Arvoisa vastaanottaja, 
 
Opiskelen Oulun ammattikorkeakoulussa tekniikan yksikössä teknologialiiketoiminnan tutkinto- 
ohjelmassa ylempää ammattikorkeakoulututkintoa. Opinnäytetyöni aiheeksi valikoitui biosimilaarit, 
jotka ovat olleet jo useamman vuoden terveydenhuollon kuuma keskustelun aihe. Opinnäytetyöni 
ohjaajana toimii tutkintovastaava Hannu Päätalo. 
 
Olen työskennellyt vuodesta 2008 lääkeyrityksessä kolmen eri biosimilaarivalmisteen kanssa 
(epoetiini alfan, filgrastiimin ja infliximabin) ja työssäni on noussut esiin kysymyksiä mm. siitä, mihin 
biosimilaareilla säästetyt rahat sairaaloissa käytetään. Opinnäytetyöni tavoitteena on avata sairaa-
lakäytössä olevien biosimilaarivalmisteiden, infliximabin ja filgrastiimin, käyttöönottoa, arvioida 
kustannussäästöjä ja -vaikutuksia, sekä pohtia mihin mahdolliset säästyneet varat on käytetty.  
Lisäksi tarkoituksena on selvittää, miten lääkevaihdot alkuperäisvalmisteilta biosimilaareille tai  
biosimilaarin vaihto toiseen biosimilaariin koetaan. Opinnäytetyöni tulee olemaan julkinen ja  
julkaistaan englanniksi. 
 
Kyselylomakkeen olen lähettänyt yliopisto- ja keskussairaaloiden sairaala-apteekkareille. Vastauk-
set tulen käsittelemään luottamuksellisesti ja tulokset esitetään yhteenvetona niin, ettei yksittäistä 
vastaajaa tai sairaalaa voi saada selville. 
 
Kysymyksien laatimiseen olen saanut asiantuntija-apua professori, osastonylilääkäri Tuulikki 
Sokka-Isleriltä, dosentti, LKT Pekka Kurjelta, sekä sairaala-apteekkarilta. 
 
Toivoisin, että antaisitte kokemuksenne käyttööni täyttämällä tämän kyselylomakkeen ja palautta-
malla sen minulle 31.10. mennessä sähköpostiosoitteeseeni xxx. Kyselyn on kahdeksan sivun mit-
tainen. 
 
Tarvittaessa vastaan kysymyksiinne ja annan mielelläni lisätietoja opinnäytetyöstäni xxx tai puh. 
xxx. 
 
Vastauksistanne kiittäen, Maarit Simi 
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COVER LETTER, OTHER TARGET GROUPS     APPENDIX 10 (2/8) 
 
Arvoisa vastaanottaja, 
 
Opiskelen Oulun ammattikorkeakoulussa tekniikan yksikössä teknologialiiketoiminnan tutkinto- 
ohjelmassa ylempää ammattikorkeakoulututkintoa. Opinnäytetyöni aiheeksi valikoitui biosimilaarit, 
jotka ovat olleet jo useamman vuoden terveydenhuollon kuuma keskustelun aihe. Opinnäytetyöni 
ohjaajana toimii tutkintovastaava Hannu Päätalo. 
 
Olen työskennellyt vuodesta 2008 lääkeyrityksessä kolmen eri biosimilaarivalmisteen kanssa 
(epoetiini alfan, filgrastiimin ja infliximabin) ja työssäni on noussut esiin kysymyksiä mm. siitä, mihin 
biosimilaareilla säästetyt rahat sairaaloissa käytetään. Opinnäytetyöni tavoitteena on avata sairaa-
lakäytössä olevien biosimilaarivalmisteiden, infliximabin ja filgrastiimin, käyttöönottoa, arvioida 
kustannussäästöjä ja -vaikutuksia, sekä pohtia mihin mahdolliset säästyneet varat on käytetty.  
Lisäksi tarkoituksena on selvittää, miten lääkevaihdot alkuperäisvalmisteilta biosimilaareille tai  
biosimilaarin vaihto toiseen biosimilaariin koetaan. Opinnäytetyöni tulee olemaan julkinen ja  
julkaistaan englanniksi. 
 
Kyselylomakkeen olen lähettänyt yliopisto- ja keskussairaaloiden gastroenterologian, reumatolo-
gian, onkologian ja sisätautien ylilääkäreille, tulosalueen johtajille ja sairaanhoitopiirien johtajayli-
lääkäreille sekä arviointiylilääkäreille. Vastaukset tulen käsittelemään luottamuksellisesti ja tulokset 
esitetään yhteenvetona niin, ettei yksittäistä vastaajaa tai sairaalaa voi saada selville. Kysymyksien 
laatimiseen olen saanut asiantuntija-apua professori, osastonylilääkäri Tuulikki Sokka-Isleriltä, do-
sentti, LKT Pekka Kurjelta, sekä sairaala-apteekkarilta. 
 
Toivoisin, että antaisitte kokemuksenne käyttööni täyttämällä tämän kyselylomakkeen ja palautta-
malla sen minulle 31.10. mennessä sähköpostiosoitteeseeni xxx. Kyselyn täyttäminen vie aikaa 
kohderyhmästä riippuen noin 15 – 30 minuuttia. 
 
Tarvittaessa vastaan kysymyksiinne ja annan mielelläni lisätietoja opinnäytetyöstäni xxx tai puh. 
xxx. 
 
Vastauksistanne kiittäen, Maarit Simi 
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Biosimilaarit        APPENDIX 10 (3/8) 
Biosimilaarit eli samankaltaiset biologiset lääkkeet ovat alkuperäisten biologisten lääkevalmistei-
den kopioita, jotka tulevat markkinoille alkuperäisen biologisen lääkkeen patentti-, dokumentaatio- 
ja markkinointisuojan umpeuduttua. Biosimilaari sisältää EU:n markkinoilla olevan myyntiluvallisen 
alkuperäislääkkeen vaikuttavan aineen uuden version ja sen kehittäminen perustuu biosimilaarin 
ja sen alkuperäisvalmisteen laadun, tehon ja turvallisuuden vertailukelpoisuuden osoittamiseen. 
Vuonna 2006 hyväksyttiin EU:n ensimmäinen biosimilaarivalmiste ja 2013 ensimmäinen monoklo-
naalinen biosimilaarivasta-aine infliksimabi (Ruskoaho 2016, 16). EU:ssa on heinäkuuhun 2016 
mennessä arvioitu 32 biosimilaarivalmisteen myyntilupahakemusta, joista 23 johti myyntilupaan 
(myyntilupa voimassa 21 valmisteella) (taulukko 1). Suomessa kesällä 2016 markkinoilla oli 10 
biosimilaarivalmistetta (taulukko 1). Useiden biologisten valmisteiden patentti- ja dokumentaatio 
suojat ovat umpeutuneet ja useita uusien biosimilaarien myyntilupahakemuksia on arvioitavana 
(taulukko 1), joten uusia biosimilaareja on tulossa markkinoille lähivuosina (taulukko 2).  
2015 Suomen kymmenen myydyimmän lääkevalmisteen joukossa on kahdeksan biologista valmis-
tetta (kuva 1). Kymmenen myydyimmän lääkevalmisteen tukkumyynti 2015 oli noin 276 miljoonaa 
euroa, josta biologisten osuus oli noin 233 miljoonaa euroa (kuva 1). Lääkkeiden kokonaismyyn-
nistä sairaalalääkkeiden osuus on noin 27 prosenttia (Lääkemarkkinat, viitattu 1.9.2016). 
Biologiset lääkkeet ovat pääsääntöisesti huomattavan kalliita ja yksi keskeinen syy korkeille         
hinnoille on ollut hintakilpailun puuttuminen. Tällä hetkellä biologisten lääkkeiden kustannukset       
lisääntyvät noin kymmenen prosenttia vuodessa (Kurki & Orvilahti 2016, 41). Biosimilaarien mark-
kinoille tulo on lisännyt kilpailua ja esimerkkinä tästä voisi mainita infliximabimarkkinat, jossa biosi-
milaarit ovat vallanneet markkinat 90 %:sti (Ruskoaho 2016, 16). Odotusarvona on, että biosimi-
laarien hinnat ovat alkuperäislääkettä halvemmat ja kilpailu laskee myös alkuperäislääkkeiden hin-
toja. 
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         APPENDIX 10 (4/8) 
TAULUKKO 1. Biosimilaarit EU:ssa (heinäkuu 2016) (Fimea 2016, viitattu 11.7.2016; European 
Medicines Agency 2016, viitattu 23.7.2016; European Medicines Agency July 2016, viitattu 
23.7.2016; Kurki, Oravilahti & Martikainen 2016, 148) 
Käsitellyt myyntilupahakemukset 32 
  Myyntilupia myönnetty 23 
  Hakija vetänyt pois hakemuksen 7 
  Hylätty 2  
  Myyntilupa peruutettu yrityksen 
toimesta 
2 
Myyntilupa voimassa 21 5 epoetiinia 
1 etanersepti 
8 filgrastiimia 
2 follitropiinia 
1 glargininsuliini 
3 infliximabia 
1 kasvuhormoni   
  
  
249 
         APPENDIX 10 (5/8) 
Käsiteltävänä olevat hakemukset 14 2 adalimumabia 
2 enoksapariinia 
1 etanersepti 
1 glargininsuliini 
4 PEG filgrastiimia 
2 rituximabia 
2 teriparatidea                 
Suomessa markkinoilla 10 1 kasvuhormoni 
3 filgrastiimia 
2 epoetiini alfaa 
1 follitropiini 
2 infliximabia 
1 glargininsuliini 
 
  
  
250 
         APPENDIX 10 (6/8) 
TAULUKKO 2. Arvio eräiden biosimilaarien markkinoille tulosta (Ruskoaho 2016, 17; WHO 2015) 
Lääkeaine  Vuosi Farmakoterapeuttinen ryhmä  
Enoksapariini 2017 Antitromboottiset lääkeaineet  
Pegfilgrastiimi 2017 Immunostimulantit  
Aspartinsuliini 2018 Diabeteslääkkeet  
Darbepoetiinialfa 2018 Anemialääkkeet  
Korifollitropiini alfa 2018 
Sukupuolihormonit ja genitaalijärjestelmään vai-
kuttavat aineet 
 
Pegvisomantti 2018 
Aivolisäkkeen ja hypotalamuksen hormonit sekä 
analogit 
 
Trastutsumabi 2018 Solunsalpaajat  
Abatasepti 2018 Immunosuppressantit  
Tosilitsumabi 2018 Immunosuppressantit  
Omalitsumabi 2018 Obstruktiivisten hengitystiesairauksien lääkkeet  
Detemirinsuliini 2019 Diabeteslääkkeet  
Adalimumabi 2019 Immunosuppressantit  
Romiplostiimi 2020 Hemostaatit  
Metoksipolyetyleeniglykoliepoetiini 
beta 
2021 
Anemialääkkeet 
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         APPENDIX 10 (7/8) 
 
KUVA 1. Kymmenen myydyintä lääkevalmistetta Suomessa 2014 ja 2015 (tukkumyynti) (Lääkete-
ollisuus ry (a), viitattu 13.7.2016; Lääketeollisuus ry (b), viitattu 13.7.2016) 
 
LÄHTEET: 
Applications for new human medicines under evaluation by the Committee for Medicinal Products 
for Human Use. July 2016. European Medicines Agency. Viitattu 23.7.2016. http://www.ema.eu-
ropa.eu/docs/en_GB/document_library/Report/2016/07/WC500209941.pdf. 
 
ATC/DDD Index 2016 2015. WHO Collaborating Centre for Drug Statistics Methodology. Viitattu 
13.8.2016. http://www.whocc.no/atc_ddd_index/. 
 
Biosimilaarit Suomessa. Lääkealan kehittämis- ja turvallisuuskeskus Fimea. Viitattu 11.7.2016. 
http://www.fimea.fi/laaketurvallisuus_ja_tieto/biosimilaarit/biosimilaarit_suomessa. 
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European public assessment reports. European Medicines Agency. Viitattu 23.7.2016. 
http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedi-
cines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=search-
ByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&sta-
tus=Suspended&status=Refused&keyword=biosimilar&searchType=name&taxonomyPath=&tree-
Number=&searchGenericType=biosimilars&genericsKeywordSearch=Submit. 
 
Kurki P, Oravilahti T. Biosimilaarit testaavat lääkkeen määrääjien kustannustietoisuuden. SIC! Lää-
ketietoa Fimeasta. 1/2016; 41-44. Viitattu 11.7.2016. https://www.julkari.fi/bitstream/han-
dle/10024/130215/1_16%2041-44%20Biosimilaarit%20testaavat%20laakkeen%20maaraa-
jien%20kustannustietoisuuden.pdf?sequence=1. 
 
Kurki P, Oravilahti T, Martikainen J E. Miksi biosimilaarit kannattaa ottaa käyttöön? Suomen lääkä-
rilehti. 2016 71 (3); 147-151. 
 
Lääkemarkkinat. Lääkemarkkinoiden ydin muodostuu korvattavista lääkkeistä. Lääketeollisuus ry. 
Viitattu 1.9.2016. http://www.laaketeollisuus.fi/laakkeet/laakemarkkinat. 
 
Ruskoaho, H. 2016 Lääkekorvausjärjestelmän tarkastelua lääkkeiden näkökulmasta vuoden 2017 
lääkesäästöihin liittyen. Selvitysmiehen raportti. Sosiaali- ja terveysministeriön raportteja ja muisti-
oita 2016:31. Viitattu 11.7.2016. https://julkaisut.valtioneuvosto.fi/bitstream/han-
dle/10024/74928/RAP2016_31.pdf?sequence=1.  
 
Top 10 tuotteet Suomessa 2015. Lääketeollisuus ry (a). Viitattu 13.7.2016. http://www.laaketeolli-
suus.fi/sites/default/files/attachments/suomen_myydyimmat_laakevalmisteet_2015.pdf. 
 
10 myydyintä lääkevalmistetta Suomessa 2014. Lääketeollisuus ry (b). Viitattu 13.7.2016. 
http://www.laaketeollisuus.fi/sites/default/files/attachments/Tilastot/07_top_10_tuotteet_0.pdf. 
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Valitse alla olevista vaihtoehdoista sopivin/sopivimmat laittamalla rasti ruutuun. Jos et 
löydä sopivaa vaihtoehtoa, kirjoita kommenttisi vapaan tekstin kenttään. Kaikki biosimilaari- 
ja alkuperäisvalmisteiden hintavertailut tulee tehdä hankintakilpailutuksessa tarjotuin  
sairaalan ostohinnoin. Jos et pysty vastaamaan johonkin kysymykseen, jätä kohta täyttä-
mättä. Jos käsittelet vastauksissasi filgrastiimin ja infliximabin biosimilaarivalmisteita, täytä 
kummastakin oma kysely. Kysely on 8 sivun pituinen. 
 
Kyselylomake tulee tallentaa ennen täyttämisen aloittamista. Palauta tallentamasi liitetie-
dosto sähköpostiosoitteeseen (xxx) lokakuun loppuun mennessä. 
 
1. Valitse sairaala, jota edustat 
☐ Yliopistollinen sairaala 
☐ Keskussairaala 
☐ Muu, mikä?       
 
2. Valitse biosimilaarivalmiste, jota käsittelet vastauksissasi ja identifioi sen asemaa  
sairaalavalikoimassa tällä hetkellä. Jos haluat käsitellä molempia biosimilaarivalmis-
teita, täytä kummastakin oma kysely. 
2.1. Biosimilaarivalmiste, johon otat kantaa   
☐ Filgrastiimi 
☐ Infliximabi 
2.2. Voimassaolevan hankintakauden kesto 
Alkoi, vuosi      , kuukausi          
Loppuu, vuosi      , kuukausi       
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2.3. Valitsemasi biosimilaarivalmisteen asema sairaalan lääkevalikoimassa voimassa 
olevalla hankintakaudella  
☐ Biosimilaarivalmiste on lääkevalikoimassa ensisijainen vaihtoehto 
Miksi?       
☐ Lääkevalikoimassa on myös biosimilaarivalmisteen alkuperäisvalmiste 
Miksi?       
☐ Lääkevalikoimassa ei ole biosimilaarivalmistetta 
Miksi?       
☐ Lääkevalikoimassa on vain biosimilaarivalmiste 
Miksi?       
Muita kommentteja?       
 
3. Kysymykset koskien biosimilaarien tehoa, turvallisuutta, vaihtoja ja käyttöönottoa 
3.1. Biosimilaarilääkkeen myyntilupaa haettaessa on osoitettava, että mahdolliset erot 
biosimilaari- ja alkuperäisvalmisteen välillä eivät vaikuta tehoon tai turvallisuuteen. 
Ovatko biosimilaarivalmisteilta vaadittavat tutkimukset riittävän kattavia  
tehon ja turvallisuuden osalta ja mistä olet saanut biosimilaarivalmisteista tietoa? 
3.1.1. Biosimilaarivalmisteiden tutkimukset ovat 
☐ Riittävän kattavia 
     Miksi?       
☐ Eivät ole riittävän kattavia 
     Miksi?       
Muita kommentteja?       
3.1.2. Mistä lähteistä olet saanut tietoa biosimilaarivalmisteista? 
☐ Lääkeyrityksiltä 
☐ Lääkeviranomaisilta 
☐ Kollegoilta 
☐ Muualta, mistä?       
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3.1.3. Koetko tarvitsevasi lisää tietoa biosimilaareista? 
☐ Kyllä 
     Seuraavista asioista       
☐ En 
3.2. Sairaaloissa on vaihdettu potilaita alkuperäisvalmisteilta biosimilaarivalmisteille. 
Miten sairaalassa valmistauduttiin vaihtoihin alkuperäisvalmisteelta valitsemallesi 
biosimilaarivalmisteelle ja vaikuttivatko vaihdot hoidon tehoon ja/tai turvallisuu-
teen? Onko vaihdoista tehty jälkiseurantaa? 
3.2.1. Miten vaihtoihin valmistauduttiin? 
☐ Vaihdot eivät aiheuttaneet erillistoimenpiteitä 
☐ Määrittämällä vasta-aine- ja lääkeainepitoisuudet ennen vaihtoja 
☐ Ohjeistamalla potilas siitä, mikä biosimilaarivalmiste on 
☐ Kouluttamalla hoitohenkilökunta siitä, mikä biosimilaarivalmiste on 
☐ Määrittelemällä vaihdettavat potilaat 
      Vaihtokriteerejä olivat:       
☐ Muuten, miten?       
3.2.2. Vaikuttivatko vaihdot hoidon tehoon ja/tai turvallisuuteen? 
☐ Kyllä 
     Miten?       
☐ Ei 
☐ En osaa sanoa 
Muita kommentteja?       
3.2.3. Onko vaihdoista tehty jälkiseurantaa? 
☐ Ei erityistä seurantaa 
☐ Lääkeainepitoisuus- ja vasta-ainemäärityksin 
  ☐ Määritetään tietyin frekvenssein 
  ☐ Määritetään tarvittaessa 
☐Seuraamalla hoidon keskeytymisen syitä 
☐Muuten, miten?       
Muita kommentteja?       
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3.3. Alkuperäisten biologisten lääkkeiden rinnalle on tulossa yhä enemmän  
biosimilaarivalmisteita. Ovatko biosimilaarivalmisteet, joilla on sama vaikuttava 
aine, mielestäsi vaihtokelpoisia keskenään sairaalassa ja mitä asioita vaihdoissa 
tulisi huomioida? 
3.3.1. Ovatko biosimilaarivalmisteet vaihdettavia keskenään? 
☐ Kyllä 
     Miksi?       
☐ Eivät 
     Miksi?       
☐ En osaa sanoa 
     Miksi?       
3.3.2. Mitä asioita tulisi huomioida vaihdettaessa biosimilaarivalmisteelta toiseen? 
       
3.4. Mitkä ovat mielestäsi biosimilaarien entistä laajemman käytön tärkeimmät esteet?  
      
 
4. Kysymykset koskien lääkekustannuksia ja säästöjä  
4.1. Kun biosimilaarivalmiste tulee markkinoille, oletetaan sen aiheuttavan hintakilpai-
lua. Kommentoi odotuksiasi valitsemasi biosimilaarivalmisteen hintaerosta alku-
peräisvalmisteeseen, sekä sen toteutumista, kun biosimilaari valittiin ensimmäi-
sen kerran sairaalan lääkevalikoimaan. Ensimmäinen biosimilaari filgrastiimi sai 
myyntilupansa Euroopassa syyskuussa 2008 ja infliximabi syyskuussa 2013. 
4.1.1. Ennen biosimilaarivalmisteen markkinoille tuloa, biosimilaarivalmisteen ja 
sen alkuperäisvalmisteen hintaeroksi arvioit 
      % 
Mihin perustit oletuksesi?       
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4.1.2. Biosimilaari- ja alkuperäisvalmisteen sairaalan ostohintaero verrattuna alku-
peräisvalmisteen sairaalan ostohintaan, kun biosimilaarivalmiste valittiin  
sairaalan lääkevalikoimaan ensimmäisen kerran 
      % 
Vuosi       
4.1.3. Biosimilaarivalmisteen tullessa hankintakilpailutukseen mukaan ensimmäi-
sen kerran, muuttuiko alkuperäisvalmisteen ostohinta verrattuna edelliseen 
hankintakilpailutuksessa tarjottuun ostohintaan? 
☐ Kyllä 
  ☐ Laski       % 
  ☐ Nousi       % 
☐ Ei 
Muita kommentteja?       
4.2. Biosimilaarivalmisteen käyttöönotto sairaalassa on mahdollistanut lääkekustan-
nussäästöjä. Millä keinoin säästöjä tavoiteltiin ja toteutuivatko säästöt? 
4.2.1. Valitsemallasi biosimilaarivalmisteella tavoiteltiin lääkekustannussäästöjä 
☐ Aloittamalla uusille potilaille 
☐ Vaihtamalla alkuperäisvalmisteelta kaikki potilaat biosimilaarivalmisteelle 
☐ Vaihtamalla tietyt potilasryhmät alkuperäisvalmisteelta biosimilaarivalmisteelle 
     Mitä potilasryhmiä/potilaita ei vaihdettu?       
Muita kommentteja?       
4.2.2. Toteutuivatko lääkekustannussäästöt? 
☐ Kyllä 
     Mitkä tekijät edesauttoivat kustannussäästöjen toteutumisessa?       
☐ Eivät 
    Miksi eivät?       
☐ Osin 
     Mitkä tekijät vaikuttivat siihen, että tavoitteeseen ei päästy?        
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4.2.3. Arviosi valitsemasi biosimilaarivalmisteen avulla saavutetuista kustannus-
säästöistä lääkeostoissa vuonna 2015 
      € 
☐ Vain biosimilaarivalmiste oli jo edellisellä hankintakaudella sairaalan lääkevali-
koimassa, joten lääkekustannussäästöt alkuperäisvalmisteeseen verrattuna eivät 
olleet enää 2015 ajankohtaisia. 
4.2.4. Jos biosimilaarivalmisteella saatiin sairaalalle lääkekustannussäästöjä, mihin 
vapautuneet varat käytettiin? 
☐ Mahdollisti useamman potilaan hoidon kyseisellä valmisteella 
☐ Mahdollisti uusien valmisteiden käyttöönoton sairaalavalikoimassa 
☐ Lääkekustannusten hallintaan 
☐ Henkilökunnan palkkaukseen 
☐ Muu, mikä?       
4.2.5. Valitsemasi bioisimilaarivalmisteen prosenttiosuus lääkeryhmän kokonais-
lääkemäärästä vuonna 2015. Inflectra mg:sta/filgrastim ruiskumääristä lasket-
tuna. Laskelmassa tulisi olla mukana valmisteet, jotka sisältyvät valitsemasi 
biosimilaarivalmisteen ATC-koodin alle: L04AB02 infliximabit tai L03AA02 fil-
grastiimit. 
Prosenttiosuus       % 
4.3. Uusia biosimilaarivalmisteita on tulossa markkinoille lähivuosina. Miten arvioisit 
niiden vaikuttavan sairaalassa käytettävien alkuperäisvalmisteiden hinnoitteluun 
ja mitä odotat biosimilaarivalmisteiden hinnoittelulta? 
4.3.1. Biosimilaarivalmisteiden hinnoittelulta sairaalahinnoissa tulevaisuudessa 
odotat 
☐ Biosimilaarivalmisteet ovat edullisempia kuin alkuperäisvalmisteet 
     Arvioimasi hintaero       % 
☐ Alkuperäisvalmisteet lähtevät hintakilpailuun mukaan biosimilaarivalmisteiden  
     saadessa myyntiluvan ja ovat yhtä edullisia kuin biosimilaarivalmisteet 
☐ Alkuperäisvalmisteiden hinta ei laske 
☐ Alkuperäisvalmisteet ovat edullisempia kuin biosimilaarivalmisteet 
    Arvioimasi hintaero      % 
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Muita kommentteja?       
4.3.2. Paljonko seuraavan 5 vuoden aikana arvioit saatavan biosimilaarivalmistei-
den aiheuttamien hintakilpailujen avulla sairaalassasi kustannussäästöjä lää-
keostoissa? 
      €/5 vuotta 
Perustelut arviollesi       
4.3.3. Biosimilaarivalmiste, jonka oletat seuraavaksi vaikuttavan sairaalanne  
lääkekustannuksiin merkittävästi 
Valmiste:       
Arvioitu kustannussäästö lääkeostoissa:       €/vuosi 
Kustannussäästöarviosi perustuu seuraaviin asioihin:       
Muita kommentteja?       
4.4. Lisääntyvät lääkekustannukset ovat haaste sairaaloille. Ovatko lääkekustannukset 
muuttuneet viimeisen viiden vuoden aikana sairaalassa ja mikä on biologisten 
lääkkeiden osuus sairaalan kokonaislääkekustannuksista? 
4.4.1. Sairaalan kokonaislääkekustannukset ostohinnoin laskettuna 2015? 
      € 
4.4.2. Sairaalan lääkekustannukset ovat viimeisen viiden vuoden aikana? 
☐ Kasvaneet       % 
     Miksi?       
☐ Pienentyneet       % 
     Miksi?       
☐ Eivät ole muuttuneet 
     Miksi?       
4.4.3. Sairaalan lääkekustannusten osuus prosentteina sairaalan kokonaismenoista 
2015? Kokonaismenoilla tarkoitetaan toimintakuluja, eli niissä ei ole  
huomioitu investointimenoja. 
Prosenttiosuus       % 
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4.4.4. Biologisten lääkkeiden prosenttiosuus sairaalan lääkkeiden kokonaiskustan-
nuksista vuonna 2015? Laskelmassa tulisi olla mukana valmisteet, jotka  
sisältyvät seuraavien ATC-koodien alle: A10A (insuliinit), B03XA (anemialääk-
keet), H01AC (somatropinit), J06 (immunogobuliinit), L03AA (sytokiinit), 
L03AB (interferonit), L04AA (immunosupressantit, pois lukien - 06, - 10, - 13, -
27,- 29,- 31,- 32), L04AB (tumoorinekroositekijä alfan estäjät), L04AC (interleu-
kiinin estäjät), L01XC (monoklonaaliset antibodit). 
Prosenttiosuus       % 
4.4.5. Onko edellä mainittujen biologisten lääkkeiden kustannusten osuus kasvanut 
kokonaislääkekustannuksista viimeisen viiden vuoden aikana?  
☐ Kyllä       % 
     Miksi?       
☐ Ei 
     Miksi?       
4.4.6. Sairaalan 3 kustannuksiltaan kalleinta (ostohinnoilla laskettuna) biologista 
lääkettä vuonna 2015 
1.      ,       € 
2.      ,       € 
3.      ,       € 
 
5. Haluan, että lähetät sähköpostiini linkin, josta pääsen lukemaan opinnäytetyösi 
Sähköpostiosoitteeni       
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QUESTIONNAIRE, OTHER TARGET GROUPS  APPENDIX 12 (1/8) 
Valitse alla olevista vaihtoehdoista sopivin/sopivimmat laittamalla rasti ruutuun. Jos et 
löydä sopivaa vaihtoehtoa, kirjoita kommenttisi vapaan tekstin kenttään. Kaikki biosimilaari- 
ja alkuperäisvalmisteiden hintavertailut tulee tehdä hankintakilpailutuksessa tarjotuin  
sairaalan ostohinnoin. Jos et pysty vastaamaan johonkin kysymykseen, jätä kohta täyttä-
mättä. Jos käsittelet vastauksissasi filgrastiimin ja infliximabin biosimilaarivalmisteita, täytä 
kummastakin oma kysely. Kysely on 8 sivun pituinen. 
Kyselylomake tulee tallentaa ennen täyttämisen aloittamista. Palauta tallentamasi liitetie-
dosto sähköpostiosoitteeseen (xxx) lokakuun loppuun mennessä. 
 
1. Valitse missä ominaisuudessa vastaat kysymyksiin, sekä sairaala, jota edustat 
1.1. Olet 
☐ Arviointiylilääkäri 
☐ Gastroenterologian ylilääkäri 
☐ Onkologian ylilääkäri 
☐ Reumatologian ylilääkäri 
☐ Sairaanhoitopiirin johtajaylilääkäri 
☐ Tulos- / palvelualueen johtaja 
 Tulos- / palvelusalueeni on       
☐ Muu, mikä?       
1.2. Edustamasi sairaala on 
☐ Yliopistollinen sairaala 
☐ Keskussairaala 
☐ Muu, mikä?       
 
2. Valitse biosimilaarivalmiste, jota käsittelet vastauksissasi ja identifioi sen asemaa sai-
raalavalikoimassa tällä hetkellä. Jos haluat käsitellä molempia biosimilaarivalmisteita, 
täytä kummastakin oma kysely. 
2.1. Biosimilaarivalmiste, johon otat kantaa 
☐ Filgrastiimi 
☐ Infliximabi 
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2.2. Voimassa olevan hankintakauden kesto 
Alkoi, vuosi      , kuukausi          
Loppuu, vuosi      , kuukausi       
2.3. Valitsemasi biosimilaarivalmisteen asema sairaalan lääkevalikoimassa voimassa 
olevalla hankintakaudella 
☐ Biosimilaarivalmiste on lääkevalikoimassa ensisijainen vaihtoehto 
      Miksi?       
☐ Lääkevalikoimassa on myös biosimilaarivalmisteen alkuperäisvalmiste 
     Miksi?       
☐ Lääkevalikoimassa ei ole biosimilaarivalmistetta 
     Miksi?       
☐ Lääkevalikoimassa on vain biosimilaarivalmiste 
     Miksi?       
☐ En käytä biosimilaarivalmistetta tai sen alkuperäisvalmistetta, koska sairaalassa on  
     siirrytty käyttämään uudempia valmisteita, joilla on sama käyttöaihe/-aiheet kuin  
     biosimilaarivalmisteella 
     Miksi?       
Muita kommentteja?       
 
3. Kysymykset koskien biosimilaarien tehoa, turvallisuutta, vaihtoja ja käyttöönottoa 
3.1. Biosimilaarilääkkeen myyntilupaa haettaessa on osoitettava, että mahdolliset erot 
biosimilaari- ja alkuperäisvalmisteen välillä eivät vaikuta tehoon tai turvallisuu-
teen. Ovatko biosimilaarivalmisteilta vaadittavat tutkimukset mielestäsi riittävän 
kattavia tehon ja turvallisuuden osalta ja mistä olet saanut biosimilaarivalmis-
teista tietoa? 
3.1.1. Biosimilaarivalmisteiden tutkimukset ovat 
☐ Riittävän kattavia 
     Miksi?       
☐ Eivät ole riittävän kattavia 
     Miksi?       
Muita kommentteja?       
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3.1.2. Mistä lähteistä olet saanut tietoa biosimilaarivalmisteista? 
☐ Lääkeyrityksiltä 
☐ Lääkeviranomaisilta 
☐ Kollegoilta 
☐ Muualta, mistä?       
3.1.3. Koetko tarvitsevasi lisää tietoa biosimilaareista? 
☐ Kyllä 
     Seuraavista asioista       
☐ En 
3.2. Sairaaloissa on vaihdettu potilaita alkuperäisvalmisteilta biosimilaarivalmisteille. 
Miten sairaalassa valmistauduttiin vaihtoihin alkuperäisvalmisteelta valitsemal-
lesi biosimilaarivalmisteelle ja vaikuttivatko vaihdot hoidon tehoon ja/tai turvalli-
suuteen? Onko vaihdoista tehty jälkiseurantaa? 
3.2.1. Miten vaihtoihin valmistauduttiin? 
☐ Vaihdot eivät aiheuttaneet erillistoimenpiteitä 
☐ Määrittämällä vasta-aine- ja lääkeainepitoisuudet ennen vaihtoja 
☐ Ohjeistamalla potilas siitä, mikä biosimilaarivalmiste on 
☐ Kouluttamalla hoitohenkilökunta siitä, mikä biosimilaarivalmiste on 
☐ Määrittelemällä vaihdettavat potilaat 
      Vaihtokriteerejä olivat:       
☐ Muuten, miten?       
3.2.2. Vaikuttivatko vaihdot hoidon tehoon ja/tai turvallisuuteen? 
☐ Kyllä 
     Miten?       
☐ Ei 
☐ En osaa sanoa 
Muita kommentteja?       
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3.2.3. Onko vaihdoista tehty jälkiseurantaa? 
☐ Ei erityistä seurantaa 
☐ Lääkeainepitoisuus- ja vasta-ainemäärityksin 
  ☐ Määritetään tietyin frekvenssein 
  ☐ Määritetään tarvittaessa 
☐Seuraamalla hoidon keskeytymisen syitä 
☐Muuten, miten?       
Muita kommentteja?       
3.3. Alkuperäisten biologisten lääkkeiden rinnalle on tulossa yhä enemmän biosimi-
laarivalmisteita. Ovatko biosimilaarivalmisteet, joilla on sama vaikuttava aine, 
mielestäsi vaihtokelpoisia keskenään sairaalassa ja mitä asioita vaihdoissa tulisi 
huomioida? 
3.3.1. Ovatko biosimilaarivalmisteet vaihdettavia keskenään? 
☐ Kyllä 
     Miksi?       
☐ Eivät 
     Miksi?       
☐ En osaa sanoa 
     Miksi?       
3.3.2. Mitä asioita tulisi huomioida vaihdettaessa biosimilaarivalmisteelta toiseen? 
      
3.4. Mitkä ovat mielestäsi biosimilaarien entistä laajemman käytön tärkeimmät esteet?  
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4. Kysymykset koskien lääkekustannuksia ja säästöjä 
4.1. Kun biosimilaarivalmiste tulee markkinoille, oletetaan sen aiheuttavan hintakilpai-
lua. Kommentoi odotuksiasi valitsemasi biosimilaarivalmisteen hintaerosta alku-
peräisvalmisteeseen, sekä sen toteutumista, kun biosimilaari valittiin ensimmäi-
sen kerran sairaalan lääkevalikoimaan. Ensimmäinen biosimilaari filgrastiimi sai 
myyntilupansa Euroopassa syyskuussa 2008 ja infliximabi syyskuussa 2013. 
4.1.1. Ennen biosimilaarivalmisteen markkinoille tuloa, biosimilaarivalmisteen ja 
sen alkuperäisvalmisteen hintaeroksi arvioit 
      % 
Mihin perustit oletuksesi?       
4.1.2. Biosimilaari- ja alkuperäisvalmisteen sairaalan ostohintaero verrattuna alku-
peräisvalmisteen sairaalan ostohintaan, kun biosimilaarivalmiste valittiin sai-
raalan lääkevalikoimaan ensimmäisen kerran 
      % 
Vuosi       
4.1.3. Biosimilaarivalmisteen tullessa hankintakilpailutukseen mukaan ensimmäi-
sen kerran, muuttuiko alkuperäisvalmisteen ostohinta verrattuna edelliseen 
hankintakilpailutuksessa tarjottuun ostohintaan? 
☐ Kyllä 
    ☐ Laski       % 
    ☐ Nousi       % 
☐ Ei 
Muita kommentteja?       
4.2. Biosimilaarivalmisteen käyttöönotto sairaalassa on mahdollistanut lääkekustan-
nussäästöjä. Millä keinoin säästöjä tavoiteltiin ja toteutuivatko säästöt? 
4.2.1. Valitsemallasi biosimilaarivalmisteella tavoiteltiin lääkekustannussäästöjä 
☐ Aloittamalla uusille potilaille 
☐ Vaihtamalla alkuperäisvalmisteelta kaikki potilaat biosimilaarivalmisteelle 
☐ Vaihtamalla tietyt potilasryhmät alkuperäisvalmisteelta biosimilaarivalmisteelle 
     Mitä potilasryhmiä/potilaita ei vaihdettu?       
Muita kommentteja?       
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4.2.2. Toteutuivatko lääkekustannussäästöt? 
☐ Kyllä 
     Mitkä tekijät edesauttoivat kustannussäästöjen toteutumisessa?       
☐ Eivät 
     Miksi eivät?       
☐ Osin 
     Mitkä tekijät vaikuttivat siihen, että tavoitteeseen ei päästy?        
4.2.3. Arviosi valitsemasi biosimilaarivalmisteen avulla saavutetuista kustannus-
säästöistä lääkeostoissa vuonna 2015 
      €  
☐ Vain biosimilaarivalmiste oli jo edellisellä hankintakaudella sairaalan lääkevali-  
      koimassa, joten lääkekustannussäästöt alkuperäisvalmisteeseen verrattuna  
      eivät olleet enää 2015 ajankohtaisia. 
4.2.4. Jos biosimilaarivalmisteella saatiin sairaalalle lääkekustannussäästöjä,  
mihin vapautuneet varat käytettiin? 
☐ Mahdollisti useamman potilaan hoidon kyseisellä valmisteella 
☐ Mahdollisti uusien valmisteiden käyttöönoton sairaalavalikoimassa 
☐ Lääkekustannusten hallintaan 
☐ Henkilökunnan palkkaukseen 
☐ Muu, mikä?       
4.2.5. Valitsemasi bioisimilaarivalmisteen prosenttiosuus lääkeryhmän kokonais-
lääkemäärästä vuonna 2015. Inflectra mg:sta/filgrastim ruiskumääristä las-
kettuna. Laskelmassa tulisi olla mukana valmisteet, jotka sisältyvät valitse-
masi biosimilaarivalmisteen ATC-koodin alle: L04AB02 infliximabit tai 
L03AA02 filgrastiimit. 
Prosenttiosuus       % 
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4.3. Uusia biosimilaarivalmisteita on tulossa markkinoille lähivuosina. Miten arvioisit 
niiden vaikuttavan sairaalassa käytettävien alkuperäisvalmisteiden hinnoitteluun 
ja mitä odotat biosimilaarivalmisteiden hinnoittelulta? 
4.3.1. Biosimilaarivalmisteiden hinnoittelulta sairaalahinnoissa tulevaisuudessa 
odotat 
☐ Biosimilaarivalmisteet ovat edullisempia kuin alkuperäisvalmisteet 
     Arvioimasi hintaero       % 
☐ Alkuperäisvalmisteet lähtevät hintakilpailuun mukaan biosimilaarivalmisteiden  
     saadessa myyntiluvan ja ovat yhtä edullisia kuin biosimilaarivalmisteet 
☐ Alkuperäisvalmisteiden hinta ei laske 
☐ Alkuperäisvalmisteet ovat edullisempia kuin biosimilaarivalmisteet 
     Arvioimasi hintaero      % 
Muita kommentteja?       
4.3.2. Paljonko seuraavan 5 vuoden aikana arvioit saatavan biosimilaarivalmistei-
den aiheuttamien hintakilpailujen avulla sairaalassasi kustannussäästöjä lää-
keostoissa? 
      €/5 vuotta 
Perustelut arviollesi       
4.3.3. Biosimilaarivalmiste, jonka oletat seuraavaksi vaikuttavan sairaalanne  
lääkekustannuksiin merkittävästi 
Valmiste:       
Arvioitu kustannussäästö lääkeostoissa:       €/vuosi 
Kustannussäästöarviosi perustuu seuraaviin asioihin:       
Muita kommentteja?       
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4.4. Lisääntyvät lääkekustannukset ovat haaste sairaaloille. Ovatko lääkekustannuk-
set muuttuneet viimeisen viiden vuoden aikana sairaalassa ja millainen osuus lää-
kekustannukset ovat sairaalan kokonaismenoista? 
4.4.1. Sairaalan lääkekustannukset ovat viimeisen viiden vuoden aikana 
☐ Kasvaneet       % 
      Miksi?       
☐ Pienentyneet       % 
     Miksi?       
☐ Eivät ole muuttuneet 
     Miksi?       
4.4.2. Sairaalan lääkekustannusten osuus prosentteina sairaalan kokonaisme-
noista 2015? Kokonaismenoilla tarkoitetaan toimintakuluja, eli niissä ei ole 
huomioitu investointimenoja. 
Prosenttiosuus       % 
 
5. Jos hoidat potilaita avohoidossa, tuletko määräämään uusia myyntiluvallisia  
biosimilaarivalmisteita avohoidon potilaille? 
☐ Kyllä 
     Miksi?       
☐ Ei 
     Miksi?       
☐ Käytän jo biosimilaarivalmisteita avohoidossa 
     Mitä valmisteita?       
     Miksi?       
 
6. Haluan, että lähetät sähköpostiini linkin, josta pääsen lukemaan opinnäytetyösi 
Sähköpostiosoitteeni       
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TERMS USED IN THE FIGURES 15 AND 17     APPENDIX 13 
 
Biosimilar + reference products 
HGH Genotropin + Humatrope + Omnitrope 
EPO (shorter acting) Epoetin alfa + epoetin zeta 
G-CSF (shorter acting) Filgrastim 
Anti-TNF Infliximab 
Biosimilar accessible market products, includes also biosimilar + reference products 
HGH Norditropin + Saizen + NutropinAq + Zomacton 
EPO (shorter acting) Epoetin beta + epoetin theta 
G-CSF (shorter acting) Lenograstim 
Total market products, includes also accessible market products 
HGH 
 
EPO (longer acting) Methoxy polyethylene glycol-epoetin beta + darbepoetin alfa 
G-CSF (longer acting) Lipegfilgrastim + pegfilgrastim + molgramostim + sargramostim 
Anti-TNF Etanercept, adalimumab, certolizumab, golimumab 
 
(IMS Health June 2016, 3 - 4, 8 - 16, 24) 
